Adenovirus Mediated Gene Transfer of Skeletal Troponin C to Myocardium by Docherty, Andrew
Adenovirus Mediated Gene Transfer of Skeletal 
Troponin C to Myocardium
A thesis submitted in fulfilment 
of the degree of 
Doctor of Philosophy
By
Andrew Docherty
Department of Medical Cardiology, Glasgow Royal Infirmary
&
Institute of Biomedical & Life Sciences, University of Glasgow
2001
©Andrew Docherty 2001
ProQuest Number: 13818443
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com plete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13818443
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
(GLASGOW )  
UNIVERSITY 
.LIBRARY: ,
COPS \
CONTENTS
List of tables and figures 8
Abbreviations 12
Acknowledgements 13
Declaration 14
Summary 15
Chapter 1 General Introduction 17
Epidemiology of Ischaemic Heart Disease and 18
Heart Failure.
Prevalence of Ischaemic Heart Disease 19
The Incidence of Coronary Heart Disease is in 21
Decline
Therapeutic Options for Established Ischaemic 25
Heart Disease.
Therapeutic Options for Established Heart Failure 26
On-going Clinical Research 27
New Molecular Targets for Intervention 27
Introduction 27
The Sarcomere 28
Myocardial Contractility 29
Excitation-contraction Coupling 30
Ischaemic Contractile Failure 32
Response to Ischaemia is Dependent on Contractile 33 
Protein Isoform Expression
Structure and Function of TnC 34
Functional Differences Between TnC Isoforms 35
The Interactions with Other Subunits 38
Troponin Hsoformsr 38
Troponin t  Isoforms, i 38
Myosin Isoform’s ri 1 39
2
Regulation of contractility 39
Calcium Sensitising Drugs Show Promise 41
Troponin C as a Therapeutic Candidate 43
Other Potential Therapeutic Targets 44
Sarcoplasmic Reticulum Calcium ATPase 44
Phospholamban 45
Apoptosis and Bcl-xL 45
Vascular Endothelial Growth Factor (VEGF) 46
Transforming Fibroblasts into Striated Muscle Cells 47 
Gene Therapy for Arrhythmias 48
Antisense DNA 48
Gene T ransfer Methods 50
Introduction 50
Plasmid DNA 50
Replication Deficient Adenoviral Vectors 51
Duration of Reporter Gene Expression 53
Efficiency of Adenoviral Vectors 54
Cationic Liposomes 55
Vaccinia Vectors (Pox viruses) 55
Retroviral Vectors 56
Herpes Virus Vectors 57
Adeno-associated Viral Vectors 57
Routes of Adenoviral Vector Administration 58
Methods of Gene Transfer to Myocardial Tissue 58
Cultured Cells 59
Cultured Trabeculae 60
Isolated Whole Heart Preparations 60
Intra-coronary Injection 62
Direct Needle Injection into the Heart 62
Aortic and Pulmonary Cross-clamp Method 63
Retro-infusion 64
Pericardial 65
Gene Transfer to Vessels 65
Gene Transfer of Skeletal Troponin C to Rabbit 65
Myocardium
Chapter 2 Methods 67
Adenoviral Vector Production 68
Materials 68
Frozen 239 Cell Stock 68
Subculture of 293 Cells 69
Maintaining Frozen Stocks 69
Small-scale Propagation of Adenoviral Vectors 70
Large-scale Propagation of Adenoviral Vectors 71
3
Purification by Caesium Gradient 71
Quality Assurance 72
Background 72
DNA Isolation 72
Ethanol Precipitation 73
HinD\\\ Restriction Enzyme Digest 74
Agarose Gel Electrophoresis 74
Tag DNA Polymerase Amplification of Adenoviral 74 
Vector DNA Fragments
Calculating Viral Concentration by Plaque Assay 76 
Plaque Purification 76
Adenoviral Vectors 77
Introduction 77
Adenoviral Vector Expressing Beta-galactosidase 77 
CMV-LacZ Ad 5 77
RSV-nLacZ Ad5 78
Adenoviral Vectors Encoding Skeletal Troponin C 79 
CMV-sTnC Ad 5 80
CMV-sT nC-A9-HA Ad5 80
HCA- sTnC Ad 5 and HCA- sTnC-A9-HA Ad5 81
Delivery T echniques 82
Surgical Methods 82
Induction of General Anaesthesia 82
Central Vessel Cannulation 83
Left Lateral Thoracotomy 83
Direct Needle Injection 84
Coronary Infusion Using a Swan-Ganz 85
Catheter
Introduction of Adenoviral Vector by 86
Pulmonary Artery and Aortic Cross-Clamp 
Selective Coronary Cannulation 87
Post-operative Analgesia 88
Histological Staining 89
Staining of Myocardial Tissue Blocks for 89
Beta-galactosidase (Method 1)
Staining of Myocardial Tissue Blocks for 89
Beta-galactosidase (Method 2)
Staining by Coronary Infusion 90
Histological Sections 91
Detection of HA-tag by Immunohistochemistry 91
Quantitative Analysis of Histological Sections 93
Photography 96
4
Physiology Methods 96
Calcium Sensitivity of Trabeculae 96
Production of Skinned Fibres 97
Measuring Calcium Sensitivity of Skinned Fibres 97
Hillfit Computer Macro 99
Statistical Methods 100
Chapter 3 Adenoviral Vector Production 101
Introduction 102
Background 103
Group Experience 104
Replication Defective Adenoviral Vectors 105
Viruses Employed 105
Possible Contamination by Wild Type Virus 108
Plaque Purification of Contaminated Vector 111
Purification of Contaminated Vector by Serial Dilution 112 
Fresh Stock Vector Obtained 112
Rates of Viral Replication 116
Adenoviral Vector Encoding Nuclear-localising 117
Beta-galactosidase
Adenoviral Vectors Encoding Skeletal Troponin C 118
Discussion 119
Conclusions 120
Chapter 4 Development of the Swan-Ganz Method of 121 
Vector Delivery
Introduction 122
Development of Swan-Ganz Catheter Mediated 123
Vector Delivery
Procedural Results 125
Histological Results 1 125
Specificity of Staining Method 1 126
Histological Results 2 127
Discussion of Direct Needle Injection Experiments 131
Conclusion of Direct Needle Injection Experiments 132
Dose Finding Study (Swan-Ganz Delivery Method) 132
5
Discussion of Swan-Ganz Viral Delivery Method 135 
Conclusions 136
Chapter 5 Development of a Selective Coronary 138
Catheterisation Method of Vector Delivery
Introduction 139
Methods 140
Results 142
Discussion 144
Conclusions 148
Chapter 6 Comparison of Selective Coronary 150
Injection and Aortic Cross-clamp Methods 
of Vector Delivery
Introduction 151
Methods 153
Adenoviral Vectors 153
Histochemical Staining 154
Quantitative Analysis 155
Results 156
Discussion 164
Inflammation 166
Specificity of Beta-galactosidase Staining 167
Conclusions 168
Chapter 7 Physiological Investigation of Right 170
Ventricular Trabeculae
Introduction 171
Experimental Design 173
Immunohistochemistry 174
Calcium Sensitivity of Permeabilised 177
Trabeculae
Histology 179
Discussion 180
Conclusions 182
6
Chapter 8 General Discussion 185
Introduction 186
Comparison of the Aortic Cross-clamp 188
Method with Selective Coronary Injection
Specificity of Histochemical and 190
Immunohistochemical Methods
Use of Serum Troponin T to Detect Early 191
Myocardial Damage
Physiology of Isolated Ventricular Trabeculae 192 
Advances in Myocardial Gene Therapy 194
Selection of Vector System 196
Adenoviral Vector Production 197
Methods of Vector Delivery to Myocardium 199
General Conclusion 202
References 205
7
List of tables and figures
Table 1.1. Prevalence of self-reported myocardial infarction 20
and symptomatic ischaemic heart disease.
Graph 1.1. Coronary Heart Disease Incidence and Mortality 1988-1997 21
Graph 1.2. All Coronary Heart Disease Continuous Inpatient Stays 22
Graph 1.3 Cumulative Incidence of Coronary Heart Disease 24
Death 1950-1989
Figure 1.1. Structure of the sarcomere 28
Figure 2.1. Method of viral introduction 87
Plate 2.1. An example of a histological section representative of 94
positively staining nuclei in the myocardium of a 
rabbit 5 days following the introduction of vector 
encoding nuclear localising beta-galactosidase.
Plate 2.2. An example of a histological section representative of 95
positively staining cells in the myocardium of 
a rabbit 5 days following the introduction of vector 
encoding beta-galactosidase.
Table 2.1. Composition of solutions 10A, 10R and 0.2R in mM 98
Table 2.2. Composition of solutions for bath change system 98
Figure 3.1. H/nDIII restriction enzyme pattern of 107
beta-galactosidase encoding adenovirus.
8
Figure 3.2. 
Figure 3.3.
Figure 3.4
Figure 3.5.
Figure 3.6.
Figure 3.7. 
Figure 3.8.
Figure 3.9.
Table 4.1. 
Table 4.2.
PCR using primers specific for E1a region of the 
adenovirus genome.
HinD\\\ restriction enzyme analysis of the wild type 
replication competent virus dl309.
Typical result of HinD\\\ restriction enzyme analysis 
of beta-galactosidase encoding viral vector held by 
other group members.
HinD\\\ restriction enzyme analysis of virus 
propagated from isolated viral plaques.
HinD\\\ restriction enzyme analysis of crude lysate 
isolated from new stock.
PCR of virus isolates.
HinDWl restriction enzyme analysis of replication 
deficient virus encoding nuclear-localising 
beta-galactosidase under the control of the RSV 
promoter.
HinDlU restriction enzyme patterns of viral vectors 
subsequently used in in vivo experiments.
Procedural Results of Swan-Ganz Experiments 
Procedural Details of Direct Needle Injection Experiments
108
109
110
112
113
114 
118
119
124
127
9
Plate 4.1 
Plate 4.2
Table 4.3. 
Plate 5.1.
Table 5.1 
Plate 5.2.
Plate 5.3. 
Plate 6.1. 
Plate 6.2.
An example of a histological section of rabbit myocardium 129 
7 days following direct needle injection of vector encoding 
beta-galactosidase.
An example of a histological section of rabbit myocardium 130
7 days following direct needle injection of vector encoding 
beta-galactosidase.
Dose Finding Study (Unfiltered Crude Lysate) 133
An example of a rabbit heart stained for beta- 143
galactosidase expression 5 days following selective 
coronary injection of an adenoviral vector encoding 
beta-galactosidase.
Procedural results of Selective Coronary Injection 144
Experiments
A histological section of right ventricle taken from arabbit 146
5 days following introduction of adenoviral vector encoding 
beta-galactosidase.
A histological section of the cut edge of right ventricle taken 147 
from a rabbit 5 days following introduction of adenoviral 
vector encoding beta-galactosidase.
An example of an H&E stained section (X10 magnification) 158 
from the right ventricle of an animal 5 days after introduction 
of low-dose adenoviral vector encoding the beta-galactosidase 
gene.
An example of an H&E stained section (X10 magnification) 160 
from the right ventricle of an animal 5 days after introduction 
of high-dose adenoviral vector encoding a nuclear-localising 
beta-galactosidase gene.
10
Plate 6.3.
Figure 6.1.
Figure 6.2. 
Table 7.1
Plate 7.1. 
Table 7.2.
An example of an H&E stained section of a trabecula 161
found in the right ventricle of an animal 5 days after 
introduction of high-dose adenoviral vector encoding a 
nuclear localising beta-galactosidase gene.
Percentage of right ventricular myocytes staining 163
positively for the reporter gene beta-galactosidase.
Percentage of micro-infarction in the right ventricle. 164
Immunohistochemistry results of direct needle injection 175
experiments
An example of a histological section of myocardium from 176
a rabbit that had been injected with the vector 
CMV-sTnC-A9-HA Ad5 five days previously
Calcium sensitivity of RV trabeculae at pH 7.0 and pH 6.5 178
11
Abbreviations
AAV Adeno Associated Virus
Akt protein kinase B
CHD Coronary Heart Disease
CMV Cytomegalovirus
cTnC Cardiac Troponin C
DAB 3 \3 ’-diaminobenzadine
DMSO Dimethyl Sulphoxide
DOTAP liposome formulation of a monocationic lipid (N-[1-(2,3-
Dioleoyloxy)]-N,N,N-trimethylammonium propane methylsulfate 
in sterile water
GFP Green Fluorescent Protein
HA haemagglutinin antigen
HEK293 Human Embryonic Kidney 293 Cell line
IGF-1 Insulin-like growth factor-1
IHD Ischaemic Heart Disease
Kb Kilo base
pfu plaque forming units
PBS Phosphate Buffered Saline
sTnC Skeletal Troponin C
SERCA Sarcoplasmic Reticulum Calcium ATPase
TM Tropomyosin
Tnl Troponin I
TnT Troponin T
12
Acknowledgements
I am indebted to many people without whose help I could not have completed 
this thesis. I wish to express warmest thanks to -
The British Heart Foundation for financial support.
Professor SM Cobbe who provided me with the opportunity to carry out this 
work and for his advice and guidance throughout my period of study.
Dr Martin Hicks for his encouragement, guidance, team building, late hours, 
explaining the difference between Medicine and Science, and friendship.
Dr Howard Prentice and Professor Godfrey Smith for their encouragement 
and direction
Dr David Miller and Miss Jamie Varghese for their expert help with isolated 
trabeculae.
Dr Yvonne Alexander for advice on adenoviral vector production
Niall Whyte for all the histological sections and Golf. Graeme Deuchar for his 
help in the Animal House
Finally, to Margaret-Mary, Laura and Jennifer, each of whom I have missed.
13
Declaration
Assistance was provided by Niall Whyte who cut and mounted all histological 
sections. Jamie Varghese snared the isolated trabeculae and assisted with 
the calcium sensitivity experiments. Otherwise, all of the experimental work 
contained within this thesis was undertaken by me. The material has not been 
submitted previously for any other degree. Some of the results presented 
have been published during the period of study.
Publications
A Docherty, MN Hicks, GL Smith, SM Cobbe, HM Prentice. Delivering 
adenoviral vectors to rabbit myocardium: effect of dose and method of 
delivery on efficiency and micro-infarction. European Heart Journal 1999; 20 
(Abstr. Suppl.): 249.
14
Summary
Ischaemic heart disease and the syndrome of congestive cardiac failure are 
increasing in prevalence within western societies. The limitations of present 
day interventions are discussed. There is a need to identify new therapeutic 
targets and the potential of molecular genetic methods is discussed. 
Experimental data from transgenic mice expressing skeletal troponin C is 
considered together with data from substitution of troponin isoforms in isolated 
preparation. The function of cardiac troponin C is significantly affected by 
intracellular acidosis and this is largely responsible for the early decoupling of 
the calcium transient and contractile dysfunction. In comparison skeletal 
troponin C is relatively unaffected by moderate degrees of intracellular 
acidosis. This led to the hypothesis that by displacing a proportion of the 
cardiac troponin C with the skeletal isoform, there would be the possibility of 
rendering cardiac muscle relatively resistant to the effects of intracellular 
acidosis. Perhaps such altered myocardium would be able to contract for 
longer in conditions of ischaemia.
Vectors for gene transfer are considered and the attractive properties of 
adenoviral vectors detailed. Routes by which to deliver vector to the heart are 
discussed and particular consideration is given to the intra-coronary injection 
of adenoviral vector.
Chapter 3 deals with the production and quality assurance of replication 
defective adenoviral vectors. The “supernatant rescue assay” method to 
detect wild type contamination is discussed but not utilised. Further 
experiments depend on the adenoviral vector which is free of wild type 
contamination. Although virus was propagated from single plaques and the
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viral DNA tested by restriction enzyme analysis, the possibility of wild type 
contamination remained. This was to undermine the value of the data from 
subsequent experiments. Chapter 4 details the failure of the Swan-Ganz 
method of viral delivery, which in part may have been due to contamination of 
vector by replication competent wild-type virus.
A selective coronary injection method of vector delivery was achieved and 
then compared with an aortic cross-clamp method of vector delivery. The 
experimental design permitted a direct comparison of the efficiency of both 
methods. The selective coronary injection method was found to be more 
efficient. Neither method achieved adequate efficiency of gene transfer to 
allow investigation of genetically altered contractile physiology by means of a 
working heart preparation. The selective coronary injection method achieved 
foreign gene expression in up to 30% of myocytes in the trabeculae rich basal 
right ventricle. Pre-injection of serotonin before injection of low dose virus 
resulted in more myocardial damage than expected. The lack of a control 
group, injected with only vehicle, limited the value of these data. Chapter 7 
details the results of physiological investigation of right ventricular trabeculae, 
isolated from rabbits following selective coronary injection of adenoviral vector 
encoding either beta-galactosidase or skeletal troponin C. The results are 
negative and the possible reasons discussed. The vector used for these 
experiments encoded a skeletal troponin C mutant where the final 9 amino- 
acids at the C-terminal had been deleted and replaced with a 12 amino-acid 
sequence which included a haemagglutinin antigen motif. In retrospect, 
confirmation of the integration of the gene product into the sarcomere should 
have been undertaken prior to proceeding to in vivo investigation. The final 
chapter places the results of this work in the context of a rapidly advancing 
field.
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Chapter 1
General Introduction
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Epidemiology of Ischaemic Heart Disease and Heart Failure.
Introduction
Ischaemic heart disease results from the atheromatous degeneration and the 
consequent narrowing of coronary arteries (Ross 1999). When the diameter of 
a coronary artery is reduced by more than 60%, this has an adverse effect on 
the coronary flow reserve and can result in an imbalance between myocardial 
oxygen supply and oxygen demand resulting in myocardial ischaemia. (Klocke 
1987). This presents as the clinical syndrome of angina pectoris. Affected 
individuals can be limited in their physical activities by anginal chest pain or 
exertional breathlessness. Patients with coronary artery disease are at risk of 
myocardial infarction and subsequent congestive cardiac failure. The term 
“heart failure” is commonly applied to patients with impaired left ventricular 
systolic function. Although ischaemic heart disease is a common cause of 
heart failure, other causes include hypertension, valvular heart disease, 
infective, metabolic and endocrine disorders (Andersson & Waagstein 1993). 
Patients with the clinical syndrome of heart failure can present with symptoms 
of impaired exercise capacity, exertional dyspnoea, orthopnoea, paroxysmal 
nocturnal dyspnoea and peripheral oedema. Survival after onset of clinically 
apparent chronic heart failure is poor (Ho et al. 1993). In men, the median 
survival is only 1.7 years with a 5-year survival of only 25%. For women, the 
outlook is moderately better with a median survival of 3.2 years and a 5-year
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survival of 38%. Although the commonest cause of symptomatic heart failure 
is systolic dysfunction, a similar clinical presentation can be found in left 
ventricular diastolic dysfunction and pericardial disease (Vasan et al. 1999). 
Symptomatic diastolic dysfunction is associated with an annual mortality of 
19% for males and 9% for females. There are ongoing clinical trials in patients 
who are thought to have diastolic dysfunction but as yet there is no 
intervention which is proven to improve survival (Cleland 1999; Swedberg et 
al. 1999).
There are well-recognised modifiable risk factors and risk predictors for both 
ischaemic heart disease and heart failure. Predictors for the development of 
ischaemic heart disease included male gender, smoking, obesity, family 
history, age over 45 years, diabetes mellitus, hypertension and 
hyperlipidaemia.
Prevalence of Ischaemic Heart Disease.
Ischaemic heart disease and congestive cardiac failure are common in the 
western world. Although the death rate for ischaemic heart disease is in 
decline, it still accounts for more than one third of all deaths in adults over 35 
years of age (Feinleib 1995). Table 1.1 shows the prevalence of self-reported 
myocardial infarction and symptomatic ischaemic heart disease as derived 
from the National Health and Nutrition Surveys (NHANES, American Heart 
Association. Heart and Stroke Facts: 1995 Statistical Supplement. American 
Heart Association 1994; Dallas TX 75231)
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Table 1.1. Prevalence of self-reported myocardial infarction and 
symptomatic ischaemic heart disease.
Age Group (yrs) Male (%) Female (%)
40-49 7 5
50-59 13 8
60-69 16 11
70-79 22 14
These data are from a North American population but the increasing 
prevalence of disease with age is similar to that found in British cohorts. In the 
United Kingdom as a whole, death rates from ischaemic heart disease over a 
recent ten-year period have fallen by over 40% (BHF, Coronary Heart Disease 
Statistics. BHF statistics database 1998). In Scotland, the CHD death rate fell 
by approximately 30% in the years 1975 to 1994 (Capewell, Morrison, & 
McMurray 1999). Half of this improvement was attributable to measurable risk 
factor reduction (predominantly smoking cessation) and forty percent was 
attributable to medical treatments. The cumulative risk of developing 
ischaemic heart disease and congestive cardiac failure increase with age 
(Lloyd-Jones et al. 1999). For healthy men aged 40 years, the lifetime risk of 
developing coronary artery disease is one in two. Women lag behind men by 
about 10 yrs and for a 40-year-old woman the lifetime risk is one in three.
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The Incidence of Coronary Heart Disease is in Decline.
The Scottish incidence of coronary heart disease has been declining and this 
has been paralleled by a reduction in mortality (Graph 1.1. Information and 
Statistics Division Common Services Agency for the NHS in Scotland).
CHD incidence and inoitalily 1988*1997
600.0
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Graph 1.1. Coronary Heart Disease Incidence and Mortality 1988-1997
Although there has been a decline in mortality, this is offset by the increasing 
age of the population. The net effect of these factors is a likely increase in the 
prevalence of CHD. In recent years the number of patients admitted to 
Scottish hospitals for treatment of CHD has increased (Graph 1.2, Information 
and Statistics Division Common Services Agency for the NHS in Scotland).
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Graph 1.2. All Coronary Heart Disease Continuous Inpatient Stays
The same is true for the North American population, where the decline in 
incidence of CHD is offset by the age-adjusted decline in death rates from 
heart disease (Feinleib 1995). Consequently, the prevalence of ischaemic 
heart disease and congestive cardiac failure is likely to increase, with an 
associated increase in demand on healthcare resources (McMurray et al. 
1998).
In the healthy population, the incidence of heart disease can be reduced by 
modification of risk factors. Smoking cessation has been associated with a 
36% reduction in heart disease (Capewell, Morrison, & McMurray 1999). In 
patients with hypertension, treatment can reduce the incidence of stroke and
coronary heart disease by more than 30% (Curb et al. 1996). In 
hyperlipidaemia, asymptomatic healthy men at risk of developing coronary 
artery disease showed a significant reduction in end points when treated with 
lipid lowering therapy (Downs et al. 1998; Shepherd et al. 1995). Glycaemic 
control in diabetics has been shown to reduce microvascular end points (UK 
Prospective Diabetes Study Group 1998). In addition, diet and exercise are 
thought to be important (Krauss et al. 1998; Lemaitre et al. 1999).
In patients with established cardiovascular disease, reductions in mortality 
and morbidity have been shown in patients where modifiable risk factors have 
been addressed. For the same relative risk reduction as applied to primary 
prevention groups, fewer patients need to be treated to achieve one life 
saved. There is evidence for the benefit of smoking cessation (Wilhelmsson et 
al. 1975), treatment of hypertension (Connolly et al. 1983), treatment of 
hyperlipidaemia (Scandinavian Simvastatin Survival Study 1994), glycaemic 
control (Malmberg 1997), exercise (Leon et al. 1987) and diet (Burr et al 1989) 
in patients with established cardiovascular disease. Medical treatments 
demonstrated to reduce the attrition rate include Aspirin (Krumholz et al. 1996; 
Antithrombotic Trialists' Collaboration 2002), Beta-blockers and ACE inhibitors 
(CIBIS-II Investigators 1999, Pfeffer et al. 1992). In part due to these 
interventions, there has been a reduction in the cumulative incidence of 
coronary heart disease death after an initial Q-wave myocardial infarction 
(Graph 1.3, Guidry et al. 1999).
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Graph 1.3 Cumulative Incidence of Coronary Heart Disease
Death 1950-1989 (adapted from Guidry et al. 1999)
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Nevertheless, in the United Kingdom, there is room for improvement in the 
secondary prevention of cardiovascular disease. In the UK ASPIRE study, up 
to a quarter of patients remained hypertensive, males more severely so than 
females. Over three quarters had a total cholesterol greater than 5.2 mmol/l. 
In patients on medication for blood pressure, cholesterol or glucose, risk factor 
profiles were little better than in those who were not. Only about one patient in 
three was taking a beta-blocker after myocardial infarction. Up to a fifth of 
patients who had had acute myocardial ischaemia were not taking aspirin at 
follow up (Bowker et al. 1996).
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Therapeutic Options for Established Ischaemic Heart Disease.
Medical therapy, percutaneous coronary intervention and coronary artery 
bypass surgery are the three treatments found to effectively relieve the 
symptoms of ischaemic heart disease. In patients with stable angina the one- 
year incidence of death, myocardial infarction or admission to hospital with 
unstable angina is approximately 5% (Murphy et al. 1977). For patients with 
newly diagnosed unstable angina the combined end point of death, 
myocardial infarction or re-admission at six months is around 12% (Yusuf et 
al. 1998). In selected patients, percutaneous coronary intervention can reduce 
early and medium term unplanned admission to hospital with acute coronary 
syndromes, but has not been shown to reduce long-term mortality ( FRISC II 
Investigators 1999). Selected subgroups may obtain a mortality benefit from 
coronary artery bypass surgery. There is data supporting a mortality benefit in 
patients with significant left-main coronary artery stenosis and in patients with 
three-vessel coronary artery disease and moderately impaired left ventricular 
function (Alderman et al. 1983). However, much of this data is from the CASS 
registry and is not randomised data. At 15 year follow-up there is no 
discernible mortality advantage in patients who had preserved left ventricular 
systolic function (Yusuf et al. 1994; Caracciolo et al. 1995a; Caracciolo et al. 
1995b).
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Therapeutic Options for Established Heart Failure
Several studies have shown that oral inotropic agents with vasodilatory 
properties such as amrinone, milrinone, enoximone, and xamoterol are 
associated with increased mortality rates irrespective of the cause of heart 
failure and its severity ( Xamoterol in Severe Heart Failure Study Group 1990; 
Massie et al. 1985; Packer et al. 1991; Uretsky et al. 1990).The same is true 
for vesnarinone and ibopamine (Hampton et al. 1997; Cohn JN. VEST results. 
Presented at the Twelfth Plenary Session of the Sixty-ninth Scientific Session 
of the American Heart Association, New Orleans, LA: Nov. 10-13, 1996)
In the syndrome of heart failure secondary to left ventricular systolic 
dysfunction there is pathological neuro-endocrine activation. Angiotensin 
converting enzyme inhibitors, Beta-blockers and the aldosterone antagonist 
spironolactone have all been shown to reduce mortality in such patients. In 
addition there is evidence to show that these agents improve patient well­
being and functional capacity in the long term. The reduction in mortality for 
ACE inhibitors and Beta-blockers is additive (SOLVD Investigators 1992; 
CIBIS-II Investigators 1999).
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On-going Clinical Research
In heart failure, there is on-going clinical research into the use of neutral 
endopeptidase inhibitors (Rouleau et al. 2000) OVERTURE (Omapatrilat 
Versus Enalapril Randomized Trial of Utility in Reducing Events), endothelin 
antagonists and aldosterone antagonists (the EPHESUS, or Eplerenone 
Neurohormonal Efficacy and Survival Study), all of which may further 
modulate neuro-endocrine responses to heart failure. TNF-alpha modulators 
are under investigation (Aukrust et al. 1999). Calcium sensitising drugs are 
being investigated for their potential to increase cardiac force of contraction 
without increasing oxygen demand or causing arrhythmias. Two large studies 
of ACE inhibition and/or angiotensin II antagonism are ongoing which include 
patients with the clinical syndrome of heart failure, normal systolic function, 
and possible diastolic dysfunction (Cleland1999; Swedberg et al. 1999).
New Molecular Targets for Intervention 
Introduction
Despite present therapeutic options, heart failure leads to a poor quality of life 
and has a five-year survival rate worse than many cancers. There is a need to 
uncover therapeutic targets out with the neuro-endocrine system.
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The Sarcomere
In striated muscle the sarcomere is the basic building block of the contractile 
apparatus. It is composed of a precise geometric arrangement of myosin- 
containing thick filaments surrounded by an hexagonal array of thin filaments, 
each of which contains actin and the troponin/tropomyosin regulatory complex 
(Tobacman 1996).
Troponin T 
( - 15%)
a-Tropomyosin
K5% )
Troponin C Troponin I Myosin-binding 
protein C 
( - 15%)
0-Myosin 
heavy chnin 
(-35% )
Myosin -  
light chain
K1% )
Myosin
rod
Myosin
head
Figure 1.1. Structure of the sarcomere. Adapted from Spirito et al, NEJM 
1997. 336(11); 775-785
Each thick filament is composed of approximately 300 myosin molecules that 
are longitudinally stacked. The actin monomers within each thin filament are 
organised in a double-helical structure with one troponin/tropomyosin complex 
associated with each repeat of seven actin monomers (Figure 1.1). Each 
troponin/tropomyosin complex contains four distinct polypeptides: troponin C
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(TnC), troponin I (Tnl), troponin T (TnT), and tropomyosin (TM). Troponin C is 
the calcium sensitive component. Troponin I is essential for inhibiting muscle 
contraction in the absence of calcium by promoting tropomyosin-actin binding 
(Eaton, Kominz, & Eisenberg 1975). Tropomyosin is a 40 nm long molecule. 
Its subunits bind together head to tail, forming a continuous chain along the 
actin thin filament. Each tropomyosin molecule has seven actin binding sites, 
each binding to an actin monomer in the thin filament. TM lies along the 
myosin binding sites on actin, preventing contraction. Troponin T can be 
thought of as the fulcrum through which TnC controls the position of 
tropomyosin on the surface of the actin filament. Each sarcomere is bound by 
Z-bands at each end and measures approximately 2.2 pm in length.
The sliding filament theory of contraction is widely accepted (Adelstein & 
Eisenberg 1980). This defines the geometry and interaction of actin and 
myosin. The myosin heads are angulated away from the axis of the thick 
filament. An array of myosin fibres is interdigitated on either side by the thin 
actin filaments. Myosin heads can specifically interact with binding sites on the 
actin molecule. By an ATP dependent process a myosin head binds actin and 
moves it parallel to the fibre axis before releasing it, ready for another cycle. 
By this means sarcomere length is reduced and in tissue, contraction is seen 
to take place. Tropomyosin prevents myosin-actin interaction in the resting 
state by means of steric blocking (Haselgrove 1972).
Myocardial Contractility
Contraction refers to the action whereby a myocardial fibre becomes shorter.
A practical definition of contractility is the velocity of contraction when other
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factors influencing the myocardial oxygen uptake, such as heart rate, preload, 
and afterload are kept constant. V max is an idealised measure of contractility, 
defined as the maximal velocity of contraction where there is no load on the 
isolated muscle or, in the intact heart, no afterload to prevent maximal rates of 
cardiac ejection. It is extrapolated from a series of measurements of the force- 
velocity relationship. Where heart rate, preload, and afterload can be kept 
constant, maximal rate of left ventricular pressure generation (max dP/dt) is 
used as an index of contractility. This can be obtained by left ventricular 
catheterisation. In a molecular context, contractility can be thought of in 
relation to the calcium-contractile protein interaction (Opie 1995).
Excitation-contraction Coupling
Depolarisation of the myocyte membrane occurs through voltage dependent 
channels. On depolarisation a small amount of calcium enters the cell from 
the extracellular space. By a process of calcium dependent calcium release 
from the sarcoplasmic reticulum (ryanodine receptor) the intracellular calcium 
concentration rises from pCa 7 to pCa 5. The crossbridges undergo cyclic 
changes, each cycle producing an ATP dependent power stroke that drives 
the actin filament along the myosin. The tension developed is related to the 
calcium concentration. Half maximal tension development occurs at a calcium 
concentration of ~2x10‘6 M Ca2+ (Fabiato & Fabiato 1978). Twofold deviations 
from the Ca2+ midpoint result in at least 90% activation or inhibition in most 
studies. This corresponds to a Hill coefficient of 3 or more (Babu et al. 1987; 
Metzger et al. 1993).
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An increase in the free calcium ion concentration of the myoplasm enhances 
the calcium occupancy of troponin C, which by a conformational change 
causes tropomyosin to move away from the actin binding sites. With the actin 
binding sites available to the myosin heads the probability of crossbridge 
attachment increases and contraction occurs. However, in conditions of low 
intracellular calcium the function of Tnl predominates and tropomyosin lies in 
such a position as to prevent actin-myosin binding. Troponin C can be thought 
of as the calcium-sensing switch for striated muscle contraction.
In cardiac, as in skeletal muscle, contractile performance is dependent on 
muscle length. In skeletal muscle, the relationship between sarcomere length 
and force development is more-or-less bell-shaped, the optimal force being 
developed at a sarcomere length of about 2.2|im (Gordon, Huxley, & Julian 
1966). In heart muscle the sarcomere length rarely exceeds 2.2-2.4pm; 
connective tissue and titin prevent excessive stretching (Trombitas, Jin, & 
Granzier 1995). There is evidence to suggest that length-dependent force 
generation in cardiac muscle is based primarily on length-dependent changes 
in the interfilamentary separation and crossbridge interaction of actin and 
myosin rather than the degree of longitudinal overlap (Fuchs & Wang 1996). 
Both Ca2+ sensitivity and Ca2+ binding were found to correlate more closely 
with changes in filament separation than with changes in filament overlap. 
This may explain the paradox of increasing tension as the degree of 
myofilament interdigitating overlap decreases with stretch.
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Ischaemic Contractile Failure
Contraction is reduced or abolished in ischaemic myocardium (Lee & Allen 
1991). In whole animal experiments acute ischaemia causes a marked decline 
in contractile function within one minute and almost complete contractile 
failure within 5 minutes (Braunwald & Rutherford 1986; Dobson & Mayer 
1973). Perhaps the most striking example of this in clinical practice can be 
seen during stress echocardiography where regional wall motion 
abnormalities develop within minutes of ischaemia (Picano et al. 1994). The 
mechanism of ischaemic contractile failure has been investigated from the 
biochemistry of contractile proteins in vitro to positron emission spectroscopy 
in vivo. Ischaemia is thought to result in hypoxia, reduced delivery of 
carbohydrate and fatty acid energy sources, depletion of high energy 
phosphate compounds and an accumulation of potentially harmful low energy 
phosphates and protons (Dobson & Mayer 1973). Contractile dysfunction is 
not simply due to an alteration in the calcium transient. Indeed, in early 
ischaemia the calcium transient may show an increase in peak calcium 
concentration. Creatine phosphate may be the form in which high-energy 
phosphates are transported from mitochondria to the sarcomere (Jennings & 
Reimer 1991). The onset of ischaemic regional contractile dysfunction 
appears to be better matched temporally to the rapid loss of myocardial 
creatine phosphate than to that of ATP (Camacho et al. 1988; Hearse 1979). 
This could explain why total cell ATP concentrations can be high but at the 
same time ATP availability to the contractile proteins from the creatine 
phosphate buffer system may be low. With consumption of ATP, inorganic 
phosphate accumulates and this is associated with a reduction in contractile
force for a given concentration of calcium (Korge, Byrd, & Campbell 1993).
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Anaerobic metabolism results in intracellular acidosis, a known cause of 
contractile failure in single cells (Eisner et al. 1989; Poole-Wilson 1978). It is 
known that intracellular pH in myocytes can fall from 7.0 at rest to 6.2 during 
acute ischaemia. In an acidic environment the free energy of hydrolysis of the 
remaining ATP is reduced (Sata et al. 1996). The early phase of contractile 
failure is temporally associated with an increase in intracellular acidosis and 
an accumulation of inorganic phosphate. Early contractile failure precedes 
significant changes in the adenosine triphosphate and creatinine buffering 
systems (Bittl, Balschi, & Ingwall 1987; Marshall 1988). There is increasing 
evidence that in acidic conditions cardiac TnC is less sensitive to calcium and 
this may explain the early decoupling of the calcium transient from mechanical 
contraction (Orchard & Kentish 1990; Metzger et al. 1993).
Response to Ischaemia is Dependent on Contractile Protein Isoform 
Expression.
If the early decoupling of the calcium transient from mechanical contraction is 
related to contractile protein pH dependent calcium sensitivity then is there 
evidence that different isoforms confer differing characteristics? In adult dog 
hearts a reduction in pH from 7.0 to 6.5 induces a 0.4 pCa unit rightward shift 
in the relationship between pCa and myofibrillar adenosine triphosphatase 
activity. However, perinatal dog hearts are resistant to the effects of acidosis 
(Solaro et al. 1986). In neonatal rat ventricular muscle, acidosis caused a 
significantly smaller fall in tension development when compared with adult rat 
ventricular muscle (Solaro et al. 1988). Replacement of the slow skeletal Tnl
present in rat neonatal myofibrils with cardiac Tnl restores pH sensitivity
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(Martin et al. 1991). In rat hearts, slow skeletal Tnl is present for up to 3 
weeks after birth (9 months in humans) (Kitsis & Scheuer 1996). There is an 
increased sensitivity of 5-day-old rabbit hearts to calcium when compared to 
22-day-old rabbit hearts. The troponin T isoform differs between the two 
groups (McAuliffe, Gao, & Solaro 1990). These studies suggest that in adult 
myocardium, alteration of contractile protein isoforms may affect contractile 
response to some components of ischaemia. This raises the possibility of 
manipulating contractile protein isoform expression as a means of attenuating 
the adverse effects of ischaemia on the force of myocardial contraction.
Structure and Function of TnC
Troponin C has two isoforms, fast sTnC and slow cTnC (Parmacek & Leiden 
1991). Both are found in skeletal muscles but only cTnC is found in cardiac 
muscle. The primary amino-acid sequences are known with sTnC being 160 
amino-acids long and cTnC 161 amino-acids long (van Eerd & Takahashi 
1975). There is a distinct gene for each isoform (Gahlmann & Kedes 1990; 
Parmacek & Leiden 1989). The three dimensional structure of sTnC has been 
defined (Satyshur et al. 1988; Shaw & Sykes 1996). It is a dumbbell shaped 
molecule 75A long with the N-domain separated from the C-domain by a 31 aa 
alpha-helix. The C terminal binding sites are non-selective and can bind Ca 2+ 
or Mg2+ with high affinity (Szczesna et al. 1996). In sTnC two sites in the N- 
domain have relatively low affinity but bind calcium specifically. These 
correspond to the sTnC calcium regulatory sites. In cardiac troponin C, site I 
in the N domain does not bind calcium. Cardiac troponin C contains a single
N-terminal Ca2+ binding site corresponding to site II in the sTnC molecule
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(Rao et al. 1995). According to the model proposed by Herzberg and James, 
when calcium binds to the N-domain there is a conformational change where 
helices B and C are thought to move away from A and D and expose a 
hydrophobic pocket, possibly providing a binding site for Tnl (Herzberg, Moult, 
& James 1986; Gange et al. 1994; Grabarek, Tao, & Gergely 1992). Calcium 
binding in the N-domain causes a conformational change in the C-domain, 
reduces the rate of dissociation of Ca2+ from, and thereby enhances the 
affinity for, the C-domain Ca2+-Mg2+ sites (Grabarek, Leavis, & Gergely 1986; 
Wang, Leavis, & Gergely 1983). There is a co-operative effect of the N- 
domain calcium binding on the C domain interaction with TnT and Tnl such 
that the other subunits move relative to TnC. The tail of TnT, which lies 
parallel with tropomyosin, moves. Tropomyosin moves relative to the axis of 
the actin filament exposing the myosin-binding site on the actin molecules 
(Lehman, Craig, & Vibert 1994). Interestingly, mutants created to test this 
model were exchanged into skinned fibres and were shown to decrease the 
Ca2+ concentration required for tension activation (da Silva et al. 1993). 
Calcium occupancy of the specific calcium binding site(s) in TnC strengthens 
the binding of TnC with Tnl, thereby decreasing the negative interaction of Tnl 
with actin/tropomyosin. These findings are consistent with the concept that 
TnC is the calcium sensitive switch of the troponin trimer, interacting with Tnl 
and TM to allow crossbridge formation between actin and myosin.
Functional Differences Between TnC Isoforms.
The two isoforms of TnC have been shown to have different physiological 
characteristics. Biochemical experiments with dog cardiac myofibrils found the
magnesium-adenosine triphosphatase activity of troponin/tropomyosin-free
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myofibrils to be independent of pCa and unaffected by a reduction of pH from 
7.0 to 6.5. The affinity of myofibrillar troponin C for calcium decreased as pH 
was reduced from 7.0 to 6.5 and to 6.2. It was concluded that the mechanism 
responsible for deactivation of adenosine triphosphatase activity of cardiac 
myofilaments in acidic pH is related to a reduction in the affinity of myofibrillary 
troponin C for calcium (Blanchard & Solaro 1984). This finding led to 
experiments designed to determine the relative sensitivities of different 
troponin C isoforms to reductions in pH. Myocardial trabeculae from Syrian 
hamsters had their cTnC chemically extracted and replaced with sTnC (Babu, 
Scordilis, Sonnenblick, & Gulati1987). In these experiments, permeabilisation 
of myocardial trabeculae was achieved using Lubrol-WX detergent. Extraction 
of TnC was achieved by repeated immersion in a rigor solution containing 
5mM EDTA and 10mM imidazole at pH7.2. The physiological consequences 
were investigated by means of conventional pCa-Force and pSr-Force 
relationships of reconstituted trabeculae. Cardiac TnT is more readily 
activated by strontium than sTnC. Cardiac muscle reconstituted with sTnC 
could reach its original level of cardiac tension. The pSr-Force relationship 
was shifted to the right as in skeletal muscle. Skeletal TnC could confer some 
physiological properties of skeletal muscle on heart tissue. However, the 
possibility that sTnC may preserve cardiac contractile function in conditions of 
acidosis was not tested in this preparation.
The first study to look specifically at the functional differences of sTnC 
expression in myocardial cells was by Metzger (Metzger et al. 1993). It was 
known that depressed contractility secondary to acidosis was more marked in 
cardiac muscle than in skeletal muscle. Therefore a transgenic mouse
expressing sTnC in myocardium under a a-myosin heavy chain promoter was
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produced. Of three independent lines produced, only one was investigated. 
Although northern blot analysis was used to prove gene expression, the 
possibility of functional change caused by insertional mutagenesis was not 
excluded. Single cells were selected for investigation only if they did not 
contract when exposed to a pSr of 5.0, indicating a relative predominance of 
sTnC in their response. The ratio of cTnC:sTnC in these single cells was not 
specified. Nevertheless in conditions of acidosis, as may occur in ischaemic 
myocardium, there were significant differences between transgenic single 
myocytes and controls. Tension-pCa curves were plotted for both groups. 
When pH fell from 7.0 to 6.2 the change in pCaso (reduction in calcium 
sensitivity) was significantly less in the transgenic cells expressing sTnC than 
in controls. The authors concluded that sTnC could remain functional in 
conditions of acidosis that significantly impair cTnC.
Using skinned psoas muscle it was demonstrated that replacing cTnC in slow 
fibres with fast sTnC decreased pH sensitivity. The reciprocal result was found 
in exchanging sTnC for cTnC in fast twitch fibres (Metzger 1996). 
Interestingly, four animals were used as a control group to show that the 
extraction process did not have a significant effect on baseline calcium 
sensitivity. It should be noted that extraction of the endogenous TnC was of 
the order of 70% and that this data represents a mixture of the isoforms in 
fibres. The altered group of n=8 was compared against a notional control of 
zero change rather than against the actual control group. The effect on 
diastolic function was not specified. Skeletal TnC did not improve calcium 
responsiveness of myocytes at pH 7.0. Its potential to act as a calcium 
sensitiser in ischaemic myocardium was not investigated. In another study 
employing skinned psoas muscle preparation, an ^KGKSEEE94 deleted sTnC
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mutant showed higher calcium sensitivity than normal sTnC. The effect of 
acidosis was not tested (Gulati et al. 1992). It is not known if expressing this 
mutant gene in whole heart preparations would have a positive inotropic 
effect. From the transgenic studies of Metzger and the TnC replacement 
studies in isolated muscle, it would appear that TnC isoform has a significant 
influence on muscle contractile response to acidosis. Of particular importance 
is that sTnC expression in cardiac muscle could confer a potentially beneficial 
resistance to acidosis in vivo. It has not been determined what effects other 
components of ischaemia may have on such tissue in vivo.
The Interactions with Other Subunits 
Troponin I Isoforms
When cellular calcium levels are low, Tnl interacts with and inhibits actin- 
myosin crossbridge formation. Cardiac Tnl differs from skeletal Tnl in that it 
has a 27-33 amino-acid long N-terminal extension which when 
phosphorylated results in a lowering of the TnC regulatory site II affinity for 
calcium (Guo et al. 1994). Phosphorylation of cardiac Troponin I increases the 
rate of cardiac muscle relaxation and reduces calcium sensitivity (Dohet et al. 
1995; Zhang et al. 1995).
Troponin T Isoforms
Rabbit ventricular muscle can express at least four troponin T isoforms. Their 
distribution changes with development. There is some evidence to suggest
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that the pCa-force characteristics of rabbit myocardium can be affected by the 
troponin T isoform (Nassar et al. 1991). TnT has no known calcium binding or 
phosporylation regulatory sites. Ischaemic injury can change the 
immunoreactivity of troponin T. This may be as a result of calcium-dependent 
activation of both calpain proteolysis and transglutaminase cross-linking 
(Gorza et al. 1996).
Myosin Isoforms
Transgenic Mice expressing fast muscle-specific myosin light chain in the 
ventricle showed reduced left ventricular contractility and relaxation (Gulick et 
al. 1997).
Regulation of Contractility
Calcium release and uptake is closely regulated by G protein-coupled beta- 
adrenergic receptors through the action of the second messenger cAMP. An 
increase in cAMP level leads to phosphorylation of key regulatory proteins 
affecting intracellular Ca2+ homeostasis. In particular, phospholamban 
phosphorylation decreases its inhibitory effect on the sarcoplasmic reticulum 
ATPase (SERCA). This results in SERCA pumping more calcium into the SR 
during diastole and an increase in SR calcium release during subsequent 
systole. The increased calcium release is associated with an increased force 
of contraction. Myosin phosphorylation enhances the calcium responsiveness 
of the cardiac contractile proteins (Morano et al. 1985). Myosin
phosphorylation is increased by cAMP in response to beta-adrenergic
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stimulation. This may explain why adrenaline increases the rate of crossbridge 
cycling independently of the degree of activation of contractile proteins by 
calcium (Saeki et al. 1990). In the heart the predominant adrenergic receptor 
is the beta 1-adrenergic receptor. The beta-adrenergic receptors themselves 
are regulated by a set of specific kinases, termed the G-protein-coupled 
receptor kinases (Ben-Yehuda & Rockman 1996). In an interesting series of 
experiments, transgenic mice over-expressing the human beta2-adrenergic 
receptor showed enhanced contractility as measured by an elevated LV 
d P / d t max (Miliano, Allen, & Rockman 1994).
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Calcium Sensitising Drugs Show Promise.
There has been interest in compounds which sensitise the contractile 
apparatus to the effect of calcium. For a given calcium transient, such 
compounds would have the potential to increase force of contraction and 
thereby act as positive inotropes. Theoretically, a calcium sensitising 
compound may have a neutral effect on contractility but be associated with 
comparatively less calcium shuttling and consequently less oxygen 
consumption. Inotropes which increase intra-cel I ular calcium have been 
associated with premature death in patients with heart failure (Packer et al.
1991). A positive inotrope, which reduced oxygen consumption without 
increasing intracellular calcium shuttling, would be an attractive treatment in 
both heart failure and ischaemic heart disease. In a rat model of endotoxic 
shock, the sensitivity of cardiac contractile proteins to calcium is decreased. 
This abnormality was reported to be reversed by the calcium sensitising drug 
MCI-154 (Ming et al. 2000). MCI-154 has been shown to increase cardiac 
output whilst decreasing relative myocardial oxygen consumption in patients 
with coronary artery disease. However, in patients with chronic heart failure, it 
had a neutral effect with no symptomatic or mortality effect (Takaoka et al.
1997).
Levosimendan binds to cTnC and can improve both systolic and diastolic 
contractile function (Sorsa et al. 2000). Levosimendan exhibits inotropic 
effects as a calcium sensitiser. Levosimendan has been tested in two clinical 
trials the preliminary results of which have been reported in abstract form. It 
has been employed in patients with low-output failure (LIDO, or Efficacy and
Safety of Intravenous Levosimendan in Severe Low-Output Heart Failure,
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trial) and patients with heart failure following myocardial infarction (RUSSLAN, 
or Randomized Study on Safety and Effectiveness of Levosimedan in Patients 
with Left Ventricular Dysfunction after an Acute Myocardial Infarction, trial). In 
the LIDO trial, levosimendan was compared with dobutamine during a 24-hour 
treatment period in 203 patients with low cardiac output and decompensated 
heart failure (Follath F et al. 1999). The primary end point was defined as the 
proportion of patients in each treatment group showing improved 
haemodynamic response at 24 hours and no need for other “rescue” therapy. 
The preliminary results of this study indicate that levosimendan was more 
effective than dobutamine in achieving the primary end point (28% vs. 15%). 
Surprisingly, after 6 months, mortality for patients receiving dobutamine was 
38%, compared with 27% for those treated with levosimendan. Levosimendan 
also resulted in more out-of-hospital days at 1-month follow-up. 
Levosimendan has an energetically favourable short-term profile in the 
treatment of congestive heart failure. It enhances cardiac output without 
oxygen wasting, particularly by improving efficiency in the right ventricle 
(Ukkonen et al. 2000). The RUSSLAN trial evaluated the effects of 
levosimendan versus placebo in 504 patients with decompensated heart 
failure following acute myocardial infarction (Moiseyev et al. 1999). Patients 
were evaluated for up to 14 days following therapy. The study results revealed 
a significant reduction in the combined risk of death and worsening failure 
during the first 24 hours following randomisation (P =0.044). All-cause 
mortality after 14 days was also significantly lower in the levosimendan- 
treated patients (11.4% vs. 19.6%, P  =0.029). Patients treated with a higher 
dose of levosimendan (0.4 pg/kg/min) showed a trend toward higher incidence 
of ischaemia and hypotension. Calcium sensitisers may generate force with 
smaller amounts of Ca2+ by increasing the responsiveness of myofilaments to
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Ca2+. They have the potential to cause diastolic dysfunction but whether this 
will be clinically significant remains to be determined. Pure calcium sensitisers 
may be inotropic without being arrhythmogenic (Kawai, Lee, & Orchard 2000).
Troponin C as a Therapeutic Candidate
Troponin C is an attractive candidate for therapeutic intervention. When 
myocardium becomes ischaemic there is rapid reduction in intracellular pH. 
The function of cardiac troponin C is significantly affected by intracellular 
acidosis and is in part responsible for the early decoupling of the calcium 
transient and contractile dysfunction. In comparison sTnC is relatively 
unaffected by moderate degrees of intracellular acidosis. By displacing a 
proportion of the cardiac troponin C with the skeletal isoform, there would be 
the possibility of rendering cardiac muscle relatively resistant to the effects of 
intracellular acidosis. Perhaps such altered myocardium would be able to 
contract for longer in conditions of ischaemia. There is however, a possibility 
of a relative increase in calcium sensitivity at lower pH leading to adverse 
effects on myocardial relaxation. Other limiting factors may be a further 
decrease in intracellular pH, an increase in free inorganic phosphate, a 
change in intracellular calcium homeostasis and possibly a pro-arrhythmic 
effect.
Troponin C isoform mutants could be used as calcium sensitising agents, 
thereby increasing the force of contraction for a given amount of calcium 
released by the sarcoplasmic reticulum (Gulati, Babu, Su, & Gulati 1992).
Perhaps more importantly, such calcium-sensitising troponin mutants may
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result in a normal force of contraction but a reduction of SR calcium release 
during each calcium transient. A reduction in the calcium released from the 
sarcoplasmic reticulum during the calcium transient would be expected to 
reduce the energy required to pump calcium back into the sarcoplasmic 
reticulum. This would have the potential of maintaining normal cardiac 
function but reducing the energy require for each contraction, increasing 
contractile efficiency and reducing oxygen demand.
Other Potential Therapeutic targets 
Sarcoplasmic Reticulum Calcium ATPase.
In heart failure, there is abnormal calcium handling within myocytes consistent 
with a reduction in SERCA activity. SERCA function is modulated by 
phospholamban. In its dephosphorylated state, phospholamban inhibits 
SERCA function. In heart failure, the apparent reduction in SERCA activity is 
a result of a down regulation in SERCA expression and a relative increase in 
dephosphorylated phospholamban. This imbalance could be improved by 
either increasing SERCA expression or increasing the proportion of 
phospholamban in its phosphorylated state (Chossat et al. 2001). This 
hypothesis has been tested in myocytes isolated from patients with end stage 
heart failure. An adenoviral vector was employed to cause over-expression of 
the gene for SERCA2a. Improvements were found in parameters of both 
contraction and relaxation (del Monte et al. 1999). Similar desirable effects 
were found in the whole heart physiology of aging rats (Schmidt et al. 2000).
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Phospholamban
In its dephosphorylated state, phospholamban modulates sarcoplasmic 
reticulum calcium sequestration by inhibiting SERCA (Davia et al. 1999). 
Increasing expression of phospholamban is likely to have detrimental effects 
on contractile function and has been found to result in premature death in 
transgenic mice (Dash et al. 2001). This finding may be explained by 
enhancement of adrenergic tone. Over expression of a phospholamban 
mutant which acts physiologically as a phosphorylated wild type molecule 
would have the potential to enhance the function of endogenously expressed 
SERCA. The phospholamban Ser(16) amino-acid residue has been identified 
as a potential target (Chu et al. 2000).
Apoptosis and Bcl-xL
In severe heart failure, there is evidence of myocytes loss secondary to 
programmed cell death (apoptosis). Bcl-xL is an anti-apopototic molecule 
which if up-regulated would have the potential to reduce the loss of viable 
cardiac myocytes by apoptosis and may slow the progression of heart failure 
(Bartling et al. 1999; Latif et al. 2000; Milting et al. 1999)
A downstream signalling molecule of insulin-like growth factor-1 (IGF-1) has 
been shown to reduce the rate of apoptosis in isolated cardiac myocytes.
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Expression of activated forms of either PI 3-kinase or Akt in cardiomyocytes 
was sufficient to inhibit hypoxia-induced apoptosis in vitro (Matsui et al. 1999).
Vascular Endothelial Growth Factor (VEGF)
There is increasing interest in using Vascular Endothelial Growth Factor 
(VEGF) to improve the blood supply of ischaemic myocardium which is 
unsuitable for either PTCA or coronary artery bypass grafting (Byun et al. 
2001; Su, Lu, & Kan 2000; Tanaka et al. 2000). Unfortunately at present there 
is no known pharmacological method for increasing endogenous production of 
VEGF. Attempts have been made to infuse the gene product, but the most 
impressive results have been with gene transfer methods. In a small pilot 
study of only five patients, plasmid DNA encoding VEGF (phVEGF165) was 
introduced into ischaemic myocardium by direct needle injection at mini­
thoracotomy. These patients had been selected because they remained 
severely limited by angina and were unsuitable for conventional treatment 
either by PTCA or coronary artery bypass surgery. In this group, objective 
evidence of ischaemia was documented using dobutamine single photon 
emission computed tomography (SPECT)-sestamibi imaging in all patients. 
More importantly, all patients had a significant improvement in their anginal 
symptoms (Losordo et al. 1998). This led to a phase one clinical trial in 20 
patients with two different doses of plasmid DNA (Symes et al. 1999). In this 
group, all patients had class III or IV angina. Similarly impressive results were 
achieved with significant symptomatic improvement in patients with 
“inoperable” coronary artery disease. An adenoviral vector encoding a 
different vascular endothelial growth factor (VEGF121) has been used as sole
therapy in a group of six patients with angina (Rosengart et al. 1999).
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Treadmill exercise assessment suggested improvement in most individuals. 
However, no long-term safety data are available for any of these studies and 
clinical trials are ongoing. It is important to note that these small studies were 
open label studies and it is possible that a placebo effect may have 
contributed to the subjective improvement in some patients. A blinded 
randomised study would be required to exclude this possibility. Other growth 
factors with potential to improve the vascularisation of ischaemic myocardium 
are under investigation. In a pig model of stress-induced myocardial 
ischaemia, intracoronary injection of a recombinant adenovirus expressing 
human fibroblast growth factor-5 (FGF-5) was associated with improved blood 
flow and histological evidence of angiogenesis (Giordano et al. 1996). Others 
have been investigating the potential of FGF-1 (Schumacher et al. 1998).
Transforming Fibroblasts into Striated Muscle Cells.
Following a myocardial infarction, an akinetic scar containing non-contractile 
fibroblasts replaces the dead myocytes. There is interest in molecular 
methods of transforming these fibroblasts into contractile cells and possibly 
improving ventricular systolic function. The gene MyoD plays a role in 
establishing and/or maintaining the differential phenotype of adult fast skeletal 
muscle fibres (Metzger, Rudnick, & Westfall 1995). An adenovirus expressing 
MyoD can cause cultured cardiac fibroblasts to express contractile proteins 
(Murry et al. 1996). Although embryonic skeletal MHC expression has been 
achieved in an in vivo model, myogenic conversion of infarcted myocardium 
has not yet been shown. In clinical practice, transformation of a proportion of
fibroblasts into contractile cells in vivo would be of little benefit if they remain
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electrically isolated from normal myocardium by surrounding fibroblasts. There 
would remain the difficulty of co-ordinating contraction of these cells with the 
contraction of healthy myocardium. Should the electrical coupling become 
possible, there would be the risk of arrhythmogenesis occurring at the 
interface of slow and fast conduction.
Gene Therapy for Arrhythmias
Genetic manipulation of cardiac excitability may be possible (Johns et al. 
1995; Lawrence et al. 1995). In a canine model of heart failure, single cells 
show altered electrical properties when exposed to an adenovirus expressing 
potassium channels (Nuss et al. 1996). The exposed myocytes showed 
shortening of the action potential duration. Some arrhythmic deaths are the 
result of single gene defects (Baroudi & Chahine 2000; Schwartz et al. 2001). 
The possibility of correcting such defects by gene transfer methods is 
attractive. However, methods such as direct needle injection as used in the 
VEGF studies would be inappropriate in this situation. Correction of a small 
part of the myocardium may lead to heterogeneity of regional refractory 
periods. Regional differences in the refractory period may lead to re-entry 
circuits with the potential for a pro-arrhythmic effect. To avoid this problem, a 
method of homogeneous gene transfer would be required.
Antisense DNA
Antisense DNA techniques, through a number of mechanisms, can effectively 
down regulate the expression of target proteins. It is possible to design a
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sequence of DNA that is complementary to the messenger RNA of an 
unwanted gene. On expression of this DNA sequence, the target gene 
expression is blocked at the level of mRNA. One potential application for this 
technology is in coronary artery re-stenosis following PTCA. It has been 
demonstrated that antisense c-myc oligonucleotides can inhibit arterial 
smooth muscle cell accumulation in a rat carotid artery injury model (Bennett 
et al. 1994; Simons et al. 1992). More recently, antisense DNA methods have 
been used in a rat model of hypertension to reduce expression of cardiac 
betal-adrenegic receptors (Zhang et al. 2000). The result was a significant 
anti-hypertensive effect that persisted for more than 18 days.
If a large number of candidate genes are to be tested for their potential as 
therapeutic targets then efficient in vitro and in vivo methods of gene transfer 
and control will be required. Methods of controlling gene expression in tissues 
ranging from single cells to whole organs need to be developed. Genetically 
manipulated mice have been used to over-express and under-express genes. 
The development of transgenic mouse lines is both time-consuming and 
expensive. There are established models of rhythm disturbance and heart 
failure in rabbits and dogs. These animals have a longer gestation period than 
mice and are therefore unattractive candidates for the production of 
transgenic lines. There is a need for gene transfer methods to such animals. 
Such methods are likely to prove a powerful tool in the evaluation of potential 
therapeutic targets.
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Gene Transfer Methods
Introduction
To investigate the potential physiological benefits of controlling target gene 
expression, methods of introducing genes of interest into cells are required. 
The perfect vector for this purpose would be simple and inexpensive to 
construct. It could accommodate large DNA sequences. It would transfect 
cells efficiently both in vitro and in vivo. It would have a low potential of 
provoking a host immune response and would integrate the desired DNA 
sequence into the host genome in a precise manner. Long-term and tissue 
specific gene expression would also need to be possible. Unfortunately, such 
a vector does not yet exist.
Plasmid DNA
Direct needle injection of plasmid DNA into muscle results in up-take of a 
proportion of the DNA into a small number of surrounding cells, including 
myocytes. This is true both for skeletal muscle and cardiac muscle. DNA is 
absorbed into typically 100-200 surrounding cells by a process of endocytosis. 
The DNA remains epichromosomal and the duration of expression of foreign 
gene is about 2-3 months. Plasmid DNA is easily produced using bacterial 
cultures. Commercially available plasmids make incorporation and 
manipulation of DNA sequences inexpensive. Direct needle injection of 
plasmid DNA is suitable for large and small animals alike. However, direct
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needle injection of DNA is an inefficient means of delivering genes of interest 
and invariably results in tissue damage along the needle track. Nevertheless, 
it is a method which has been used to study the characteristics of gene 
promoters for their tissue specificity and hypoxic responsiveness, and remains 
a valuable tool for this purpose (Prentice et al. 1997). In a gene therapy 
context, it has potential where the gene of interest is a chemo-tactic molecule 
such as in VEGF or is hormonal such as erythropoeitin. However, direct 
injection of plasmid DNA would not be appropriate where the application 
required homogenous gene expression throughout an entire organ (Acsadi et 
al. 1991; Prentice et al. 1997; Wolff et al. 1992).
Replication Deficient Adenoviral Vectors.
Adenoviral vector mediated gene transfer to the heart was first demonstrated 
by Stratford-Perricaudet. Replication deficient adenoviral vector encoding 
beta-galactosidase was injected intravenously. Gene product became 
detectable in a small proportion of myocytes (Stratford-Perricaudet et al.
1992). Adenoviruses are a family of viruses (over 40 serotypes) that cause 
benign respiratory tract infections in humans. A benign clinical profile is 
expected, based on their long-term use as a vaccine for adenovirus 
respiratory tract infections by the US Army (Takafuji, Gaydos, & Allen 1997). 
Adenoviruses are non-enveloped icosahedral double-stranded DNA viruses. 
They gain entry into cells by receptor-mediated endocytosis via the coxsackie 
receptor (Roelvink et al. 1998). Adenoviral vectors which can gain entry to 
cells without the need for a coxsackie receptor are under development. These 
may have an application in cancer gene therapy where target cells may not
express coxsackie receptors (Krasnykh et al. 2000).
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The pathological effect of adenoviruses is due to the host mediated 
inflammatory responses and to the lysis of infected cells as viral replication 
proceeds. Viral replication takes place in the nucleus of the host cell without 
integration into the host DNA (Schneider & French 1993). The adenoviral 
genome is about 36Kb long with the E1 region being essential for viral 
replication. Replication deficient viruses can be produced by replacing the E1 
region of the viral genome with a gene of interest (Hitt et al. 1995; Wilson 
1996). The virus is then amplified in a permissive E1-expressing human 
kidney 293 cell line. The resulting vector is capable of infecting a broad range 
of cell types. However, in the absence of E1 gene products, the virus cannot 
replicate. Theoretically, such a replication deficient virus would not cause lysis 
of infected cells. Nevertheless, the viral capsid and other viral gene products 
have the potential to provoke an immune response. As wild-type viruses are 
ubiquitous, the possibility of recombination of wild type virus with replication 
deficient vectors exists. There is a possibility of a foreign gene of interest 
“escaping” from a replication deficient virus into a replication competent wild- 
type virus through a process of homologous recombination. Interestingly, 
some cells which have been infected with the Ebstein-Barr virus have been 
found capable of sustaining chronic infection of both replication competent 
and replication incompetent adenoviruses (Horvath et al 1991).
E1 deleted adenoviral vectors are limited to an insert capacity of 8Kb. An 
adenoviral vector has been developed which has almost all viral coding 
sequences removed (E1,E2,E3 and E4) and can carry an expression cassette 
of more than 28Kb (Kochanek et al. 1996).
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Duration of Reporter Gene Expression
Although long-term gene expression in heart muscle was reported following 
simple intravenous injection of adenovirus (Stratford-Perricaudet, Makeh, 
Perricaudet, & Briand. 1992), this has not been found in subsequent 
experiments involving arterial injections. In direct-injection or catheter- 
mediated delivery into heart muscle, expression was detectable within 3 days 
(Guzman et al. 1993; Li et al. 1995). However, by day 21 not only was the 
reporter gene beta-galactosidase not detectable but neither was the reporter 
gene cDNA. In adenovirus-mediated gene transfer the adenoviral DNA 
remains epichromosomal and would be vulnerable to intracellular 
mechanisms of DNA clearance. However, a more likely explanation for 
transient gene expression following adenoviral-mediated gene transfer is an 
inflammatory response. Both humoral and cell-mediated responses have been 
described. Pre-immunisation of rats to a beta-galactosidase expressing 
adenovirus reduced the expression duration of the reporter gene from 21 days 
to 6 days. However, neonatal intrathymic injection of vector induced long-term 
beta-galactosidase expression for more than 2 months after direct ventricular 
injection (Gilgenkrantz et al. 1995). Intrathymic injection in early development 
could allow the host immune system to recognise the adenoviral vector 
antigens as self. The finding of Gilgenkrantz et al supports the hypothesis that 
the host immune system can limit duration of foreign gene expression 
following adenoviral vector mediated gene transfer. These studies suggest 
that the immune response to adenoviral-infected cells is at least in part 
antibody mediated. There is strong evidence to suggest that the early 
inflammatory response to cells infected by adenovirus is cell-mediated (Yang 
et al. 1994). Both adenovirus-specific proliferative CD4+ T cells and CD8+
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cells are implicated (Flomenberg et al. 1995; Flomenberg et al. 1996). Host 
immunosuppression prolongs the therapeutic effect of adenovirus-mediated 
gene expression (Fang et al. 1995).
Although adenoviral vectors deleted for all viral coding sequences result in 
extended expression of their transgenes, the E3 region of wild type 
adenovirus has been implicated in evading host defences and may be a 
desirable component of an adenoviral vector (Bennett et al. 1999; Gooding et 
al. 1988; Morsy et al. 1998). Gene Products encoded in the E3 region can 
interfere with MHC expression within infected cells and reduce the potential 
for a cell-mediated inflammatory response. The presence of the E3 region has 
been found to render infected cells less susceptible to the effects of TNF- 
alpha (Gooding et al. 1988). The mechanism for this effect is poorly 
understood.
Efficiency of Adenoviral Vectors
Adenoviral vectors infect cells by a receptor-mediated process. The efficiency 
of adenoviral mediated gene transfer is at least one order of magnitude 
greater than that for naked plasmid DNA (Guzman et al. 1993; Kass-Eisler et 
al. 1993).
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Cationic Liposomes
Cationic liposomes are positively charged artificial lipid vesicles that 
incorporate negatively charged DNA and deliver nucleic acid to cells through 
fusion with cell membranes. They are more efficient at transfecting cells than 
naked plasmid DNA. However, they are inefficient when compared with 
adenoviral vectors but have the advantage that they are not thought to be 
immunogenic in themselves. Cationic liposomes have been used in 
preliminary clinical studies of gene therapy in cystic fibrosis (Caplen et al. 
1995). In dogs, gene transfer to the coronary circulation has been achieved 
using a porous perfusion balloon catheter system in the coronary artery 
(Chapman et al. 1992). Cationic liposomes have been used to introduce 
foreign genes to rabbit myocardium via the coronary circulation. By this route 
they have been associated with micro-infarction (Wright et al. 1998). Cationic 
liposomes have been successfully employed in gene transfer to peripheral 
arteries (Takeshita et al. 1994).
Vaccinia Vectors (Pox viruses)
Pox viruses have been used extensively in smallpox vaccination. They are 
186 Kb DNA viruses with a double envelope. Their DNA remains in the 
cytoplasm and the risk of insertional mutagenesis is thought to be low. 
Poxviruses have not been successfully used to achieve foreign gene 
expression in myocardium but have mainly been used in cancer gene therapy 
(Peplinski, Tsung, & Norton 1998).
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Retroviral Vectors.
The first retroviral gene-transfer vector was described in 1981 (Wei, Gibson, & 
Spear 1981) and the first patient treated (for adenosine deaminase deficiency) 
was in 1990 (Anderson, Blaese, & Culver 1990). Retroviruses are diploid 
positive-stranded RNA viruses packaged in a glycoprotein envelope. Using 
reverse transcriptase the RNA is transcribed into DNA, which is pseudo- 
randomly integrated into the host genome. The normal cellular machinery is 
then utilised to make proteins as encoded by the virus. Ischaemic/reperfused 
myocardium has been shown to express recombinant protein following direct 
needle-injection of retroviral vector (Prentice et al. 1996). Gene transfer to the 
arterial wall by retrovirus has resulted in gene expression for more than 5 
months without the need for immunosuppression (Nabel, Plautz, & Nabel 
1990). However, compared with adenoviral vectors, infection efficiency is low 
and it is more difficult to produce high titre vector (Flugelman et al. 1992). 
However, for genomic integration the target cells must divide. This limits their 
use in the myocardium as cardiomyocytes are terminally differentiated and do 
not undergo mitosis (Miller, Adam, & Miller 1990). This is true for first 
generation murine leukaemia viruses. However, lentiviruses do not require cell 
division for genetic integration (Goldman et al. 1997). Insertional mutagenesis 
of the viral DNA has the potential to cause a tumorigenic event and safety 
concerns have been raised. A retroviral vector has been successfully 
employed to improve the lipid profile of patents with homozygous familial 
hypercholesterolaemia by corrective gene transfer to hepatocytes (Grossman 
et al. 1995).
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Herpes Virus Vectors
Herpes virus vectors are large enveloped double-stranded DNA vectors that 
are capable of infecting myocytes in vivo (Coffin et al. 1996, Wright et al. 
2001). They can accommodate very large foreign DNA fragments and can be 
rendered replication deficient by deletion of immediate early genes (typically 
deletion of ICP27). In infected cells, the episomal viral DNA structure remains 
stable and there is the potential for long-term gene expression. However, it is 
difficult to produce herpes vector with a titre of more than 109 infective 
particles per millilitre. Adenoviral vectors can be propagated to titres of 1013 
pfu/ml and for this reason have been favoured over herpes vectors.
Adeno-associated Viral Vectors.
Adeno-associated virus (AAV) is a 4.7 Kb long single stranded DNA 
parvovirus. It integrates into the host genome and shows a predilection for a 
specific site in chromosome 19. Integration into the host genome can be in a 
site-specific manner (Russell & Hirata 1998). Perhaps the greatest advantage 
of AAVs over adenoviral vectors is that they can efficiently transduce muscle 
fibres in vivo without activation of cellular of humoral immunity (Jooss et al.
1998). No viral genes are expressed and they have the potential to cause 
long-term foreign gene expression (Kaplitt et al. 1996, Lynch et al. 1997). The 
main disadvantage of AAVs when compared with adenoviral vectors is the 
difficulty of producing AAVs at high titre. Systems to produce adeno- 
associated viruses have required potentially contaminating helper adenovirus.
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Methods of improving production efficiency are under investigation (Maxwell, 
Harrison, & Maxwell 1997). As production methods improve, adeno- 
associated viruses are likely to replace adenovirus vectors both as 
investigative tools and for gene therapy applications
Routes of Adenoviral Administration.
Intravenous injection of replication deficient adenoviral vector by Stratford- 
Perricaudet showed that myocardium could take up adenovirus. This is an 
inefficient route when attempting to infect heart tissue as the highest uptake 
was found in the liver and only 0.2% of myocytes expressed the reporter 
gene. Efficiency of gene transfer was greatly improved by selective coronary 
injection. In 1993 Barr et al injected 109-1010 plaque forming units (pfu) of 
adenoviral vector using a selective coronary catheter. They reported peri­
vascular gene transfer and found reporter gene expression in 10%-30% of 
myocytes within the distribution of the injected artery. A co-author has since 
reported that infection of 60% of myocytes has been achieved (Leinwand & 
Leiden 1996). However, these findings have proved difficult to reproduce. 
Indeed, in the six years that followed the original report, no group reported any 
change of myocardial function following gene transfer by this method.
Methods of Gene Transfer to Myocardial Tissue.
Important physiological information can be obtained from investigation of 
single cardiac myocytes. Infection and investigation of single myocytes would
be sufficient to answer important questions for some genes of interest.
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However, transfer to whole organs and investigation of intact live animals may 
be required for other genes. Thus, a variety of gene transfer methods will be 
required.
Cultured Cells
Adult myocytes are difficult to isolate and maintain in culture for gene 
expression studies. They de-differentiate in long-term culture. Adenoviral 
vectors can infect cultured myocytes with high efficiency (Krishenbaum et al. 
1993). Potentiation of p-adrenergic signalling by adenoviral-mediated gene 
transfer has been demonstrated in cultured adult rabbit ventricular myocytes 
(Drazner et al. 1997). Interestingly, adenoviral infection of myocardial cells per 
se has been reported to induce an enhanced sensitivity to p-adrenergic 
agonists by increasing the concentration of the stimulatory G-protein (Novotny 
et al. 1994). Cultured cells can be reliably transfected using a relatively small 
amount of virus. Single cells can be used to investigate intra-cellular 
secondary messenger signalling. Investigation of the electro-physiological 
characteristics of single cells is possible by means of patch clamping. 
However, it is difficult to measure the force of contraction in single cells. 
Studies of the contractile properties of single cardiac myocytes have largely 
been limited to measuring frequency and velocity of contraction and relaxation 
in unloaded systems.
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Cultured Trabeculae
Trabeculae have the advantage over single cells in that they can be readily 
manipulated and attached to force transducers. Small trabeculae can be 
maintained in Ringer solution for extended periods. These preparations are 
suited to the investigation of contractile physiology. The intracellular 
environment of such preparations can be controlled by chemically skinning the 
tissues. By permeabilising the cell membranes, the bathing solution 
surrounding the preparation becomes an extension of the intracellular 
environment. This allows control of all intracellular ions and energy sources. 
Alterations in pH, potassium, lactate, inorganic phosphate and creatine buffer 
can be made to simulate components of ischaemia. The main disadvantage of 
this preparation over a whole heart preparation is that ischaemia is mimicked 
and true ischaemia, either supply or demand, is not possible. Isolated 
trabeculae have been transfected with adenoviral vector and it has proved 
possible to keep such tissue viable for up to 3 days following transfection 
(Janssen et al. 1998).
Isolated Whole Heart Preparations
Ex vivo whole heart physiology can be investigated in Langendorff perfusion 
models. Typically, the whole heart is rapidly removed from a euthanised 
animal and retrogradely perfused by a cannula placed in the ascending aorta. 
In a working heart preparation, control of pre-load, after-load and after-load 
compliance is possible. External pacing can control both atrial and ventricular
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rate. Components of ischaemia can be mimicked by alteration in the 
constituents of the perfusate. Restricting or occluding coronary flow using a 
coronary artery snare can produce true ischaemia. Measurement of force of 
contraction, cardiac output and regional EMG is possible. A Langendorff 
apparatus has been used to transfect rabbit myocardium by re-circulating 
adenoviral vector in a limited volume of perfusate. Donahue et al reported 
highly effective gene transfer to rabbit heart and identified critical parameters 
influencing the efficiency of adenoviral gene transfer. These included the use 
of crystalloid solution as opposed to whole blood; high coronary flow rate; 
exposure time; virus concentration, and temperature. More recently, the same 
group found that decreasing perfusate calcium concentration, or pretreating 
with serotonin or bradykinin, significantly decreased the exposure time 
necessary to achieve widespread infection (Donahue et al. 1997; Donahue et 
al. 1998). The disadvantage of such an approach is that it can take several 
days for foreign gene expression to become detectable. Conventional isolated 
preparations will not continue to contract for several days. One group have 
attempted to over-come this shortcoming by transplanting transfected hearts 
into recipient animals for a period to allow gene expression prior to further 
investigations (Pellegrini et al. 2000).
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Intra-coronary Injection
Using 1x1010 pfu/ml of adenovirus injected into the left coronary artery of 4Kg 
New Zealand white rabbits, 30% of myocytes in the distribution of the 
coronary artery have been shown to express reporter gene (Barr et al. 1994). 
Adenoviral vectors have the potential to induce an inflammatory response. In 
keeping with previous studies no reporter gene expression was evident at, or 
after, day 21. Even though histology was taken at 5 days, 2 weeks, 1 month 
and 2 months, no inflammatory response was noted in any of the hearts 
following intra-arterial adenovirus infusion. This finding remains unexplained. 
In minipigs intracoronary adenoviral vector was delivered at thoracotomy 
using a needle in the circumflex artery. Despite 2x1010 pfu of virus being 
injected, only low-level gene expression was observed in the myocardium 
(Muhlhauser et al. 1996). This was in contrast to the very high levels of gene 
expression found in rabbit. The attraction of the intracoronary injection method 
is that it is minimally invasive and animals can recover, allowing gene 
expression to occur before physiological investigation.
Direct Needle Injection into the Heart.
Direct injection of adenoviral vector into the myocardium results in high levels 
of reporter gene expression when compared with naked plasmid and can be 
achieved in both large and small animal models (Gal et al. 1993; Guzman et 
al. 1993; Lin et al. 1990; Magovern et al. 1996). Unfortunately, tissue damage 
occurs along the needle track, but the extent of inflammation induced by
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adenoviral injection is not significantly different from that induced by injection 
of saline (Li et al. 1995). When direct injection of adenoviral vector was 
performed in models of myocardial infarction, transgene expression was 
restricted to residual cardiomyoctes in the periphery of the infarct area (Leor 
et al. 1996).
Injection of adenoviral vector into the ventricular cavity results in gene 
expression particularly in the heart, intercostal muscles, and thymus. 
Intravenous injection causes significant expression in the liver but is an 
inefficient method of gene transfer to the heart (Huard et al. 1995). It is 
possible to restrict reporter gene expression to the heart by use of a ventricle- 
specific-myosin light chain-2 promoter (Rothmann et al. 1996). Although this 
may result in lower levels of expression than can be achieved using a 
constitutive viral promoter, this may be adequate for application such as 
revascularisation by VEGF expression (Buttrick et al. 1992). For homogenous 
gene transfer to whole hearts a more efficient method of gene transfer would 
be required.
Aortic and Pulmonary Cross-clamp Method
In this approach, a catheter is inserted in the left ventricular apex and 
advanced beyond the aortic valve. A high-concentration adenoviral 
preparation is then injected through the catheter while the aorta and 
pulmonary artery are cross-clamped distal to the catheter tip for a period of 10 
to 40 seconds. In rats this method has achieved grossly homogeneous 
transduction of cardiac myocytes throughout the left and right ventricles of the
heart (Hajjar et al. 1998). More importantly, this technique can produce
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dramatic, transgene-specific physiological effects on ventricular function in 
vivo. The success of this approach likely reflects in vivo optimisation of the 
parameters previously shown to be important for ex vivo gene transfer, as well 
as high-perfusion pressure that presumably allows the opening of capillaries 
and optimises the myocardial area of virus exposure (Donahue et al. 1997). 
By cross-clamping both the pulmonary artery and the aorta, blood return to 
the left ventricle is minimal, and the left ventricular end-diastolic pressure does 
not increase. This allows perfusion of the coronary circulation at relatively low 
downstream pressure, and the endocardium can be efficiently infected. 
Correlates of this method in humans have not yet been established and a 
minimally invasive catheter based method of homogenous gene transfer 
would be preferable.(Hajjar et al. 1998)
Retro-infusion
It has proved possible to transfect myocardium using adenoviral vectors retro- 
infused down the coronary veins. This method has potential for creating 
homogeneous transgene expression in an intact organ but may prove difficult 
where animals are required to recover.
(Boeckstegers et al. 2000)
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Pericardial
Transfection of a thin epicardial layer of heart cells is possible by injection of 
adenoviral vector into the pericardial space. As in transduction of single cells 
in culture, this method has the advantage of long exposure times and requires 
only a small amount of virus (Fromes et al. 1999).
Gene Transfer to Vessels.
In vivo gene transfer to uninjured blood vessels is possible using a replication 
deficient adenoviral vector (Mazur et al. 1994). Using a respiratory syncitial 
virus promoter, peak gene expression occurred on day 7 and was no longer 
evident by day 28 (Lemarchand et al. 1993). Similar results were found in 
balloon injured rat carotid arteries (Landau et al. 1995; Lee et al. 1993).
Gene Transfer of Skeletal Troponin C to Rabbit Myocardium.
Data from transgenic mouse studies and protein substitution studies suggest 
that sTnC may confer advantageous properties to myocardial tissue. These 
include increased calcium sensitivity and relatively preserved contractile 
function in conditions of acidosis. These properties would be particularly 
relevant in the context of ischaemic myocardial dysfunction. It remains to be 
seen if skeletal troponin C confers an advantage in whole heart physiology in 
normal and pathological conditions. In particular, its potential to cause
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abnormal relaxation has not been investigated. It is proposed to develop gene 
transfer methods which will cause skeletal troponin C expression in rabbit 
myocardium and to test the physiological consequences in isolated tissues.
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Chapter 2
Methods
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Adenoviral Vector Production
Materials
Unless otherwise stated, tissue culture media was obtained from Gibco BRL 
(Life Technologies Ltd, Paisley), tissue culture grade chemicals from Sigma 
(Sigma-Aldrich Co Ltd, Irvine) and tissue culture plasticware from Corning 
(Corning Incorporated, Corning, USA). Dishes 140mm x 20mm for large-scale 
viral propagation were obtained from Nunc (Nalge Nunc International, 
Rochester, NY, USA). All solutions used were prepared using microbiology 
grade chemicals and distilled water. After preparation they were sterilised by 
autoclaving or filtration through a 0.22jiM filter. Nobel Agar 3.2% and Tris 
Saline (137 mM NaCI, 2.7mM KCI, 28mM Tris Base; pH 7.4) were stock items 
produced in the Department of Virology, University of Glasgow.
Frozen 239 Cell Stock
Human embryo kidney 293 cells were obtained at passage 28 (Microbix, 
Toronto, Canada). The passage number indicates the number of times the 
cells have undergone subculture since they were originally transformed by 
sheared Adenovirus type 5 DNA (Graham et al. 1977). A 2ml vial of cells was 
taken from storage in liquid nitrogen and rapidly thawed in a water bath at
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37°C. The surface of the vial was then disinfected with 70% ethanol and all 
further procedures carried out within a Class II microbiological safety cabinet. 
Growth Medium (Minimum Essential Medium with Earle’s Salts and 
Glutamine, 10% by volume Foetal Bovine Serum and Penicillin 90 iu/ml, 
Streptomycin 90pg/ml) was used to resuspend the cells. The cells were 
transferred to a sterile tissue culture flask with a surface area of 75-cm2 and 
Growth Medium added to make a final volume of 20ml. After 6 hours of 
incubation (at 37°C, 5%C02) the cells became attached to the flask. The 
Growth Medium was changed to remove the cryopreservative (Dimethyl 
Sulphoxide). After 2-4 days a monolayer of cells typically covered 70-90% of 
the surface area of the tissue culture flask.
Subculture of 293 Cells
The cells were maintained in a subconfluent logarithmic growth phase by 
subculturing every 3-4 days. The cells were detached from the tissue culture 
vessels by washing twice with Citric Saline (135mM KCI, 15mM Tri-sodium 
Citrate) and incubating at 37°C for 5 minutes or until the cells freely detached 
from the surface of the culture vessel. The cells were then dispersed in fresh 
Growth Medium before distribution to three new culture vessels. Cells were 
not used beyond passage 50.
Maintaining Frozen Stocks
At passage 31 a proportion of the cells was refrozen for future use. These 
cells were detached using Citric Saline as above. They were resuspeded in
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Foetal Bovine Serum with 10% Dimethyl Sulphoxide (DMSO). The vials were 
then frozen in a Cryol Freezing Container (Nalgene Nunc, Rochester, NY, 
USA) at -70°C  for 48 hrs. A single vial was thawed and checked for cell 
viability prior to transfer of the remaining vials to liquid nitrogen for long-term 
storage.
Small-scale Propagation of Adenoviral Vectors
Small-scale propagation of adenoviral vectors was undertaken using 60mm 
diameter tissue culture dishes or tissue culture flasks with a surface area of 
175cm2. A tissue culture flasks with a surface area of 175cm2 can grow a 
maximum of 7x107 cells. However, this capacity is only possible if the cells 
are grown as a confluent monolayer. When the monolayer of 293 cells 
reached 70% confluency, the Growth Medium was aspirated and 1ml of Tris 
Saline containing stock adenoviral vector at a multiplicity of infection of 3 
plaque forming units (pfu) per cell was carefully added.
To promote efficient transfection, cells were then incubated at 37°C 5%C02 
for 45 minutes before adding Growth Medium. After 1-3 days, cells infected 
with viral vector exhibited a cytopathic effect, characterised by obvious 
rounding and eventual detachment from the culture vessel. The cells were 
harvested when at least half their number showed evidence of a cytopathic 
effect and before significant numbers spontaneously lysed and lost their viral 
load to the Growth Medium. At this point a cell scraper was used to manually 
detach all cells from the tissue culture vessel. The resuspended cells and 
growth media were transferred into sterile 50ml conical polypropylene tubes
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and centrifuged at 1000 rpm for 10 minutes (Sigma Laborzentrifugen 4K15). 
The supernatant Growth Medium was discarded and the remaining cell pellet 
resuspended in 1 ml of Tris Saline and transferred to 1.5ml Eppendorf tubes. 
The virus within the 293 cells was then released into the Tris Saline by freeze- 
thaw cell lysis. Each Eppendorf tube underwent 3 cycles of freezing on dry ice 
and thawing in a 37°C water bath, vortexing vigorously between cycles. The 
Eppendorf tube was then centrifuged at 6000 rpm for 5 minutes (Biofuge 15, 
Heraeus Instruments, Hanau, Germany) to clarify the supernatant. The 
resulting crude lysate supernatant was then stored at -20°C  or immediately 
further purified using a caesium chloride gradient (see below).
Large-scale Propagation of Adenoviral Vector
Large-scale propagation of adenoviral vector was similar to small-scale 
propagation. However, 14cm diameter dishes were used in place of flasks. 
Seventy such dishes occupy a similar volume to 24 175cm2 flasks and gave 
2.5 times more surface area for cell growth.
Purification by Caesium Gradient
Viral vector was isolated from crude lysate by ultracentrifugation on a 1.3 to 
1.4 g/ml CsCI step density gradient at 100,000 g for 90 min at 4°C. Ultraclear 
centrifuge tubes (Sorval Instruments, Du Pont) were loaded with 2mls of CsCI 
(0.05M Tris containing 4.25M CsCI; pH 7.9). 3mls of CsCI (0.05M Tris 
containing 2.8M CsCI; pH 7.9) was carefully layered on top, followed by 2ml of 
Glycerol (0.1 mM EDTA, Glycerol 40% w/v, 0.01 M Tris; pH7.9) and then finally
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7 ml of crude lysate supernatant and the tube weights balanced with Tris 
Saline before transfer to a TST41 rotor for ultracentrifugation at 25000 rpm for 
90 minutes at 4°C. Following this, a distinct band, containing viral vector, was 
visible in the lowest most layer of the tube with cellular debris apparent above. 
The virus was isolated by puncturing the tube below the band with a 19-gauge 
hypodermic needle and drawing the virus into a 2ml syringe together with the 
surrounding caesium chloride solution. The virus was desalted by dialysis in a 
Collodion bag (Sartorius AG, Gottingen, Germany) against a total of 5L of 
dialysate buffer (0.01 M Tris, 0.001 M EDTA, pH 7.9, 4°C) overnight. The 
desalted virus was then transferred into Eppendorf tubes and stored at -20°C.
Quality Assurance 
Background
For each of the adenoviral vectors used, a H/nDIII restriction enzyme DNA 
fragment pattern was known for the stock vector. Prior to use, all virus 
produced was subjected to restriction enzyme DNA analysis and the pattern 
produced compared with that from the stock vector and with that from 
replication competent wild type virus.
DNA Isolation
To 340jnl of crude lysate supernatant was added, 20pl 100mM EDTA, 20pl 
10% SDS, 20pl Proteinase K (20mg/ml), giving a total volume of 400jnl in a
1.5ml Eppendorf tube. The mixture was incubated at 37°C for at least 4hrs.
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Proteinase K was used to disrupt the viral capsid and the proteins bound to 
the viral DNA. Contaminating proteins and high molecular weight DNA was 
removed by two cycles of phenol extraction. Liquefied Phenol washed in Tris 
Buffer (Fisher Scientific, Loughborough) was added to an equal volume of 
Proteinase K digested lysate. After mixing, the organic and aqueous phases 
were separated by centrifugation at 6000rpm for 10 min (Biofuge 15, Heraeus 
Instruments, Hanau, Germany). The final aqueous phase was drawn off and 
mixed in a fresh Eppendorf tube with an equal volume of chloroform:Iso-amyl- 
alcohol (24:1). Again, the organic and aqueous phases were separated by 
centrifugation and the aqueous phase containing the viral DNA carefully 
drawn off.
Ethanol Precipitation
The aqueous phase containing viral DNA was mixed with 2.5 times by volume 
of absolute alcohol and 0.1 times of 3M Sodium Acetate pH5.4 by volume. 
The DNA was precipitated by cooling to -70°C  overnight and pelleted by 
centrifugation at 15000rpm 4°C, for 10 minutes (Biofuge 15, Heraeus
Instruments, Hanau, Germany). The liquid phase was discarded and the DNA 
pellet allowed to dry for 20 minutes at room temperature before resuspension 
in an appropriate volume of sterile water. For caesium purified virus the 
method of DNA extraction was the same except that only 100pl of virus was 
used and the volume made up to 340pl by addition of 240pl of Tris Saline.
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HinD\\\ Restriction Enzyme Digest
The DNA pellet was dissolved in 33pl of distilled water to which was added 
1pl of RNAase, 4pl of 10X React 2 buffer (GibcoBRL) and 2pl of H/nDIII 
restriction enzyme (GibcoBRL) giving a total volume of 40jul. This was 
incubated at 37°C for at least 4 hrs. 10pl of loading buffer was added (0.25%  
Bromophenol Blue, 40% w/v glycerol) and the mixture loaded into an agarose 
gel for electrophoresis.
Agarose Gel Electrophoresis
The fragmented DNA product of the restriction enzyme digest was loaded into 
a well on a 0.8% (w/v) agarose gel made with 0.5X TBE (44.5mM Tris Base, 
44.5mM Boric Acid 2mM EDTA pH8) and Ethidium Bromide 1|ng/ml. 
Electrophoresis at 25-100V was undertaken until sufficient resolution of DNA 
bands was obtained, typically 75V for 4 hrs. A 1Kb DNA ladder (Gibco BRL) 
was run concurrently.
Taq DNA Polymerase Amplification of Adenoviral Vector DNA 
Fragments.
PCR was used to detect and amplify two different DNA fragments. The first 
was a fragment from the beta-galactosidase gene. The second was a 
fragment from the E1 region of the wild type adenovirus. The primers used 
were as follows:
74
Adenovirus Serotype 5 E1 region Estimated Melting Point
Ad5-E1 a629Forward 5’ATCGAAGAGGTACTGGCTGA 60°C
Ad5-E1a1045Reverse 5’ CCTCCGGTGATAATGACAAG 60°C
Beta-galactosidase (LacZ) Estimated Melting Point
LacZ 645 Forward 5’GCATAAACCGACTACACA 52°C
LacZ 1218 Reverse 5’ GCTTCATCCACCACATAC 54°C
Oligonucleotide primers were obtained from Sigma-Genosys Ltd, Cambridge.
Each PCR reaction was undertaken in 5 0 0 jlaI thin walled PCR tubes. Each 
tube contained 5pl 10X PCR Buffer (100mM Tris-HCI, pH8.3, 500mM KCI, 15 
mM MgCI2 and 0.01% gelatin) 8pl of dNTP (10mM dATP, 10mM dCTP, 
10mM dGTP, 10mM TTP) 1pM of each Primer, 0.5^1 of taq DNA Polymerase 
(2.5units) (Sigma Aldrich, Poole, Dorset) and one tenth of the DNA from a 
small-scale viral propagation. Distilled water was added to a final volume of 
50pl. The reagents were mixed on ice, adding the taq polymerase as the final 
step. The tubes were immediately transferred to a top heated Hybaid Omn-E 
thermocycler, pre-heated to 95°C. For beta-galactosidase fragment 
amplification the following program was used: Denaturing temperature of 95°C 
for 4 min then 30 cycles of 92°C for 1 min, annealing at 56°C for 1min and 
extension at 72°C for 1 min. The annealing temperature was above the 
estimated melting point for the primers used but this programme had been 
successfully employed within the group by Yvonne Alexander when working 
with genomic mouse DNA. Using the E1 specific primers the following 
program was used: Denaturing temperature of 95°C for 4min then 30 cycles 
of 94°C for 30 sec, annealing at 62°C for 30 sec and extension at 72°C for 1 
min. The amplified DNA was evaluated by agarose gel electrophoresis.
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Calculating Viral Concentration by Plaque Assay
The concentration of virus produced was determined by plaque assay. This 
was performed in duplicate and the result expressed as the mean of the two 
values. For each assay 293 Cells were grown to 80%-90% confluency in 
60mm tissue culture dishes. A vial of viral vector was thawed and 10pl of virus 
was serially diluted by a factor of 10 using Tris Saline over the range 10"2 -  
10'14. A fresh pipette tip was used at each dilution. Growth Medium was 
removed from the tissue culture dishes and 10Opil of a viral dilution carefully 
dripped onto the cells of an appropriately labelled dish. The cells were then 
incubated at 37°C 5% C 0 2 for 45 minutes before being overlaid with 2mls of 
Agar Mixture (38ml Growth Medium, 2ml Foetal Bovine Serum, and 10ml 
molten 3.2% Noble Agar). After three days of incubation, a further layer of 
Agar Mixture was added. A viral plaque was characterised by a new hole in 
the cell sheet with cells at the margin showing features of a cytopathic effect. 
The number of viral plaques was counted 7 days following infection and the 
concentration of viral vector expressed in plaque forming units per ml of 
undiluted virus (pfu/ml).
Plaque Purification
The stock viral vectors were derived from single plaques picked from agar 
overlay dishes produced as described above. Only dishes with fewer than 10
plaques were used. The dishes were allowed to incubate for up to 9 days. The
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positions of the plaques were marked and the dishes allowed to cool at 4°C 
for 10 minutes. A sterile Pasteur pipette with a bulb was used to aspirate both 
the cells and surrounding agar of a single plaque. The material was then 
resuspended in Tris Saline and agitated before being used to infect a 175-cm2 
flask of 293 cells. For vectors encoding beta-galactosidase, positively staining 
plaques were identified by X-gal staining. 250mg of X-gal was dissolved in 
5ml of tissue culture grade DMSO. Each 60mm dish had 10Opil of X-gal 
solution carefully dripped onto the surface of the agar. The plates were 
incubated for 4 hours and the number of positively staining areas counted. 
Where the number of positively staining areas numbered fewer than ten, 
plaques were individually aspirated and stored for future use.
Adenoviral Vectors 
Introduction
Six adenoviral vectors were available and are described below. All were E1a 
deleted, replication deficient and serotype 5.
Adenoviral Vector Expressing Beta-galactosidase 
CMV-LacZ Ad 5
This vector encoded beta-galactosidase under the control of the 
cytomegalovirus promoter. This was a kind gift from Ron Hay, St Andrews
University, UK and had been constructed using the plasmids available from
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Microbix (Microbix Inc, Toronto, Canada). The Ad5 genome plasmid pJM17 
has a 4.4Kb insert from a bacterial plasmid inserted at the Xba\ site in the E1 
region of the wild type adenovirus genome Ad5-dl309. The insert allows 
replication of the plasmid pJM17 within bacterial culture systems. However, 
pJM17 exceeds the packaging capacity of the adenovirus capsid. When 
pJM17 is co-transfected into HEK293 cells with the appropriate shuttle 
plasmid encoding beta-galactosidase, replication deficient adenoviral vector 
can result. On the shuttle plasmid, the gene of interest is flanked by DNA 
sequences that are homologous to sequences within pJM17. By a process of 
homologous recombination the bacterial DNA insert and E1a region is 
replaced by the smaller sequence, including the gene of interest, from the 
shuttle plasmid. The resulting plasmid is smaller and can be packaged within 
the adenoviral capsid. Although E1a deleted and replication defective, the 
recombinant virus can be propagated in the complementing, E1a expressing 
HEK293 cell line.
RSV-nLacZ Ad5
This vector encoded a nuclear localising beta-galactosidase under the control 
of the Rous Sarcoma Virus promoter. This was a kind gift from Roger Hajjar, 
Boston, USA. This vector had been constructed to be both E1a and E3 
deficient (Dong et al. 1996). The method used by Dong is briefly described. 
The following plasmids were obtained: pSP72 (Promega, Madison, Wl); 
pAdRSV4 (Dr. Blake Roessler, University of Michigan); pLZ11 (Dr. Joshua 
Snes, Washington University). A Bg/ll fragment containing the Rous sarcoma 
virus (RSV) long terminal repeat (LTR) promoter and SV40 polyadenylation 
sequence (termed “SvpA”) was excised from pAdRSV4 and ligated into
BamHI-digested pSP72. The resulting plasmid, designated pSP72Bglll, was
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digested with Smal and BamHI then ligated to a blunt-ended, Bgl\\-Xba\ 
fragment of pLZ11. This Bgl\\-Xba\ fragment of pLZ11 contained a nuclear- 
targeted Escherichia coli beta-galactosidase gene (nLacZ). The plasmid 
product of the ligation of the Bgl\\-Xba\ fragment to pSP72Bglll, termed 
pSP72p-Gal, contained nLacZ fused to SvpA. The plasmid pAdRSVnLacZ 
was constructed as follows. pSP72p-Gal was digested with Bg/ll and BamHl, 
releasing the nLacZ sequences. This fragment was ligated into the BamHl site 
of the pAdRSV4, creating an expression cassette consisting of the RSV LTR 
promoter driving nLacZ-SvpA. The adenoviral vector was generated by 
cotransfection of linearised plasmid pAdRSVnLacZ with the 35-Kb C/al of Ad- 
dl327 (an E3-deleted Adenovirus) in 293 cells. Freeze-thaw lysates made 
from plaques were tested for their ability to transfer beta-galactosidase 
expression to 293 cells. This adenoviral vector was successfully used by 
Dong et al to infect calf pulmonary artery cells in vitro and rat coronary arteries 
in vivo.
Adenoviral Vectors Encoding Skeletal Troponin C
Obeid Khan and Yvonne Alexander constructed all the original vectors 
encoding skeletal troponin C under the supervision of Howard Prentice (Khan
1999). The plasmids encoding skeletal Troponin C and the Human Cardiac 
Actin Promoter (pLK419 and pl_K350 respectively) were obtained from Larry 
Kedes, University of Southern California, CA, USA. The sTnC cDNA was 
subcloned into the vector pLECM using PCR amplification and cutting both 
the PCR product and pLECM with the restriction enzymes EcoRI and Bg/ll. 
The resulting plasmid was designated pLECM/sTnC. To obtain a sTnC clone
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with SV40-polyA sequence as the 3’ end of the gene, a PCR product of 
pLECM/sTnC was inserted into pCA13 using the restriction enzymes EcoRI 
and BamHI. This plasmid was designated pCA13/sTnC. The restriction 
enzymes BsfEII and Awl I were used to isolate the cDNA for sTnC which was 
then inserted into the vector pSP72 following digestion of this vector by Smal. 
The resulting plasmid was designated pSP72/sTnC. For the vectors encoding 
the HA tag, a 12 codon sequence was added to a truncated PCR product of 
the sTnC. Sequencing of the resulting plasmids was used to ensure 
appropriate orientation of inserted fragments. Adenoviral vectors were 
produced by calcium phosphate transfection of HEK293 cells with both the 
appropriate shuttle plasmid and the large adenoviral plasmid pJM17 (Microbix 
Biosystems Inc, Toronto, Canada). Resulting plaques were screened by 
restriction enzyme analysis and PCR using E1 region specific primers.
CMV-sTnC Ad5
This vector encoded human skeletal troponin C under the control of the 
cytomegalovirus promoter. The cDNA had been isolated from a human 
muscle DNA library (Gahlmann et al. 1988). The virus was constructed using 
a plasmid pLK419 (Larry Keddes, University of South California, USA)
CMV-sT nC-A9-HA Ad5
This vector was similar to CMV-sTnC Ad5. However, the sequence encoding
the C-terminal nine amino acids had been removed and replaced with a 12 
amino-acid sequence. This new sequence encoded 3 linker amino-acids 
attached to a 9 amino-acid haemagglutinin antigen motif.
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HCA- sTnC Ad 5 and HCA- sTnC-A9-HA Ad5
These vectors were similar to their CMV promoter equivalents but gene 
expression was under the control of the human cardiac actin promoter.
CMV-sTnC-A9-HA Ad5 and HCA-sTnC-A9-HA Ad5 were used by Dr Khan to 
infect NIH3T3 mouse fibroblasts cells in culture. A western blot for the 
presence of HA tag was positive in fibroblast cells infected with CMV-sTnC- 
A9-HA Ad5 but negative for cells infected with HCA-sTnC-A9-HA Ad5 and in 
uninfected cells. Both vectors were used to infect rat neonatal cardiocytes. 
Immunostaining for the HA product was positive in CMV-sTnC-A9-HA Ad5 
infected cardiocytes and to a lesser extent HCA-sTnC-A9-HA Ad5 infected 
cardiocytes, but was negative in negative control groups. Dr Khan concluded 
that the vectors could cause foreign gene expression and that the HCA-sTnC- 
A9-HA Ad5 vector demonstrated characteristics of tissue specific expression. 
However, from these experiments it was not known if the HA tagged product 
integrated into the sarcomere of infected myocytes. The C-terminal 9 amino- 
acids had been replaced by a 12 amino-acid sequence including the 9 amino- 
acid sequence for the HA tag. The C-terminal of TnC sits close to and 
interacts with the other troponin sub-units and the possibility remained that the 
lengthened HA tagged mutant may not integrate into the sarcomere. In 
retrospect, confirmation of integration of sTnC-HA into the sarcomere in cell 
culture should have been sought prior to proceeding to in vivo functional 
experiments.
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Delivery Techniques
Surgical Methods
Male adult New Zealand white rabbits supplied by Harlan-Olac Ltd weighed 
2.5-3.5Kg at the time of surgery unless otherwise stated. All animal 
procedures were in accordance with Home Office requirements and all 
surgery was undertaken under general anaesthesia.
Induction of General Anaesthesia
Surgical procedures were performed under the supervision of Dr Martin Hicks, 
Glasgow Royal Infirmary. Fifteen minutes prior to any surgical procedure, 
animals were premedicated with 0.4ml/kg of intramuscular Hypnorm (Fentanyl 
Citrate 0.315 mg/ml, Fluanisone 10mg/ml, Janssen Animal Health, Beerse, 
Belgium). Following adequate sedation with Hypnorm, the surgical area was 
shaved and a solution of 0.5% chlorhexadine in 70% alcohol applied. A 
peripheral venous cannula was secured by introducing a 23-gauge butterfly 
needle into the auricular vein. For several minutes prior to endotracheal 
intubation the sedated animals breathed a mixture of oxygen and nitrous 
oxide by facemask. (Oxygen 1L/min, NO 0.8L/min mixed by a Boyle’s 
anaesthetic machine). Immediately prior to intubation the animal was deeply 
sedated using Hypnovel (Midazolam 10mg/2ml, Roche, Welwyn Garden City) 
0.17mg/kg given as an intravenous bolus. A paediatric laryngoscope was 
used to visualise the epiglottis and vocal cords. Xylocaine throat spray (Astra
Pharmaceuticals, Langley) was used as a local anaesthetic to the vocal cords
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before a paediatric endotracheal tube (3.0-3.5mm Portex, Berk Sur Mer, 
France) was introduced and the trachea intubated under direct vision. 
Ventilation of both lungs was confirmed by auscultation. Excessive 
advancement of the tube can result in selective ventilation of only one lung. 
The animal was mechanically ventilated at a minute ventilation of 1.2-1.6L 
using oxygen and nitrous oxide mixture as above. Maintenance of general 
anaesthesia was achieved using 1%-2% Halothane (Zeneca Ltd, 
Macclesfield).
Central Vessel Cannulation
Following a small right paratracheal incision and longitudinal dissection of the 
paratracheal musculature, the internal jugular vein was identified. The vessel 
was isolated by means of a silk tie proximally (Mersilk) and a bulldog clip 
distally. The vessel was then entered and a cannula secured with silk suture 
prior to removal of the bulldog clip, after which the cannula could be advanced 
if required. Cannulation of the common carotid artery was similarly achieved. 
The common carotid artery was carefully isolated to avoid damage to the 
adjacent vein and vagus sympathetic trunk.
Left Lateral Thoracotomy
The skin was incised along the line of the left 4th intercostal space. The 
intercostal muscles were identified following dissection of the subcutaneous 
fat, fascia and serratus anterior muscle. The intercostal muscles were divided 
in two layers to facilitate an airtight seal upon subsequent closure. The pleural
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cavity was entered by blunt dissection, minimising the risk of damage to the 
lung that could result in a postoperative pneumothorax. The 4th and 5th ribs 
were separated using a self-retaining rib retractor, giving adequate access for 
instrumentation within the chest. The left lung was manually collapsed and 
held in position with a small cotton swab. The animal was ventilated with 0.5- 
1cm H2O of positive end expiratory pressure. The pericardium was opened 
with scissors at the level of the atrio-ventricular groove and the incision 
extended towards the apex as required, allowing the apex to be displaced 
from the pericardial sac. The position of the left ventricular apex was 
controlled using a transmural 4/0 Ethibond suture (Ethicon, NJ, USA). This 
gave adequate control for direct needle injection of adenoviral vector into the 
myocardium both at the apex and left baso-lateral wall. Following the required 
procedure, the apical tie was removed and haemostasis achieved by direct 
pressure. The heart was placed back into the pericardial sac. The swab 
holding the collapsed lung in place was removed and at least 3 interrupted 3/0 
chromic catgut sutures used to appose the fourth and fifth ribs. The left lung 
was re-inflated before securing the chromic ties. The wound was then closed 
in layers using interrupted 3/0 Ethibond suture and the skin closed with a 
continuous subcuticular Dexon 2-0 suture (Sherwood Davis and Geek, St 
Louis, MO, USA).
Direct Needle Injection
At open thoracotomy, adenoviral vector was injected directly into the 
myocardium of the left ventricular free wall using a 26-gauge needle attached 
to a 100pl glass Hamilton syringe. The position of the heart was controlled
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using an apical tie and the tip of the needle was bent to a right angle and 
introduced into the myocardium at an oblique angle. These precautions were 
taken in order to reduce mechanical trauma and to minimise the risk of 
injecting the vector into the ventricular cavity. The injection was deemed 
satisfactory if there was blanching of the surrounding myocardium at the time 
of injection. Before closing the chest, the position of the injection site was 
noted relative to the branching epicardial vessels.
Coronary Infusion Using a Swan-Ganz Catheter
A Swan-Ganz catheter (sized 5-6 French) was introduced into the right 
common carotid artery via a right paratracheal skin incision. Under 
fluoroscopic guidance (Siemens GRA 1030, Siemens Elema, Sweden) the 
catheter was manipulated into the ascending aorta. The distal port was 
attached to a pressure transducer (Elcomatic EM 751A, Elcomatic Ltd, 
Glasgow) and pressure at the distal tip monitored on an oscilloscope trace 
(144 Monitor, Roche, Basel, Switzerland). A hard copy of the pressure tracing 
could be made using a paper recorder (Mingograf 803, Siemens Elema, 
Sweden). The Swan-Ganz catheter balloon was then inflated and occlusion of 
the ascending aorta confirmed by an increase in the aortic pressure tracing 
from the distal port and visually by injection of radio-opaque contrast below 
the balloon (Omnipaque, Nycomed, Birmingham). Having confirmed that the 
ascending aorta was effectively occluded, virus was then infused into the 
distal port and the catheter flushed with 0.9% saline. With an occluded 
ascending aorta above and a competent aortic valve below the virus was
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injected into a space where the only means of escape was through the 
coronary arteries.
Introduction of Adenoviral Vector by Pulmonary Artery and Aortic 
Cross-Clamp
This method required an open thoracotomy and a left ventricular puncture. 
The method was first described in the rat and was adapted for use in rabbits 
where the heart and great vessels were exposed following a left 3rd rib-space 
thoracotomy (Hajjar et al. 1998). An inverted T skin incision was necessary 
for adequate access. The pericardial sac was opened and the left ventricular 
apex controlled using a silk suture. An 18-gauge cannula was introduced into 
the left ventricular cavity by direct puncture through the left ventricular apical 
notch. After removing the needle, the tip of the catheter was manipulated into 
the ascending aorta. The aorta and pulmonary arteries were simultaneously 
clamped using a large pair of forceps and the cannula withdrawn to lie 
immediately below the clamp but above the aortic valve (Figure 2-1). To avoid 
a prolonged period of ischaemia, the clamp was then briefly released before 
being tightly applied. Adenoviral vector was then injected as a bolus through 
the cannula and the clamp kept in place for 10 seconds after the injection. As 
an indicator of the effectiveness of the pulmonary clamp, it was noted if it was 
possible to draw blood back into the syringe following injection. After the 
clamp was released, the cannula was removed and haemostasis achieved by 
direct pressure. The chest was closed as previously described.
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Figure 2.1. Method of viral introduction adapted from Hajjar (Circ Res 2000 Vol 
86(6) p616-621) SVC -  Superior Vena Cava, IVC -  Inferior Vena Cava
 Aorta
SVC
Pulmonary
Artery
IVC
Selective Coronary Cannulation
Selective cannulation of the coronary arteries proved possible using a custom 
made 3 French nylon coronary catheter with a hockey-stick tip (Royal Flush II 
Radiopaque Nylon Catheter, Type N3.0-21-20-P-NS-MAC1, William Cook 
Europe A/S, Bjaeverskov, Denmark, a kind gift from Professor Michael 
Marber, Rayne Institute, St. Thomas’ Hospital, London). The catheter was 
introduced into the ascending aorta via the internal carotid artery. Heparinised
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saline was then injected (1ml with 200iu mucous heparin Leo Labs Ltd, 
Risborough) before the catheter was manipulated into one of the coronary 
ostia under fluoroscopic guidance. The position of the catheter was confirmed 
by a small injection of radio-opaque contrast (<0.5ml). If necessary the 
catheter was advanced until it occluded the coronary artery. In this position, 
injected contrast material would remain in the coronary artery until flushed 
away with injected saline solution. Following injection of adenoviral vector the 
catheter was flushed with 1ml of heparinised saline and a small injection of 
contrast used to confirm the catheter position. The catheter was then removed 
and coronary patency confirmed by continuous screening until the contrast 
material flushed away.
Post-operative Analgesia
Immediately following surgery the animals received intramuscular 
Buprenorphine (0.15mg in 0.5ml as hydrochloride, Animalcare Ltd, York). This 
was repeated 16 hours later.
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Histological Staining
Staining of Myocardial Tissue Blocks for Beta-galactosidase (Method 1)
Blocks of myocardium were immersed in Fixing Solution (Phosphate Buffered 
Saline; pH7.4 containing 2% formaldehyde and 0.2% gluteraldehyde) for 15 
minutes. The Fixing Solution was removed and the cells washed 3 times with 
PBS. The tissue was then immersed in X-gal Stain (5mM Potassium 
Ferrocyanide, 3mM Potassium Ferricyanide, containing 1 mg/ml X-gal 
dissolved in Dimethyl Formamide 0.1% v/v) and the dishes incubated at 37°C 
for 4-16 hours.
Staining of Myocardial Tissue Blocks for Beta-galactosidase (Method 2)
Myocardial tissue of 3mm thickness was stained as a block before histological 
sectioning. At room temperature, the tissue was rinsed in 0.1M Phosphate 
Buffer pH 7.3 (0.1M Sodium Phosphate Monobasic:0.1M Sodium Phosphate 
Dibasic, ratio 1:3 v/v) and then fixed for 30 minutes (0.1M Sodium Phosphate; 
pH7.3, 0.2% Gluteraldehyde, 5mM EGTA; pH 7.3, 2mM Magnesium 
Chloride). The tissue was then washed 3 times at 15-minute intervals in Wash 
Buffer (0.1M Sodium Phosphate; pH 7.3, containing 2mM Magnesium 
Chloride, 0.1% v/v deoxycholate and 0.2% v/v Nonidet-P40). The tissue was 
then stained with X-gal Solution (0.1M Sodium Phosphate; pH 7.3, containing 
1 mg/ml X-gal dissolved in Dimethyl Formamide, 5mM Potassium
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Ferrocyanide, 3mM Potassium Ferricyanide, 0.1% v/v Deoxycholate and 0.2%  
v/v Nonidet-P40) for 16 hours at 37°C. After staining the tissue was kept in 
Wash Buffer at 4°C overnight before being taken for histological sectioning.
Staining by Coronary Infusion
To ensure that the full thickness of the myocardium was exposed to the 
staining solutions for beta-galactosidase expression, a coronary infusion 
method was developed. Hearts were removed under terminal anaesthesia. 
Each heart was suspended above a glass funnel by sliding the ascending 
aorta over a custom-made aluminium cannula and securing it with a Mersilk 
tie. Solutions were perfused under constant flow into the ascending aorta and 
down the coronary arteries at a rate of 20ml/min. The glass funnel below 
collected the effluent from the coronary sinus. The apex of the left ventricle 
was vented by piercing with a pair of watchmaker forceps. At room 
temperature the heart was perfused with 0.1M Phosphate Buffer pH 7.3 (0.1M 
Sodium Phosphate Monobasic:0.1M Sodium Phosphate Dibasic, ratio 1:3 v/v) 
for 10 minutes, followed by Fixing Solution (0.1M Sodium Phosphate; pH7.3, 
0.2% Gluteraldehyde, 5mM EGTA; pH 7.3, 2mM Magnesium Chloride) for 12 
minutes, and finally with Wash Buffer (0.1M Sodium Phosphate; pH 7.3, 
containing 2mM Magnesium Chloride, 0.1% Deoxycholate and 0.2% v/v 
Nonidet-P40) for 15 minutes. The heart was then stained by perfusion with X- 
gal Solution (0.1M Sodium Phosphate; pH 7.3, containing 1 mg/ml X-gal 
dissolved in DMSO, 5mM Potassium Ferrocyanide, 3mM Potassium 
Ferricyanide, 0.1% v/v Deoxycholate and 0.2% v/v Nonidet-P40). The X-gal 
solution was heated in a water bath to 37°C and perfused at 20ml/min. The
effluent collected by the funnel was returned to the reservoir and re-circulated.
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Each heart was infused with X-gal solution for 1 hour. After staining the tissue 
was kept in Wash Buffer at 4°C overnight before being taken for histological 
sectioning.
Histological Sections
Niall Whyte of the Department of Pathology, Western Infirmary, Glasgow, 
performed all processing of tissue blocks for histological sectioning and 
cutting of histological sections. Standard 6-micron sections were cut and 
stained with Haematoxylin and Eosin (H&E). Unstained sections were left 
uncovered on aminopropyltriethoxysilane (APES) covered glass slides for 
future immunohistochemistry. When unfixed sections were required, frozen 
sections were cut using a cryotome.
Detection of HA-tag by Immunohistochemistry
Some tissues were exposed to vector encoding gene products which included 
the haemagglutinin antigen (HA) motif. The antibodies used for detection of 
the HA epitope were supplied by Boehringer Mannheim. A literature review 
and the technical assistance of Boehringer Mannheim failed to find an 
established method for using these antibodies on sections of rabbit 
myocardium, and therefore the following method was developed. Anti-HA high 
affinity Rat monoclonal antibody (Clone 3F10) was used as the primary 
antibody in a three-step procedure. Anti-rat Ig-biotin, F (ab ’)2 fragment was 
used as a secondary antibody. Streptavidin biotinylated peroxidase was used
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to conjugate to the secondary antibody. Finally, the sections were developed 
using 3’,3’-diaminobenzadine (DAB).
Both frozen sections and wax sections were used. The wax sections were 
dewaxed by placing them in Xylene for 10 minutes, rinsing 3 times in alcohol 
and once in water. All slides were placed in 3% Hydrogen Peroxide for 10 
minutes to inhibit endogenous peroxidase activity. The slides were rinsed with 
water and then TBS (0.05M Tris, 145mM NaCI; pH 7.6) containing 0.5%  
Tween 20. The antibodies were diluted with a solution of TBS containing 0.5%  
Tween 20 and 1% Bovine Serum Albumin (BSA). A wax pen was used to 
draw around the section on each slide. Non-specific binding of protein was 
blocked by covering each section with 100|il of 1% BSA for 15 minutes. This 
was dripped off and 100p,l of primary antibody was placed on each slide at 
varying dilutions. The dilutions used were 1:50, 1:100 and 1:200. At each 
stage the slides were allowed to sit in a humidifying box for 30 minutes before 
being washed with TBS containing 0.5% Tween. A 1:100 dilution of Anti-rat Ig- 
biotin, F (ab ’)2 fragment was used as a secondary antibody and a 1:100 
dilution of ABC (Peroxidase complex by Vector Laboratories Inc, Burlingame, 
CA, U.S.A.) used for the third step. The slides were washed 3 times with TBS 
containing 0.5% Tween before being stained with S’.S’-diaminobenzadine 
(DAB). The DAB staining was performed in a fume cupboard using a solution 
of 0.05M Tris buffer pH 7.6 containing 0.33mg/ml DAB, 0.067mM imidazole 
and 0.6% hydrogen peroxide.
Tissue obtained from a rabbit heart that had been directly injected with CMV- 
sTnC-A9-HA Ad5 five days before sacrifice served as a positive control. 
Tissue obtained from rabbit myocardium, which had not been injected with
viral vector, was used as a negative control. The primary antibody was
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omitted from a full set of slides and these served to control for the possibility 
of the secondary antibody having non-specific binding to rabbit myocardium.
Quantitative Analysis of Histological Sections
Using light microscopy (Model DM1L, Leica, Wetzlar, Germany), H&E stained 
histological sections were examined for evidence of foreign gene expression, 
cell death and inflammatory infiltrate. The proportion of myocardium with 
detectable foreign gene expression was determined by point counting. An 
England Finder Grid (Graticules Pyser-SGI Ltd, Tonbridge) was inverted and 
randomly placed over the histological slide. At 40X magnification both the 
histological section and the grid were in focus. At each intersection of the grid, 
the underlying cell type was identified by its morphological features. 
Cardiomyocytes were identified by their cross striations( Plate 2.1; Plate 2.2). 
The number of cardiomyocytes staining positively for the foreign gene product 
was noted together with the total number of intersections counted. Where a 
cell did not overlay the intersection, the cell to the immediate upper left was 
counted. This was performed separately for the right ventricular free wall, 
trabeculae rich basal right ventricle and left ventricular free wall. For each 
region, the count was performed five times.
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Plate 2.1. An example of a histological section (magnification X100) 
representative of positively staining (blue) nuclei in the myocardium of a rabbit 
5 days following the introduction of vector encoding nuclear localising beta- 
galactosidase. Myocytes can be identified by their cross-striations
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Plate 2.2. An example of a histological section (magnification X100) 
representative of positively staining (blue) cells in the myocardium of a rabbit 5 
days following the introduction of vector encoding beta-galactosidase. Spillage 
of the X-gal stain product to neighbouring cells is seen.
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Photography
A 35mm SLR camera (Model XR-X 3PF, Ricoh, Tokyo, Japan) was attached 
to the light microscope. Tissue culture cells and sections were photographed 
using Kodak ET75 (Ektachrome-tungsten) slide film.
Physiology Methods 
Calcium Sensitivity of Trabeculae
Animals were sacrificed by intravenous Euthatal (0.5ml/kg) five days after viral 
introduction. The hearts were removed following a right parasternal incision 
and immediately placed in Modified Ringer’s solution (150 mM NaCI, 5mM 
KCI, 2mM CaCI2, 1mM MgCI2, 5mM HEPES, 10mM Glucose; pH 7.4) 
containing 30mM 2,3-Butanedione Monoxime (BDM). The right ventricle was 
freed from the intra-ventricular septum anteriorly. Using a dissecting 
microscope, right ventricular trabeculae of suitable proportions were identified 
and carefully dissected. Only trabeculae with a diameter of 150pm or less 
were used for physiological experiments. Selected trabeculae were mounted 
between two nylon monofilament snares. One snare was fixed and the other 
attached to a force transducer (Akers AE875, SensorNor a.s. Norway). The 
whole assembly was mounted on a micromanipulator (Narashige MM3) which 
allowed movement in 3 planes. A second micromanipulator facilitated fine 
adjustments to sarcomere length.
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Production of Skinned Fibres
Complete disruption of surface and intracellular membrane diffusion barriers 
was achieved by immersing the preparation in a well containing 10R solution 
(Table 2.1), 1% Triton X-100 for 40 minutes.
Measuring Calcium Sensitivity of Skinned Fibres
A modified Vickers M-16 microscope with differential interference contrast 
optics was used to examine each trabecula and set the sarcomere length to 
2.2\i. Solution changes were achieved using a computer controlled step motor 
driving a block of Perspex into which had been cut a series of wells. Solution 
10R contained the calcium chelator EGTA at a concentration of 10mM (Table 
2.1.). When permeabilised trabeculae were exposed to this solution, the free 
calcium was low and the preparation remained relaxed. Solution 10A 
contained CaEGTA at a concentration of 10mM. By mixing solutions 10A and 
10R, solutions of differing free ionic calcium were produced. The wells 
contained solutions of varying calcium concentrations prepared at pH 7.0 and 
pH 6.5. (Table 2.2). Preparations were moved to the well of the test calcium 
concentration after equilibration in solution 0.2R, thereby producing a rapid 
increase in the calcium buffer concentration at the same time as the free 
calcium concentration.
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Table 2.1. Composition of solutions 10A, 10R and 0.2R in mM.
Solutions K+ Mg2+ ATP CrP Na+ CaEGTA EGTA Hepes pCa
pH
7.0
10A 140 7 5 15 40 10 0 25 4.29
10R 140 7 5 15 40 0 10 25 9.63
0.2R 140 7 5 15 40 0 0.2 25 7.91
Table 2.2. Composition of solutions for bath change system (10A Full is 10A + 
50pL 10mM CaCI2
Ratio
10A.10R
1:1 2:1 5:1 8:1 15:1 10A 10A
Full
10R 0.2R
pCa @ 
pH 7.0
6.32 6.02 5.62 5.42 5.15 4.29 4.06 9.63 7.91
pCa @ 
pH 6.5
5.36 5.05 4.67 4.47 4.24 3.79 3.71 8.66 6.96
The method employed for calculating the free calcium ion concentration has 
been reported elsewhere (Harrison, Lamont, & Miller 1988). REACT is a 
computer program which calculates the equilibrium position for solutions 
containing a mixture of several ions and polyvalent buffers of the type used in 
these experiments (Miller & Smith 1984; Smith & Miller 1985). All 
physiological experiments were performed at room temperature (20-22°C).
98
After permeabilisation, the preparation was transferred to a thin glass-sided 
chamber. A Vickers M-16 microscope with Differential Interference Contrast 
optics attached to a video camera was used to examine and set sarcomere 
length. A graticule was placed within the video tube and the fine 
micromanipulator adjusted to give a sarcomere length of 2.1-2.2jim. The total 
length and width of the preparation was measured using the graticule. The 
depth was determined by focusing backwards and forwards and reading the 
micrometer on the microscope stage. The isometric force produced by the 
preparation was recorded on an Apple Macintosh computer using a MacLab 
analogue to digital converter (ADI Instruments Pry Ltd, Australia) and Apple 
Macintosh Chart software. Off-line Computer analysis was performed. Force 
generation for each calcium concentration was expressed as a proportion of 
the maximal force generated for a saturating calcium solution. A computer 
programme was used to fit a Hill equation curve through the data obtained.
Hillfit Computer Macro
The Hill equation Cx/C max = [CaJh/(EC5oh+[Cax]h ) describes the relationship 
between steady-state force and Ca2+ concentration where Cmax is the force at 
a saturating Ca2+ concentration; EC50 is the Ca2+ concentration that gives 50%  
of Cmax and h is the Hill coefficient. A macro running in the Mac application 
‘Igor Pro’ (Written by Dr D Miller, using a Levenberg-Marquadt least squares 
algorithm) was used to generate a best-fit curve to the Hill equation for each 
preparation examined. From the curve thus derived, the EC50 for each 
preparation could be calculated.
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Statistical Methods
Statistical calculations and graphs were produced using SigmaStat software 
(SPSS, San Rafael, CA, USA). A Student two-tailed, unpaired t-test was used 
for continuous variables where the data were normally distributed. For non- 
parametric data, the Mann-Whitney test was applied. Rejection of the null 
hypothesis was accepted at p<0.05.
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CHAPTER 3
Adenoviral Vector Production
101
Introduction
W e wished to test the hypothesis that adenoviral mediated gene transfer of 
skeletal troponin C to myocardial tissue would result in resistance of the 
myocardium to the calcium desensitising effects of ischaemia in tissue 
expressing sTnC but not in controls. It has been reported that adenoviral 
vectors in themselves can alter the contractile characteristics of infected 
myocytes (Novotny, J., Gustafson, B., Kvapil, P., & Ransnas, L. A. 1994). It 
was for this reason that the control groups should have included a group 
infected with empty adenoviral vector. Beta-galactosidase is thought to be 
physiologically inert and is not known to alter the contractile characteristics of 
infected myocytes. However, this is not certain and although we used an 
adenoviral vector encoding beta-galactosidase, a better adenoviral vector 
control would have been empty virus. It is possible that the method employed 
to introduce the vector, or the vehicle in which the vector was delivered, could 
have had an effect on the myocardial tissue. For these reasons, tissue from 
animals exposed to vehicle alone should have been investigated. Whilst 
developing the selective coronary injection method of adenoviral mediated 
gene transfer, one group was pre-injected with a solution containing serotonin. 
The lack of data from a control group injected only with vehicle was a serious 
shortcoming and limited the conclusions which could be drawn from these 
data. For the purpose of physiological investigation, a prerequisite was to 
achieve gene transfer to a large proportion of rabbit myocardium in vivo. 
Following gene transfer, it was anticipated that an interval of several days
would be required to allow gene expression and accumulation of the gene
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product prior to physiological investigation. Ideally, the vector employed would 
be of high titre, capable of efficiently infecting non-dividing cardiac myocytes 
and would not in itself evoke a significant inflammatory response prior to 
physiological investigation. The vector would have an insert capacity sufficient 
to accept genes of interest and their controlling regions. For reasons of safety, 
an absolute requirement was that the vector be replication defective and 
incapable of amplification in humans or live animals.
Background
In vivo gene transfer of rabbit myocardium by a replication defective 
adenoviral vector had been reported previously (Barr et al. 1994). Wild type 
adenovirus serotype 5 is a minor respiratory pathogen. It is a capsulated 
double stranded linear DNA virus capable of infecting and replicating in a wide 
variety of mammalian cells. The viral genome is 36Kb long and has been 
classified into 4 regions designated E1, E2, E3 and E4. Replication of 
adenovirus requires early expression of genes within the E1a region. Viruses 
defective in the E1a region have an insert capacity of up to 4Kb and although 
capable of infecting mammalian cells, are incapable of replication. Vectors 
that have had both the E1a and E4 regions removed have an insert capacity 
of almost 8Kb. However, replication defective virus can replicate in cells co­
infected by wild type virus; cell lines genetically modified to express E1a 
genes and possibly cells infected by the Ebstein Barr virus (Horvath, Faxing, 
& Weber 1991). The human embryonic kidney 293 cell line (HEK293) contains 
the genetic sequence for the E1a region of the adenovirus serotype 5. This 
cell line has been used to propagate replication deficient adenoviral vector for
use in in vivo experiments. Although replication deficient adenoviral vectors
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seemed ideal for the planned experiments, other vector systems were 
considered. Liposome vectors had the attraction of being devoid of potentially 
antigenic viral proteins. However, the efficiency of transfection found with 
adenoviral vectors had not been matched by liposome vector systems. 
Adeno-associated virus could not be produced to the high titre possible with 
adenoviral vector. Retroviral vectors infect dividing cells and were not 
attractive candidates as vectors to non-dividing cardiac myocytes.
Group Experience
Dr Prentice and his group were experienced in propagating replication 
defective adenoviral vectors and had used these experimentally in cultured 
neonatal myocytes. In addition, shuttle plasmids encoding skeletal troponin C 
were under construction and these were suitable for insertion into 
commercially available adenoviral plasmids. It was anticipated that vectors co­
expressing green fluorescent protein would allow identification of infected 
myocytes in vivo. Vector encoding mutants of skeletal troponin C with HA tags 
which were under construction had the potential to characterise the 
intracellular location of sTnC-HA within infected cells by use of appropriate 
antibodies and use of confocal microscopy. Given the group’s experience, a 
decision was taken to utilise replication defective adenoviral vector in the in 
vivo rabbit experiments.
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Replication Defective Adenoviral Vectors
The adenoviral vectors employed in the in vivo experiments were originally 
constructed by DOTAP or calcium precipitation transfection of 293 cells with a 
mixture of 40Kb long adenovirus plasmid DNA including the E1a region and 
shuttle plasmid containing the genetic sequence of interest, flanked on either 
side by sequences homologous to those flanking the E1a region of the large 
adenoviral plasmid. By a process of homologous recombination, the E1a 
region of the adenoviral plasmid is replaced by the gene of interest from the 
shuttle plasmid. The resulting adenoviral plasmid encodes the gene of 
interest, is E1a deficient and is within the limit to be packaged as an 
adenovirus within the complementing E1a expressing HEK293 cell line.
However, there is the possibility that such a system could produce replication 
competent virus, small enough to be packaged but still containing the E1a 
region. It is for this reason that vector produced by this method must be 
screened for replication competent virus. Where the process has produced a 
mixture of replication competent virus and replication defective adenoviral 
vector, the vector must be purified prior to use in vivo.
Viruses Employed
The first virus to be propagated encoded the gene beta-galactosidase (also 
known as LacZ) under the control of the ubiquitously expressing CMV 
promoter. This was a kind gift from Professor Ron Hay of the University of St 
Andrews. The vector had been constructed some years earlier, using the
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plasmids available from Micobix (Microbix Inc, Toronto, Canada). The gene 
product is not known to have any specific effects on cardiac contractile 
function. Beta-galactosidase can metabolise X-gal to produce a blue dye and 
is commonly used as a reporter gene to identify cells that have been infected 
by vector. This vector had been propagated by the Howard Prentice group for 
some years and had been successfully employed in tissue culture 
experiments. Figure 3-1 is a typical HinD\\\ restriction enzyme analysis of this 
vector.
HinD\\\ specifically cleaves the sequence
5 ... AAA G C T T ... 3 ' 
3 .. .  T T C G A AA .. .5 '
to produce DNA fragments of differing lengths. The gel was run with a 
standard 1Kb ladder to help identification of specific fragments. This HinD\\\ 
restriction enzyme pattern was similar to those produced by other group 
members when producing virus for use in cultured neonatal rat myocytes.
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Figure 3.1. HinD\\\ restriction enzyme pattern of beta-galactosidase 
encoding adenovirus. Note double band at 3Kb.
An aliquot of vector was propagated by the method previously described 
(Chapter 2, Page 71) and the resultant cellular lysate used for in vivo delivery 
to rabbit myocardium by the Swan-Ganz Catheter method (Chapter 2, Page 
82). When an adult New Zealand white rabbit was exposed to 20x1010 pfu of 
this virus, it died within 2 days. At post mortem examination, an unexpected 
finding was of inflammation within the large airways and lungs. A second 
animal exposed to 21x1010 pfu of this virus died within one day. At post 
mortem examination, this animal had developed pleural effusions and 
congestion within the large airways. One possible explanation for these 
findings was contamination of the vector by replication competent wild type
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virus. The wild type virus used in the lab was dl309. On restriction enzyme 
analysis with HinD\\\ this virus has a characteristic doublet at 3Kb.
In vivo experiments were suspended, and further analysis of the vector was 
undertaken.
Possible Contamination by Wild Type Virus
Using primers specific for the E1a region of replication competent virus, a 
PCR analysis of the beta-galactosidase encoding vector was undertaken 
(Figure 3.2).
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Figure 3.2. PCR using primers specific for E1a region of the adenovirus 
genome. pCA13 is a plasmid encoding the gene for beta-galactosidase. dl309 is 
a replication competent adenovirus and gave a strongly positive band. B-gal 1 
was propagated from original seed stock and was thought to be replication 
deficient. B-gal 1 had been purified by caesium gradient prior to analysis. B-gal 
2 was unpurified crude lysate. Both B-gal 1 and B-gal 2 gave strongly positive 
bands in keeping with the presence of the E1a region and by inference, 
replication competence.
108
Figure 3.3 is a HinDIM restriction enzyme analysis of the replication competent 
virus dl309. The double band at 3Kb was similar to that found in the analysis 
of B-gal (Figure 3.1). On looking back through lab records when the original 
virus was gifted to Dr Prentice, this doublet was not detected.
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Figure 3.3. Hin Dill restriction enzyme analysis of the wild type replication 
competent virus dl309.
From the restriction enzyme analyses and PCR results, together with the early 
death of animals exposed to high doses of B-gal, it was concluded that the B- 
gal virus was contaminated by replication competent virus or was replication
competent but also contained the sequence encoding beta-galactosidase.
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Hin DIM restriction enzyme analyses were undertaken on viruses held by other 
group members. A typical result is shown (Figure 3.4).
Figure 3.4 Typical result of Hin DIM restriction enzyme analysis of beta- 
galactosidase encoding viral vector held by other group members. Note the 
double band at 3Kb as previously found in the replication competent virus 
dl309.
All samples tested revealed a doublet band at 3Kb and it was concluded that 
all samples were potentially replication competent and not safe for use in vivo.
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Plaque Purification of Contaminated Vector
The most likely explanation for the finding of replication competent adenovirus 
in all samples of the vector held by the group was that some time previously, 
the replication defective virus had been contaminated by wild type dl309 
replication competent virus. The conclusion was that all samples of the vector 
encoding beta-galactosidase were a mixture of replication defective virus and 
replication competent virus. A decision was taken to isolate replication 
defective virus by a method of plaque purification. Serial dilutions of stock 
virus were used to infect dishes of HKE293 cells. A mixture of agar and 
growth medium was then carefully layered on top as previously described 
(Chapter 2, Page 76). Following up to seven days of incubation, dishes with 
fewer than ten plaques were selected. Individual plaques, isolated using 
sterile Pasteur pipettes, were used to infect dishes of HKE293 cells. After 
three or more days of incubation, the cells from infected tissues were 
harvested and the resulting crude lysate was characterised by HinD\\\ 
restriction enzyme analysis. Figure 3.5 is representative of a typical result. 
Over 100 individual plaques were grown, carefully isolated to avoid cross­
contamination, and used to infect dishes of HKE293 cells. Each was 
investigated by restriction enzyme analysis. Despite this time-consuming 
process, none of the virus isolated was free of the double band at 3Kb, 
indicative of contamination by wild type, replication competent virus.
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Figure 3.5. 1 Kb ladder in first and last lane. All other lanes show result of
HinD\\\ restriction enzyme analysis of virus propagated from isolated viral 
plaques. Arrow (>) at 3Kb with double band detected in all samples, indicative 
of contamination by replication competent virus.
Purification of Contaminated Vector by Serial Dilution
Twenty-four well tissue culture dishes were used to grow 293 cells to a 
confluency of 50%. Following serial dilution of contaminated virus, wells were 
infected and propagated for up to one week. This method failed to isolate 
replication defective virus encoding beta-galactosidase.
Fresh Stock Vector Obtained
Fresh stock virus was obtained from Prof Ron Flays, University of St. 
Andrews. Following serial dilution, six discrete plaques were isolated from 
dishes overlayed with agar/growth medium mixture. Three plaques were
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isolated on day 6 and a further three plaques isolated on day 8. Of these six 
plaques, the crude lysate grown from the 3 plaques picked on day 8 produced 
a blue dye when mixed with X-gal, indicating expression of beta- 
galactosidase. The crude lysate grown from the 3 plaques picked on day 6 
failed to produce a blue dye when mixed with X-gal, indicating that beta-
galactosidase had not been expressed. The HinDWl restriction enzyme
analysis of crude lysate grown from the beta-galactosidase expressing 
plaques is shown in Figure 3.6.
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Figure 3.6. Hin DIM restriction enzyme analysis of crude lysate grown from 3 
plaques (LZ4.1, LZ5.1, LZ6.1) isolated from new stock as gifted by Prof Ron 
Hays, University of St. Andrews. Note the double band at 3Kb found in the 
replication competent dl309 virus was not detected in the plaques isolated 
from the new stock virus encoding beta-galactosidase.
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Importantly, there was no double band detectable at 3Kb in any of the three 
isolates analysed. These were thought suitable for use in in vivo experiments 
and were used as seed stock for viral propagations.
A PCR analysis was undertaken to confirm the presence on the beta- 
galactosidase DNA sequence and exclude the presence of the E1a DNA 
sequence from the replication defective viruses.
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Figure 3-7 PCR of pCA13 (plasmid encoding the sequence for beta- 
galactosidase), Distilled water, LZ 4.1, 5.1, 6.1 (Plaques purified from new seed 
stock from University of St Andrews, the crude lysate of which produced a blue 
dye when incubated with X-gal), B-gal (Original stock virus, thought to be 
contaminated with replication competent virus), LZ 3.1 (plaque purified from 
new seed stock from University of St Andrews but did not produce a blue dye 
when incubated with X-gal), 1Kb (standard 1Kb DNA ladder). The PCR 
performed with the E1a primers was not undertaken with a standard “hot start” 
which may explain some of the non-specific smearing.
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A strongly positive signal for E1a was found with the original B-gal virus as 
would be expected with contamination by wild type virus. No signal was found 
in the distilled water blank indicating that the PCR reagents were not 
contaminated. Non-specific banding was found in the pCA13 lane in keeping 
with non-specific binding associated with a cold start PCR. Faint bands were 
detected at416bp in LZ 4.1, 5.1, 6.1 and LZ 3.1. These bands could represent 
either contamination of these plaque-purified isolates by replication competent 
virus or amplification of E1a region DNA carried from the 293 cells in which 
the virus was propagated.
The PCR using primers for the Beta-galactosidase sequence gave positive 
signals for the positive control pCA13, negative signal for the water blank and 
strongly positive signal for the viral isolates that had produced a blue dye 
when incubated with X-gal. LZ 3.1 gave only a very weak signal for beta- 
galactosidase. These results indicate that the new seed stock from the 
University of St Andrews was a mixture of virus encoding for beta- 
galactosidase and virus not encoding for beta-galactosidase. The HinD\\\ 
restriction enzyme analysis of LZ 4.1, 5.1 and 6.1 did not detect a double 
band at 3Kb suggesting that these isolates were free of contamination by 
replication competent virus. However, although the weak PCR signal for the 
presence of E1a in these samples could be explained by carry over of 293 cell 
DNA containing E1a, the possibility of some contamination of these isolates 
by replication competent virus remained.
The issue of possible low-level contamination of adenoviral vector by 
replication competent virus can be addressed by amplification of replication 
competent virus in cell lines that are permissive to replication competent virus
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but non-permissive to replication defective virus. Such a method has been 
developed and has been termed the “Supernatant rescue assay” (Dion, Fang, 
& Garver, Jr. 1996). Such methods can detect one replication competent 
particle in a mixture of 109 replication defective particles. Sensitive methods 
such as these are mandatory for vector intended for use in clinical trials. For 
the purpose of the experiments intended in this project, a pragmatic decision 
was taken that virus with a satisfactory H/nDIII restriction enzyme pattern 
could be used within the confines of the laboratory with the precaution that all 
potentially contaminated instruments be autoclaved and any waste products 
incinerated.
Rates of Viral Replication
Why was it not possible to isolate replication deficient adenovirus from the 
original beta-galactosidase encoding vector held in the lab? If the fresh stock 
of virus from the University of St Andrews contained a mixture of virus 
expressing and not expressing beta-galactosidase, why did the non­
expressing virus produce plaques 2 days before the beta-galactosidase 
expressing virus? The answer to both of these questions may in part be 
explained by a property of adenoviral vectors first described by Bett et al in 
1993 (Bett, Prevec, & Graham 1993). Adenovirus type 5 can package genome 
sizes up to 108% of wild type genome length. However, Bett et al found that 
vector consisting of 108% of the wild type genome had a replication rate of 
half that of wild type virus. This property of smaller genomic sized viruses 
replicating more quickly than larger genomic size vectors would explain why it
proved difficult to isolate non-wild type virus from the original heavily
116
contaminated beta-galactosidase encoding stock vector. The wild type 
plaques may have developed and spread across the layer of HEK293 cells 
before the replication defective virus plaques could become apparent. 
Similarly, when the fresh vector from the University of St Andrews was used to 
produce plaques, the virus that did not express beta-galactosidase (potentially 
smaller genome) produced plaques 2 days ahead of the virus that did express 
beta-galactosidase.
Adenoviral Vector Encoding Nuclear-localising Beta-galactosidase
Dr Hajjar of Harvard Medical School, Boston, USA kindly gifted a replication 
defective adenoviral vector encoding a nuclear-localising beta-galactosidase 
under the control of the RSV (Rous sarcoma virus) promoter. The method of 
construction had been published, and this virus has been successfully used in 
vivo in the rat (Dong, Schulick, DeYoung, & Dichek 1996; Hajjar et al. 1998). 
HinD\\\ restriction enzyme analyses of virus propagated from single plaques 
were performed. Reassuringly, there was no detectable double band at 3Kb 
(See Figure 3.8).
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Figure 3.8. HinDWl restriction enzyme analysis of replication deficient virus 
encoding nuclear-localising beta-galactosidase under the control of the RSV 
promoter. RSV 1.2, 2.2 were propagated from two isolated plaques.
Adenoviral Vectors Encoding Skeletal Troponin C
Dr Obeid Khan had constructed replication defective adenoviral vector
encoding skeletal troponin C under the supervision of Dr Prentice (Khan
1999). The HinD\\\ restriction enzyme pattern for the various constructs was
known. Figure 3-9 demonstrates the HinD\\\ restriction enzyme patterns for
sTnC HA HCA and sTnC HA CMV. These were found to be similar to those
produced by Dr Khan and these isolates were used to propagate virus for in
vivo experiments. In Figure 3-9, RSVLZ1.3 was the HinDWl restriction enzyme
pattern of nuclear-localising beta-galactosidase encoding adenoviral vector
gifted by Dr Hajjar. RSVLZ1.3.2 and RSVLZ1.3.3 were the HinDWl restriction
enzyme patterns of virus produced by propagation of RSVLZ1.3 and were
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found to be similar. These viruses were subsequently used in in vivo 
experiments.
(D
-73-73
05
CM cn
CO CO CO
•<— T— T—
a y
> > >
CO CO CO
a : c r c r
<
o
oc
>
o
<X
o
-o~n
03
Figure 3.9. H/nDIII restriction enzyme patterns of viral vectors subsequently 
used in in vivo experiments. With the exception of RSV LZ 1.3, all viruses had 
been concentrated and purified using a caesium chloride gradient. The right 
hand lane for each virus was a 1:10 dilution of the left hand lane. No doublet at 
3Kb found in any of these viruses.
Discussion
Contamination of the original beta-galactosidase expressing adenoviral vector 
stock by replication competent wild type virus may have contributed to the 
inflammatory reaction in the respiratory tract of the rabbits exposed to
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20x1010 pfu of virus. The data from the HinDWl restriction enzyme analyses 
support this conclusion. Cellular debris and antigenic proteins from the crude 
lysate may have contributed to the inflammatory reaction. Although PCR was 
used to confirm the presence of E1a DNA in the lysate from contaminated 
plaques, this in retrospect was not informative since carry over of HEK293 cell 
DNA encoding E1a cannot be excluded. Dion et al have developed a sensitive 
bioassay method of detecting viral E1a DNA (Dion, Fang, & Garver, Jr.1996). 
This requires serial propagation through HeLa cells. Even this method does 
not exclude wild type contamination completely, the detection limit being one 
replication competent viron in 109 replication deficient virons.
Conclusions
Viral lysate contaminated with wild type replication competent virus is 
unsuitable for in vivo use. The most sensitive method of detecting replication 
competent contamination is by the supernatant rescue bioassay method 
(Dion, Fang, & Garver, Jr. 1996). The sensitive bioassay method for detecting 
replication competent virus is more sensitive than PCR methods but has a 
detection threshold of 1 in 109 and therefore contamination by replication 
competent virus can never be excluded. For in vivo animal experiments we 
used vector propagated from single isolated plaques, concentrated and 
purified of cellular debris on a caesium chloride gradient, and with no 
evidence of wild type contamination on DNA restriction enzyme analysis. 
However, the possibility remained that there was wild type contamination of 
virus despite these measures.
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RESULTS 4
Development of the Swan-Ganz Method of Vector
Delivery
121
Introduction
Studies on single cardiac myocytes isolated from transgenic mice expressing 
sTnC have reported a relative resistance to the calcium desensitising effects 
of intracellular acidosis (Metzger et al. 1993). Acidosis is only one component 
of ischaemia and although cells expressing sTnC may remain responsive to 
the calcium transient in conditions of acidosis, there may be other 
components of ischaemia that might limit the potentially beneficial effects of 
sTnC expression in the heart. In order to test the hypothesis that adenoviral 
gene transfer of sTnC to rabbit myocardium would result in a desirable 
physiological change, an effective method of delivering viral vector to the 
intact heart was required. Although components of ischaemia can be tested in 
isolated myocytes and trabeculae, our aim was to investigate the effect of 
ischaemia on whole heart preparations in which a large proportion of 
myocytes expressed a foreign gene of interest. Coronary occlusion can be 
used in anaesthetised whole animal preparations to study the effects of true 
ischaemia (Bauer et al. 1993). Similarly, coronary ligation can be used in 
isolated working heart preparations. However, in working heart preparations, 
metabolism is switched from fatty acid utilisation to carbohydrate utilisation. In 
order to use whole animal or working heart preparations a method of viral 
delivery was required which would maximise the proportion of myocytes 
infected and minimise any traumatic or inflammatory process. It was 
anticipated that 5 to 7 days would be required following viral introduction for 
optimal gene expression (Guzman et al. 1993). Barr et al had described an 
efficient method of viral delivery (Barr et al. 1994). This group employed 
selective coronary catheterisation to deliver adenoviral vector directly into one 
of the coronary arteries. Using this method, up to 32% of the ventricular
cardiac myocytes within the distribution of a single coronary artery display 
foreign gene expression. W e wished to develop a catheter based method of 
delivering adenoviral vector simultaneously down both left and right coronary 
arteries, allowing multiple injections without risking mechanical trauma to the 
coronary arteries. It was hoped that multiple injections of viral vector may 
result in a proportion of infected cardiac myocytes greater than that produced 
by Barr et al. Adenoviral gene transfer to myocardium had been reported 
using direct needle injection (Guzman et al. 1993). Although this method 
reliably infects cells around the injection site, it results in trauma and 
inflammation around the needle tract. In rabbits, direct needle injection would 
require open thoracotomy and was an unattractive method of achieving 
transfection of the relatively thin right ventricle (risk of rupture) and 
inaccessible intra-ventricular septum.
Development of a Swan-Ganz Catheter Mediated Vector Delivery
There had been no prior reports of using a Swan-Ganz catheter to deliver 
adenoviral vector to the coronary circulation. The Swan-Ganz method 
developed here was relatively non-invasive and did not require a thoracotomy 
(Chapter 2, Page 82). Table 4.1 summaries the procedural results of the 
preliminary experiments.
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Table 4.1. Procedural Results of Swan-Ganz Experiments
Rabbit ID 
and Weight
Procedural Details Outcome
Rabbit
96/736 
3.1 Kg
Unable to occlude aorta with 5F balloon 7F very 
difficult to pass but balloon occludes ascending 
aorta
Able to tolerate 30sec inflation.
Died on
90sec
inflation.
Rabbit
96/712
3.7Kg
Able to pass 7F catheter and occlude aorta. 
Tolerated one 30sec inflation and one 10 sec 
inflation.
Injected 3x108 pfu CMV LacZ Ad5 lysate in a 
volume of 9 ml Tris Saline
Sacrificed 
day 6
Rabbit
96/738
3.3Kg
Unable to pass 7F catheter on lighter animal. Able 
to pass 6F catheter, 1.5ml balloon occluded aorta. 
Injected 2x3ml of 1x109 pfu/ml CMV LacZ Ad5 
lysate, 30sec inflation with each 3ml injection.
Rupture 
carotid on 
withdrawal of 
catheter.
Died
Rabbit
96/740
3.3Kg
Able to pass 6F catheter and occlude aorta. 
Injected 12 ml of 5x108 pfu CMV LacZ Ad5 lysate 
as 4 X 3ml injections. Each injection with 15-20 
sec inflation.
Sacrificed 
day 6
Rabbit
96/769
3.2Kg
Able to pass 6F catheter and occlude aorta. 
Injected 8 ml of 1x109 pfu/ml CMV LacZ Ad5 
lysate as 8 x 1 ml. Each injection with a 30 second 
balloon inflation.
Heart
progressively 
larger, died 
on last 
inflation.
Rabbit
96/784
3.4 Kg
Able to pass 6F catheter and occlude aorta. 
Injected 22ml of 5 x 109 pfu/ml CMV LacZ Ad5 
lysate as 22 x 1ml injection, 10sec balloon 
inflation with each. 3 min recovery between 
injections. Intra-aortic BP monitoring satisfactory
Sacrificed 
day 6
Rabbit97/849
2.9Kg
Unable to pass 6F catheter. On passing 
5F, fatal 
leakage of 
carotid artery.
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Procedural Results
A 3.2Kg New Zealand white rabbit could be reliably cannulated using a 6F 
Swan-Ganz catheter and the aorta occluded by inflating the 1.5ml balloon. 
Rabbits under 3.0Kg could have their carotid arteries cannulated with a 5F 
Swan-Ganz catheter. However, the smaller catheter had a correspondingly 
smaller balloon, making occlusion of the ascending aorta difficult. Occlusion of 
the ascending aorta was thought important in preventing spillage of virus into 
the systemic arterial system and restricting the flow of virus injected below the 
balloon to the coronary circulation. Repeated short inflations were well 
tolerated but prolonged inflations of 30 seconds or more were associated with 
procedural deaths.
Histological Results 1
Rabbit 96/712 was the first animal to survive the Swan-Ganz catheter method 
of delivery. This was a relatively large animal that had a carotid artery large 
enough to pass a 7F Swan-Ganz catheter and achieve occlusion of the 
ascending aorta on inflation of the balloon. Only 3x108 pfu of virus encoding 
beta-galactosidase was used, one order of magnitude less than that used by 
Barr et al. Six days following viral introduction, the animal was sacrificed and 
the heart taken fresh for histological staining. The method of staining this 
whole heart was similar to that used by other group members in staining 
infected neonatal cardiac myocytes (Chapter 2, Page 86, Method 1). After 24 
hours of incubation in X-gal solution the whole heart appeared dark blue,
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almost black. This preliminary result was surprising and initially suggested 
very efficient transfection of a large proportion of the myocardium with a 
relatively small amount of viral vector. However, on histological sectioning it 
became apparent that the dark pigmentation was restricted to a thin coating 
on the epicardial surface and that no blue staining was apparent in the 
myocytes. There was no negative control tissue stained concurrently with this 
heart and a false positive result was suspected.
Specificity of Staining Method 1
To test the specificity of the staining method, direct needle injection of 
adenoviral vector was attempted in rats and then rabbits (Chapter 2, Page 
82). Direct needle injection was chosen as a method of guaranteeing that 
some cells around the needle tract would be infected. The procedural details 
are tabulated (Table 4.2). Two rats died immediately after injection of high 
concentration adenoviral vector. However, direct needle injections were 
successfully performed on two rabbits using low concentration of virus. Each 
heart was injected with a quantity of stock virus and in a separate area, virus 
propagated from stock virus. The hearts were harvested seven days following 
the introduction of viral vector.
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Table 4.2. Procedural Details of Direct Needle Injection Experiments
Animal ID 
and Weight
Procedural Details
Rat 51/96u 500g 200pl of 1010 pfu/ml CMV LacZ Ad5 crude lysate. 
Asystolic, died on table.
Rat 52/96b 500g 200(a.l of 1010 pfu/ml CMV LacZ Ad5 crude lysate. 
Asystolic, died on table.
Rabbit 774 3.4Kg 100fil of 5x108 pfu/ml CMV LacZ Ad5 crude lysate to 
apex. 100pl of 1:10 dilution of Lab Stock CMV LacZ Ad5
Rabbit 750 3.4Kg 100pl of 5x108 pfu/ml CMV LacZ Ad5 crude lysate to 
apex. 100pl of 1:10 dilution of Lab Stock CMV LacZ Ad5
Histological Results 2
The tissue from rabbit 96/712 had been stained using stock solutions used by 
the group for staining rat neonatal cardiac myocytes. Fresh solutions were 
used to stain tissue from the direct needle injection animals. The fixative was 
changed to 10 minutes of 4% paraformaldehyde as this was thought less 
likely to denature the beta-galactosidase enzyme. Three blocks of tissue were 
cut from each heart. These consisted of the two injected areas and an un­
injected area. Each block was halved, with one half being stained immediately 
and the other sent for frozen sectioning by Niall Whyte, Department of 
Pathology, Western Infirmary, Glasgow. The frozen sections were stained the 
same day with the same solutions. All tissue samples were incubation in X-gal 
solution for 3 hours. No counter-stain was used for fear of washing out the 
blue pigment from tissue expressing beta-galactosidase. Tissue blocks, which
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had been stained immediately, were sent the same day for processing and 
sectioning from wax blocks.
No blue staining was detected in un-injected areas. Blue staining was evident 
in the tissues that had been injected with vector encoding beta-galactosidase. 
The sections stained immediately and subsequently cut from wax blocks 
displayed blue staining on the periphery of the injection site (Plate 4.1.). Direct 
needle injection is known to cause trauma and inflammation and it was not 
surprising that the centre of the injection area did not stain positively for beta- 
galactosidase expression. A similar appearance was found in the frozen 
sections. On examination of the frozen sections of rabbit 96/774 there seemed 
to be more staining more centrally (Plate 4.2). Since no counter-stain was 
used, the morphology of positively staining cells could not be determined.
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Plate 4.1 An example of a histological section (magnification X40) of rabbit 
myocardium 7 days following direct needle injection of vector encoding beta- 
galactosidase. Some blue staining is visible on the periphery of the injection 
site. No counter-stain was used.
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Plate 4.2 An example of a histological section (magnification X25) of rabbit 
myocardium 7 days following direct needle injection of vector encoding beta- 
galactosidase. Some blue staining is visible on the periphery of the injection 
site. No counter-stain was used.
Discussion of Direct Needle Injection Experiments.
The purpose of these experiments was to ensure the specificity of the
modified staining method used to stain tissue expressing beta-galactosidase.
The use of the uninjected control in the direct needle injection experiments
suggested that the staining method used was specific. In retrospect, better
negative controls would have been direct needle injection using saline and a
separate group injected with empty virus. This is because subsequently
published data in which liposomes not encoding beta-galactosidase were
injected into the coronary circulation of rabbits resulted in blue staining of the
myocardium on exposure to X-gal (Wright et al. 1998). Using their staining
method, blue staining was noted in damaged myocardium without there
having been delivery of an exogenous beta-galactosidase gene. Therefore,
from the direct needle injection data alone, the possibility of false positive
staining secondary to myocardial damage could not be excluded. X-gal is an
indole derivative attached to a carbohydrate molecule Beta-galactosidase
cleaves the X-gal molecule, releasing an indoxyl monomer. The monomers
can become dimeric by a process of non-enzymatic oxidation. A ferro-ferri-
cyanide redox buffer is commonly used to promote the dimerisation of the
monomers, producing a water insoluble blue dye. However, in acidic
conditions, the iron from the ferro-ferri-cyanide redox buffer can precipitate out
of solution, coating tissues with a dark blue, almost black pigment (Prussian
Blue). This may be the mechanism by which false positive staining occurred in
the first rabbit to survive the Swan-Ganz delivery method. This false positive
staining can be avoided by the use of pH buffers or copper-cyanide (which
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gives a green precipitate, distinguishable from true staining of beta- 
galactosidase expressing tissue). The hearts from animals 96/740 and 96/784 
had been frozen for later analysis. On defrosting and staining of these hearts, 
no evidence of beta-galactosidase expression was detected.
Conclusion of Direct Needle Injection Experiments
It was felt that the staining method was sufficiently specific to proceed with 
dose finding experiments employing the Swan-Ganz viral delivery method. 
However, we did not include control animals where only vehicle was injected. 
It was subsequently reported that false positive staining can occur in areas of 
micro-infarction within rabbit myocardium (Wright et al. 1998). In retrospect, 
myocardium injected with vehicle alone should have been included as a 
negative control. In addition, a third group injected with empty virus would 
have controlled for the possibility that adenovirus in itself could cause false 
positive staining.
Dose Finding Study (Swan-Ganz Delivery Method)
In total seven rabbits were exposed to between sixteen and 20 ml of 
adenoviral vector encoding beta-galactosidase. The concentration of virus use 
varied from 5x109 pfu/ml to 4.2x1010 pfu/ml. The procedural and histological 
results are tabulated (Table 4-3).
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4-3. 
Dose 
Finding 
Study 
(Unfiltered 
Crude 
Lysate)
Only three of the six animals exposed to the viral vector survived to day 
six. These animals received relatively low concentrations of virus and 
positive staining for the presence of beta-galactosidase was apparent in 
animal 97/904 only. Animal 97/915 died during the procedure. To ensure 
occlusion of the ascending aorta, in this particular animal, the catheter 
had to be pushed against the aortic valve. Because of this it proved 
impossible to measure the aortic pressure during balloon inflations. This 
animal’s death was recorded as procedural in nature. Similarly, the left­
sided weakness found in animal 97/953 following instrumentation of the 
right carotid artery was recorded as a procedural complication and the 
animal was immediately euthanised.
The early deaths of animals 97/962 and 97/1065 were not thought to 
have been procedural in aetiology. At post-mortem examination both 
animals had evidence of gross congestion and inflammation within their 
respiratory system. Perivascular regions within the right ventricle of 
animal 97/962 stained positively for the reporter gene product beta- 
galactosidase. Contamination of the replication deficient adenoviral vector 
by wild type virus was suspected and for reasons of safety, the heart of 
animal 97/1065 was not taken for histology. Restriction enzyme analysis 
of the viral vector and stock virus used subsequently confirmed 
contamination by wild-type virus dl309 (Chapter 3, Page 108)
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Discussion of Swan-Ganz Viral Vector Delivery Method
It was encouraging that using the Swan-Ganz delivery method, at least 
two animals displayed evidence of foreign gene expression. However, 
when compared with the results obtained by Barr et al using selective 
coronary injection, the Swan-Ganz method of delivery appeared 
disappointingly inefficient. In at least two animals more virus was used 
than in any of Barr’s selective coronary injection animals and no evidence 
of gene transfer was found. During the time taken to analyse and attempt 
to purify the contaminated stocks of original adenoviral vector encoding 
beta-galactosidase, Donahue et al published their findings on factors 
determining adenoviral mediated gene transfer to rabbit myocardium in 
vitro (Donahue et al. 1997). In tissue culture experiments, Donahue found 
that mixing adenoviral vector with whole blood, but not sera, reduced the 
efficiency of transfection. The conclusion was that the presence of red 
blood cells reduced the efficiency of transfection. Similarly, mixing vector 
with iodine containing radio-opaque contrast material reduced the 
efficiency of viral infection in tissue culture. Using a re-circulating 
Langendorff isolated heart preparation, Donahue et al demonstrated that 
long exposure time, high viral concentration and high coronary flow were 
factors favouring efficient uptake of viral vector in the intact heart. Given 
this new information, the Swan-Ganz method had several potential flaws. 
The dead space between the aortic valve and the inflated balloon of the 
Swan-Ganz catheter provided a potential space for mixing of adenoviral 
vector and red blood cells from the left ventricle. In addition, there was
the possibility of exposing the vector to radio-opaque contrast injected to 
confirm satisfactory balloon inflation. The mixing of red blood cells and 
contrast material with the adenoviral vector may have reduced the 
efficiency of gene transfer to the myocardium. Coronary artery flow 
occurs during diastole when the aortic pressure exceeds trans-myocardial 
pressure. The rate of coronary artery flow during diastole is related to the 
difference in pressure between the aorta and the left ventricular cavity. It 
is possible that with the ascending aorta completely occluded by the 
Swan-Ganz balloon, the pressure in the left ventricular cavity would 
increase, limiting coronary artery flow. This was a further potential 
disadvantage of the Swan-Ganz method. The main theoretical advantage 
of using a Swan-Ganz catheter was the potential for multiple 
simultaneous exposures of both the coronary arteries to vector without 
risking trauma from use of a selective catheter. These preliminary results 
suggested that the Swan-Ganz catheter method of delivery was 
substantially inferior to Barr’s selective coronary injection method. Given 
the labour-intensive and time-consuming nature of adenoviral 
propagation, this made the Swan-Ganz method very unattractive.
Conclusions
In the adult New Zealand white rabbit it is possible to deliver adenoviral 
vector to the coronary circulation using a Swan-Ganz catheter. Given the 
limitations of the histological methods used it was not possible to confirm 
that cardiac myocytes had been infected. The discovery that the vector
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used was heavily contaminated with replication competent virus made 
comparison of the efficiency of this method with a historical selective 
coronary injection method impossible. In addition, the supernatant from 
crude lysate was used and this would have included potentially antigenic 
material from the human embryonic kidney cell line in which the vector 
had been propagated. This may have contributed to the inflammatory 
reaction seen in some animals. The volumes of virus used approached 
10% body weight and it is likely that larger volumes would be poorly 
tolerated and may have resulted in pulmonary oedema. It is possible that 
the theoretical advantage of multiple injections using the Swan-Ganz 
catheter would be offset by disadvantageous changes in coronary artery 
flow rate during balloon inflations. In addition, the data presented by 
Donahue et al that mixing of the adenoviral vector with blood and radio­
opaque contrast can reduce the efficiency of gene transfer to isolated 
myocytes, made the Swan-Ganz catheter method an unattractive 
candidate for further development.
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CHAPTER 5
Development of a Selective Coronary 
Catheterisation Method of Vector Delivery
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Introduction
An in vivo selective coronary injection method of adenoviral mediated 
gene transfer to rabbit myocardium was first published some four years 
before the experiments detailed in this chapter (Barr et al. 1994). In that 
time no other group had published using this method. It was anticipated 
that development of a selective coronary injection method of adenoviral 
delivery would be problematic. Selective coronary injection required 
custom-made catheters suitable for use in rabbits and fluoroscopic 
screening equipment with adequate resolution to visualise rabbit coronary 
arteries. Anticipated complications included bleeding at the carotid artery 
vascular entry site, damage to the ascending aorta, and damage to the 
instrumented coronary artery itself. However, the method of selective 
coronary injection had theoretical advantages over the Swan-Ganz 
method (Chapter 2, Page 84). By plugging the coronary artery with the 
catheter and transiently isolating the coronary artery from the aorta, there 
was the possibility of preventing viral vector from mixing with red blood 
cells. In addition, selective coronary injection had the potential of 
controlling the rate of flow of vector down the coronary artery. Exclusion 
of red blood cells and optimal coronary flow had been found to be 
important determinants of efficiency of adenoviral mediated gene transfer 
in vitro (Donahue et al. 1997). Given the labour intensive and time- 
consuming nature of adenoviral vector production, an efficient method of 
vector delivery was desirable.
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The aim of these preliminary selective coronary injection experiments 
was to assess the feasibility of causing foreign gene expression in rabbit 
cardiomyocytes by selective coronary injection of replication deficient 
adenoviral vector.
Methods
Either the left or the right coronary artery was selectively cannulated and 
adenoviral vector injected as previously described (Chapter 2, Page 84). 
A custom-made 3 French nylon coronary catheter with a hockey-stick tip 
(Royal Flush II Radiopaque Nylon Catheter, Type N3.0-21-20-P-NS- 
MAC1, William Cook Europe A/S, Bjaeverskov, Denmark) was a kind gift 
from Professor Michael Marber, Rayne Institute, St. Thomas’ Hospital, 
London. His group had used this catheter to deliver cationic liposomes 
into rabbit coronary arteries (Wright et al. 1998). The catheter was 
advanced into the chosen coronary artery until the coronary artery was 
occluded. This was done because Donahue et al had suggested that in 
isolated cultured rabbit ventricular myocytes, mixing of adenoviral vector 
with either red blood cells or radio-opaque contract material could reduce 
the efficiency of adenoviral mediated gene transfer (Donahue et al. 
1997). Coronary occlusion by the catheter was confirmed by injection of 
radio-opaque contrast but this contrast was flushed from the coronary 
artery with 0.9% sodium chloride before injection of the adenoviral vector. 
In the original paper by Barr et al the concentration of virus used was of 
the order of 109 to 101° pfu/ml with a volume of 1ml injected over 60 
seconds. W e chose to inject virus of similar concentration and volume but
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decided to inject the virus over 6-10 seconds. The reason for this 
variation was that in isolated whole hearts, which had been infected by 
recirculation of adenoviral vector, optimal combined flow rate down both 
coronary arteries had been found to be 30 ml/min (Donahue et al. 1997). 
W e estimated that right coronary flow would be less than one third of total 
coronary flow.
The procedural outcome of these experiments is tabulated (Table 5.1). 
Surviving animals were sacrificed 5 days following virus introduction and 
a 4mm horizontal section cut from mid ventricle. These tissue samples 
were stained for beta-galactosidase expression using the method 
previously described (Chapter 2, Page 86, method 2). Histological 
sections of the stained tissue samples were cut from wax blocks and 
counter-stained with Haematoxylin and Eosin as previously described 
(Chapter 2, Page 88). On light microscopy, characteristic blue 
cytoplasmic staining identified cells expressing the reporter gene product, 
beta-galactosidase. Cardiomyocytes were identified morphologically by 
their cross-striations.
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Results
Of the four rabbits that underwent selective left coronary artery 
catheterisation, only one survived. The other three animals died during 
the procedure. These animals died despite resuscitative attempts 
including external direct current shock. Examination of the histological 
sections from the one surviving rabbit revealed groups of cardiomyocytes 
staining positively for the foreign gene product beta-galactosidase. The 
positively staining cells were in a perivascular and epicardial distribution.
Of the five animals that underwent selective right coronary artery 
catheterisation, all survived the procedure. However, one animal died 
within 24 hours of the procedure. Reassuringly, post-mortem examination 
of this animal revealed no evidence of respiratory tract inflammation as 
had been found in animals injected with contaminated virus in Chapter 
four. On examination of histological sections taken from the four surviving 
animals, cells staining positively for the foreign gene product beta- 
galactosidase were found in the epicardial, endocardial and trabeculated 
areas of the right ventricle. The left ventricular free wall served as a non­
infused control when staining for the reporter gene product. In animals 
infused via the right coronary artery, no positively staining cells were 
detected in the distribution of the non-infused left coronary artery. The 
right coronary artery supplies blood to the right ventricular free wall and a 
portion of the posterior septum (Plate 5.1.).
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Plate 5.1. An example of a rabbit heart stained for beta-galactosidase 
expression (blue) 5 days following selective coronary injection of an 
adenoviral vector encoding beta-galactosidase. The heart is viewed from 
behind and the demarcation separating the left and right coronary 
territories is demonstrated.
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Table 5-1 Procedural results of Selective Coronary Injection Experiments
Rabbit
No
Weig
ht
(Kg)
Coronary
Artery
Injected
Day
Sacrificed
Vector
Concentration 
(xlO 9 pfu/ml)
Volume
Injected
(ml)
Histology 
w ith X-gal 
stain
1613 3.4 Left Died on 
table
0 0 None
1609 2.7 Left 5 13 0.3 Positive
1626 2.1 Left Died on 
table
0 0 None
1637 2.3 Left Died on 
table
0 0 None
1641 2.3 Right 1 4 2 None
1640 2.4 Right 5 4 1 Positive
1653 2.5 Right 5 4 0.9 Positive
1659 2.6 Right 5 2.5 1 Positive
1661 2.4 Right 5 5 1 Positive
Discussion
The long-term aim of the group was to deliver adenoviral vector encoding 
skeletal troponin C into the left coronary circulation with the intention of 
causing foreign gene expression in a large proportion of the left 
ventricular cardiac myocytes. If this method were successful, infected 
hearts would be suitable for physiological investigation using working 
heart methods. However, three of the four animals that underwent 
selective left coronary artery cannulation died quickly following 
introduction of the catheter. ECG monitoring was not performed during 
these procedures but the likely mechanism of death was ischaemia- 
induced arrhythmia. After injection of radio-opaque contrast material 
down a coronary artery, the artery typically remained radio-opaque until
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either injection of physiological saline or withdrawal of the catheter. This 
would suggest that the selective coronary catheter completely occluded 
the coronary artery and that blood could not flow from the aorta into the 
cannulated coronary artery.
In the right coronary injection group the distribution of positively staining 
cells was curious. Although positively staining cells were found in the 
endocardial and epicardial regions of the right ventricular free wall, the 
middle region was devoid of positively staining cells (Plate 5.2.). 
However, there were some sections where the free right ventricular wall 
had been cut at an angle. In some of these sections positively staining 
cells were found in the middle region, but only at the cut edge (Plate 5.3.). 
This unusual appearance was consistent with non-penetrance of the X- 
gal stain beyond the surface layers of each tissue block.
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Plate 5.2. A histological section (magnification X10) of right ventricle 
taken from a rabbit 5 days following introduction of adenoviral vector 
encoding beta-galactosidase. Blue staining indicative of beta- 
galactosidase expression was detected in a trabecula and in the 
endocardial region of the right ventricular free wall.
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Plate 5.3. A histological section (magnification X25) of the cut edge of 
right ventricle taken from a rabbit 5 days following introduction of 
adenoviral vector encoding beta-galactosidase. Blue staining indicative of 
beta-galactosidase expression was detected at the cut edge but not 
throughout the full thickness of the section, suggesting non-penetrance of 
the staining solutions.
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Conclusions
These experiments indicated that intra-coronary injection of adenoviral 
vector could not only cross the endothelial barrier but that it was possible 
to cause foreign gene expression in rabbit cardiomyocytes by this route. 
Although the method of staining used appeared specific for beta- 
galactosidase expression, there remained a concern about the sensitivity 
of the staining method used. In addition sham operated controls, and 
controls injected with vehicle or empty virus were not included during this 
development stage and the possibility of false positive staining, due to the 
procedure or virus in itself, was not excluded. The number of animals in 
these preliminary experiments was small. Nevertheless, temporary 
occlusion of the left coronary artery was poorly tolerated. The majority of 
the left coronary injection group died very quickly after selective coronary 
cannulation. Right coronary cannulations seemed better tolerated.
Selective right coronary artery injection became the preferred route for 
further development. The mass of the right ventricle is less than that of 
the left and it was anticipated that in a dose finding study, the total 
amount of virus required would be less if the right coronary artery route 
were used. Given the time-consuming nature of adenoviral vector 
propagation, this was an important practical consideration. There was 
local expertise in characterising the contractile physiology of rabbit
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isolated skinned ventricular trabeculae. The methods used were suitable 
for determining the calcium sensitivity of infected and uninfected 
ventricular trabeculae over a range of pH. Ventricular trabeculae of 
suitable size had previously been found to be more numerous in the right 
ventricle than in the left (Denvir et al. 1996). The observation that right 
ventricular trabeculae had displayed foreign gene expression following 
introduction of adenoviral vector into the right coronary artery circulation 
made this the route of choice for further development.
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CHAPTER 6
Comparison of Selective Coronary Injection and 
Aortic Cross-clamp Methods of Vector Delivery.
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Introduction
The aim of this work was to determine the best practicable method of 
producing rabbit myocardial tissue suitable for investigation of contractile 
physiology. Within the group, attempts to produce an adenoviral vector 
which co-expressed skeletal troponin C and green fluorescent protein 
were unsuccessful. Such a vector would have had an application in 
selecting isolated single cardiac myocytes expressing foreign gene 
product. Other physiological methods available included the working 
heart preparation and measurement of isometric contraction in isolated 
ventricular trabeculae. To employ the working heart preparation would 
require a large proportion of the left ventricular cardiac myocytes to 
express the foreign gene of interest. This was unattractive given the 
practical difficulties encountered with both the Swan-Ganz and the 
selective left coronary cannulation methods. To address the question of 
whether adenoviral vector mediated expression of skeletal troponin C in 
rabbit myocardium can protect against the calcium desensitising effects 
of acidosis, isolated right ventricular trabeculae seemed the most 
attractive preparation. Efficient infection of right ventricular trabeculae 
would require introduction of vector into the right coronary circulation.
From the preliminary selective coronary injection experiments it was 
concluded that delivery of adenoviral vector into the coronary circulation 
could result in foreign gene expression in cardiac myocytes and non­
myocytes. It was known from these preliminary experiments that infection 
of cells within right ventricular trabeculae was possible. However, the
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concentration of virus required to infect a large proportion of cardiac 
myocytes had not been determined. To determine the effect of vector 
concentration on efficiency of infection, it was decided to perform further 
selective right coronary artery injections comparing vector concentrations 
of ~109 pfu/ml with ~101° pfu/ml. The proportion of cardiac myocytes 
expressing foreign gene product would be determined by quantitative 
analysis of histological sections.
Whilst these experiments were being undertaken, discussion with Dr R 
Hajjar (Boston, Mass) led to consideration of an alternative approach. Dr 
Hajjar’s group had been delivering replication defective adenoviral 
vectors encoding a nuclear-localising beta-galactosidase into the rat 
coronary circulation by a method analogous to the Swan-Ganz method. 
At open thoracotomy a cannula was introduced into the ascending aorta 
by direct puncture of the left ventricular apex and manipulation of the 
cannula through the aortic valve. The aorta above the catheter was 
clamped. However, by simultaneously clamping the pulmonary artery, left 
ventricular filling was reduced. When the virus was injected into the 
ascending aorta the only means of escape was down the coronary 
circulation. The transduction efficiency of this method as applied to the 
rabbit was unknown. This method had two theoretical advantages over 
the Swan-Ganz method. Firstly, the volume of the dead space in the 
ascending aorta could be minimised and the potential for mixing of vector 
with red blood cells limited. Secondly, by reducing left ventricular filling, 
the pressure within the left ventricular cavity could be maintained at a low
152
level favouring continued coronary flow. It was decided to compare the 
selective coronary injection method with this promising new method.
Donahue et al reported acceleration of widespread adenoviral gene 
transfer to isolated rabbit hearts by prior coronary perfusion with Tyrodes 
solution containing a low calcium content alone and more efficiently with 
the addition of serotonin (Donahue et al. 1998). They suggested that with 
procedures to increase vascular permeability, a single pass of adenoviral 
vector through the coronary circulation could be sufficient for transduction 
of a substantial proportion of the whole myocardium. It was decided to 
include a group of animals where 5-HT was pre-injected down the right 
coronary circulation before low dose adenoviral vector.
Methods
Adenoviral Vectors
A replication defective adenoviral vector encoding a beta-galactosidase 
reporter-gene under the control of the cytomegalovirus promoter had 
been constructed using a commercially available kit (Microbix Biosystems 
Inc, Toronto, Canada) and was the kind gift of Prof. Ron Hays, St 
Andrews University. A replication defective adenoviral vector
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(pAdRSVpgal) encoding a nuclear localising beta-galactosidase gene 
under the control of the Rous Sarcoma Virus promoter was a kind gift 
from Roger Hajjar, Harvard Medical School, Boston (Dong, Schulick, 
DeYoung, & Dichek 1996). A replication defective adenoviral vector 
encoding skeletal troponin C with a haemagglutinin tag was constructed 
by Dr Obeid Khan (Khan 1999) with pE1A (Microbix) employing a 
previously described method (Hitt et al. 1995).
Histochemical Staining
Five days following vector introduction, the animals were sacrificed by 
intravenous injection of Euthetal and the hearts stained by Coronary 
Infusion as previously described (Chapter 2, Page 90). The composition 
of the staining solutions was as before but the solutions were infused 
down the coronary circulation to ensure that the full thickness of the 
myocardium was exposed to each solution. A 4mm thick horizontal 
section was cut from the mid ventricle and (with the exception of the low- 
dose selective coronary injection group) a separate tissue block cut from 
the trabeculae rich basal right ventricle. Tissue blocks were encased in 
wax from which standard 6-micron histological sections were cut and 
counter stained with Haematoxylin and Eosin as before (Chapter 2, Page 
91).
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Quantitative Analysis
Using light microscopy ( Model DM1L, Leica, Wetzlar, Germany), H&E 
stained histological sections were examined for evidence of foreign gene 
expression, cell death and inflammatory infiltrate. The proportion of 
myocardium with detectable foreign gene expression was determined by 
point counting. An England Finder Grid (Graticules Pyser-SGI Ltd, 
Tonbridge) was inverted and randomly placed over the histological slide. 
At 40X magnification both the histological section and the grid were in 
focus. At each intersection of the grid the underlying cell type was 
identified by its morphological features. Cardiomyocytes were identified 
by their cross striations. The number of cardiomyocytes staining positively 
for the foreign gene product was noted together with the total number of 
cardiomyocytes counted. Where a cell did not overlay the intersection, 
the cell to the immediate upper left was counted. This was performed 
separately for the right ventricular free wall, trabeculae rich basal right 
ventricle and left ventricular free wall. For each region, the count was 
performed on five randomly selected grid positions. On three separate 
tissue samples, an independent observer who was blinded to the results 
was able to reproduce a count of the total number of cardiac myocytes 
per section to within 7% of the original estimated.
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Results
Four groups of animals received adenovirus vector encoding a beta- 
galactosidase gene. The groups were termed “High-dose aortic cross­
clamp”, “High-dose selective coronary injection”, “Low-dose selective 
coronary injection” and finally, “Low-dose selective coronary serotonin 
pre-injection”. Animals were sacrificed five days following viral 
introduction and their hearts removed for histo-chemical analysis to 
detect beta-galactosidase expression.
In animals that underwent selective right coronary cannulation and viral 
infusion, the left ventricular free wall served as a non-infused control. 
Animals infused with 1 ml of 1x1010 pfu/ml of adenoviral vector encoding 
a skeletal troponin C mutant under the control of a human cardiac actin 
promoter pHCAsTnCHA served as infused controls (n=4). None of the 
tissues from non-infused control or infused control animals stained 
positively for the reporter gene product beta-galactosidase.
In the high-dose aortic cross-clamp group (n=8) each animal received 1ml 
of vector at a concentration of 1x1010 pfu/ml. Only occasional positively 
staining cardiomyocytes were found in the epicardial region of both 
ventricles, amounting to less than 1% of ventricular cardiomyocytes (data 
not shown). None of the right ventricular trabeculae from this group 
stained positively for the reporter gene product.
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In the low-dose right coronary injection group, each animal received 1ml 
of vector at a concentration of 5x109 plaque forming units (pfu)/ml (n=6). 
On histological examination, beta-galactosidase reporter gene expression 
was localised morphologically to perivascular cardiac myocytes and non­
myocytes in the right ventricles of 5 animals (Plate 6.1). In these animals 
2% (range 1.1%-3.3%) of right ventricular (RV) cardiomyocytes stained 
positively for the reporter gene product. The heart of only one animal 
displayed clear areas of inflammatory infiltration with associated 
cardiomyocyte cell death. This phenomenon has been termed micro­
infarction and has been reported in previous studies involving myocardial 
infusion of liposomes (Wright et al 1998).
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Plate 6.1. An example of an H&E stained section (X10 magnification) from 
the right ventricle of an animal 5 days after introduction of low-dose 
adenoviral vector encoding the beta-galactosidase gene. Cells staining 
positively for the reporter gene product appear blue.
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In the high-dose right coronary injection group each animal received 1 ml 
of vector at a concentration of 1x1010 pfu/ml (n=8). On histological 
examination, reporter gene expression was detected in the hearts of 7 
animals. In these animals 4.4% (range 0.2%-11%) of RV free wall 
cardiomyocytes and 10% (range 0.2%-31%) of RV trabecular 
cardiomyocytes stained positively for the reporter gene product beta- 
galactosidase (Plate 6.2, Plate 6.3). The level of reporter gene expression 
in the right ventricle was significantly greater in this group than in the 
high-dose aortic cross-clamp group, p<0.05. However, in this group, 
areas of inflammatory infiltration with associated cardiomyocyte cell death 
affected 32% (range 0%-64%) of the right ventricular free wall which 
differed significantly from levels obtained from the low-dose selective 
coronary injection group, p<0.05. In the group infused with 1 ml of 1x1010 
pfu/ml of control virus encoding the troponin C mutant, myocardial 
infarction affected 24.2% (1.9%-64.4%) of the right ventricular free wall. 
Again, this differed significantly from levels obtained in the low-dose 
selective coronary injection group p<0.05.
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Plate 6.2. An example of an H&E stained section (X10 magnification) from 
the right ventricle of an animal 5 days after introduction of high-dose 
adenoviral vector encoding a nuclear-localising beta-galactosidase gene. 
Cells staining positively for the reporter gene product have blue nuclei. In 
this representative section there is an area of micro-infarction.
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Plate 6.3. An example of an H&E stained section (X25 magnification) of a 
trabecula found in the right ventricle of an animal 5 days after introduction 
of high-dose adenoviral vector encoding a nuclear localising beta- 
galactosidase gene. Cells staining positively for the reporter gene product 
have blue nuclei.
In the final group, right coronary injections were performed using 1ml of 
vector at a concentration of 5x109 plaque forming units (pfu)/ml (n=6). 
However, in this group, the radio-opaque contrast was flushed from the 
coronary circulation prior to virus injection with 1ml of 10‘5mol/l_ serotonin 
and not physiological saline as before. This group was termed “low-dose 
serotonin pre-injection group.” On histological examination, beta- 
galactosidase reporter gene expression was localised morphologically to 
perivascular cardiac myocytes and non-myocytes in the right ventricles of 
5 animals. In these animals 4.5% (range 1.4-6.8% ) of RV free wall 
cardiomyocytes stained positively for the reporter gene product, which 
differed significantly from that obtained for infused or non-infused controls 
(p<0.05). However, in this group, areas of inflammatory infiltration with 
associated cardiomyocyte cell death affected 54% (range 7%-79%) of 
the right ventricular free wall and this was significantly greater than the 
low-dose coronary injection group without serotonin pre-injection 
(p<0.05). In the rabbits that underwent serotonin pre-injection, blood was 
taken before and one day after vector introduction. The blood was tested 
using the only commercially available kit to detect the presence of cardiac 
troponin T (Cardiac Reader System, Roche Diagnostics Ltd, East 
Sussex). All pre-injection samples were negative for troponin T. However, 
every sample taken one day following vector introduction tested positive 
for cardiac troponin T, indicating that some myocardial damage had 
occurred within one day of vector introduction. The histological data from 
the selective coronary injection groups are summarised in figure 6.1 and 
figure 6.2.
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Figure 6.1. Percentage of right ventricular myocytes staining positively 
for the reporter gene beta-galactosidase. Point plot of all 4 coronary 
injection groups with mean and standard deviation for each group. 
Percentage of positive staining was Low Dose (n=6) 1.7+/- 1.2, 5HT+Low 
Dose (n=6) 3.7+/-2.6, High Dose (n=8) 3.8+M.4, TnC-HA Controls (n=4) 
0.0+/-0.0
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Figure 6.2. Percentage of micro-infarction in the right ventricle. Point plot 
of all 4 coronary injection groups with mean and standard deviation for 
each group. Percentage of micro-infarction was Low Dose (n=6) 1.1+/- 2.6, 
5HT+Low Dose (n=6) 54.5+/-34.0, High Dose (n=8) 32.0+/-24.9, TnC-HA 
Controls (n=4) 24.2+7-28.4
Discussion
For the purpose of in vivo myocyte transduction of adult New Zealand 
white rabbit right ventricular trabeculae or right ventricular free wall, both 
the low and high-dose selective coronary injection method were found to 
be more efficient than the high-dose aortic cross-clamp method. In 
previously reported experiments involving cultured isolated cardiac 
myocytes the presence of red blood cells decreased transduction 
efficiency of adenoviral vector. Occluding the coronary artery with the 
catheter prior to viral injection reduced the risk of contaminating the viral
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vector with red cells. In addition, the coronary artery was pre-injected with 
nominally calcium-free physiological saline before viral delivery, a 
process that in isolated Langendorff heart preparations has been reported 
to increase the proportion of viral load reaching cardiac myocytes. The 
mechanism of this effect was thought to be an increase in endothelial 
permeability to adenovirus (Donahue et al. 1998). The decision to inject 
the viral vector over 6-10 seconds was based on the coronary flow 
required for efficient gene transfer in the earlier reports of Langendorff 
adenovirus re-circulation experiments (Donahue et al. 1997).
In the high-dose selective coronary injection group, right ventricular 
trabeculae were found in which up to one third of their cardiomyocytes 
stained positively for the reporter gene product. It is possible to isolate 
right ventricular trabeculae suitable for studies in isometric tension 
measurement (Denvir, MacFarlane, Miller, & Cobbe 1996). One of the 
principal aims of the study was to investigate the calcium sensitivity of 
myocardial tissue that expressed skeletal troponin C following adenoviral 
mediated gene transfer. Permeabilised trabeculae can be used to 
investigate the effects of components of ischaemia and in particular, 
acidosis. Although the aortic cross-clamp method had failed to produce 
adequate efficiency of gene transfer to allow investigation of a whole 
heart preparation, it was hoped that important questions could still be 
answered by utilising isolated trabeculae.
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Inflammation
In immune competent animals, inflammatory reactions associated with 
tissue transduction with first generation adenovirus vectors have been 
reported previously (Gilgenkrantz et al. 1995; Knowles et al. 1995; Li et 
al. 1995). In the low-dose selective coronary injection group there was 
little evidence of significant myocardial damage in all but one of the 
animals. All hearts were examined 5 days following viral introduction and 
this may be too early for a significant antibody mediated immune 
response. Nevertheless, these results were achieved without the use of 
an immunosuppressant such as methylprednisolone which has been 
used to decrease inflammatory reactions in studies of adenovirus delivery 
to myocardium (Shah et al. 2000).
Significantly more myocardial damage was seen in both the high-dose 
group and in the low-dose serotonin pre-injection groups (Student t test 
p<0.05, Mann-Whitney Rank Sum Test p<0.05 respectively). In both 
these groups significant micro-infarction was observed and could have 
been the result of a cell-mediated response or a prompt humoral 
response. The high proportion of infarcted myocardium found in the 
serotonin pre-injection group could be as a consequence of either a direct 
effect of serotonin on the myocardium or an indirect effect by substantially 
increasing the proportion of viral vector reaching the cardiac myocytes. 
The data from these experiments does not help distinguish between the 
two possibilities. The possibility remains that with modified adenovirus 
vector, serotonin may facilitate vascular permeability without increasing
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micro-infarction. Further work is required to increase efficiency of delivery 
through the endothelial barrier and determine optimal dose requirements. 
It is likely that work performed in optimising vascular permeability to 
adenoviral vectors would be applicable to modified adenoviruses 
(Kochanek et al. 1996) and potentially to adeno-associated virus 
(Svensson et al. 1999).
Specificity of Beta-galactosidase Staining
In rabbit hearts infused with cationic liposomes, non transduced areas of 
micro-infarction were reported as staining positively using a method 
thought specific for beta-galactosidase activity (Wright et al. 1998). W e  
found our staining method to be specific for nuclear-localising beta- 
galactosidase. In a group of rabbits with areas of micro-infarction 
following the introduction of high dose adenoviral vector encoding a 
skeletal troponin C mutant pHCAsTnC-HA, no positively staining cells 
were detected. In addition, the use of a nuclear-localising beta- 
galactosidase reporter gene simplified the morphological identification of 
striated cardiomyocytes. Why did some animals which had been exposed 
to a vector encoding a beta-galactosidase reporter gene fail to show any 
evidence of foreign gene expression? One possibility is that there was 
incomplete occlusion of the selected coronary artery by the catheter. This 
would allow blood to pass down the coronary artery, reducing the effect of 
nominally low-calcium saline injection on the endothelium and allow
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vector to mix with red blood cells. Both of these factors would be 
expected to reduce transfection efficiency.
Conclusions
From these experiments it was concluded that the aortic cross-clamp 
method of vector delivery was inadequate for the efficient transduction of 
a sizable proportion of left ventricular cardiac myocytes. Indeed, the 
selective right coronary injection method was found to be a more efficient 
method of producing right ventricular trabeculae that expressed foreign 
gene product. The selective right coronary artery injection could produce 
right ventricular trabeculae with up to one third of their myocytes 
expressing foreign gene product. However, selective coronary injection of 
high concentration vector resulted in significantly more myocardial micro­
infarction when compared with low concentration injections. Pre-injection 
of serotonin resulted in substantial myocardial damage even when low 
concentration vector was used. It is not clear from these data whether the 
mechanism by which damage was caused was by serotonin perse  or by 
more vector reaching the myocytes through a more permeable 
endothelium. Further control groups should have included sham operated 
animals, and animals injected with vehicle alone or empty virus. The data 
from these negative control groups would have excluded the possibilities 
of both false positive staining and of a procedural cause for the micro­
infarction seen. In addition two control group of animals pre-injected with 
serotonin and then injected with either vehicle alone or empty virus
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should have been included. Data from these control groups would have 
helped clarify the mechanism by which serotonin resulted in substantial 
myocardial damage even when low concentration of vector was used. 
The lack of these important control groups seriously undermined the 
conclusions which could be reached from the data presented.
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CHAPTER 7
Physiological Investigation of Right Ventricular
Trabeculae.
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Introduction
Selective right coronary injection of 1 ml of adenoviral vector at a 
concentration of 1x1010 pfu/ml had been found to result in expression of 
foreign gene product in up to one third of myocytes within the 
trabeculated area of the basal right ventricle. When the same volume and 
concentration of adenoviral vector was administered by the aortic cross­
clamp method, only small numbers of left ventricular myocytes stained 
positively for foreign gene product (Chapter 6). The original hypothesis 
was that when compared to controls, adenoviral mediated expression of 
skeletal troponin C within rabbit myocardium would render the 
myocardium relatively resistant to the calcium desensitising effects of 
acidosis, a component of ischaemia. For the purposes of testing the 
original hypothesis the selective coronary injection method showed 
promise. It had been a pre-stated aim of the group to develop an 
adenoviral vector that would co-express both skeletal troponin C and 
Green Fluorescent Protein (GFP). If co-expression of GFP could be 
achieved then infected individual trabeculae could be distinguished from 
uninfected trabeculae by their visual appearance and isolated for 
physiological investigation. Using the selective right coronary injection 
method of adenoviral vector delivery, the proportion of positive staining 
cells within individual trabeculae was variable and the ability to pre-select 
only those trabeculae demonstrating foreign gene expression was
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important. However, attempts at producing a suitable co-expressing 
vector had been unsuccessful.
CMV-sTnC-A9-HA Ad5 was a vector produced by Obeid Khan (Khan 
1999). It was an adenoviral vector encoding skeletal troponin C. 
However, the sequence encoding the C-terminal nine amino acids had 
been removed and replaced with a 12 amino-acid sequence. This new 
sequence encoded 3 linker amino acids attached to a 9 amino-acid 
haemagglutinin antigen motif. Monoclonal antibodies with high affinity to 
the haemagglutinin antigen were commercially available. This vector had 
been constructed with the original intention that it be used in conjunction 
with confocal microscopy to determine the intracellular location of foreign 
gene product, and in particular, the incorporation of foreign gene product 
into the sarcomere. CMV-sTnC-A9-HA Ad5 was used by Dr Khan to 
infect NIH3T3 mouse fibroblasts cells in culture. A western blot for the 
presence of HA tag was positive in fibroblast cells infected with CMV- 
sTnC-A9-HA Ad5 but negative for cells infected with HCA-sTnC-A9-HA 
Ad5 and in uninfected cells. Both vectors were used to infect rat neonatal 
cardiocytes. Immunostaining for the HA product was positive in CMV- 
sTnC-A9-HA Ad5 infected cardiocytes and to a lesser extent HCA-sTnC- 
A9-HA Ad5 infected cardiocytes, but was negative in negative control 
groups. Dr Khan concluded that the vectors could cause foreign gene 
expression and that the HCA-sTnC-A9-HA Ad5 vector demonstrated 
characteristics of tissue specific expression. However, from these 
experiments it was not known if the HA tagged product integrated into the
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sarcomere of infected myocytes. The C-terminal 9 amino-acids had been 
replaced by a 12 amino-acid sequence including the 9 amino-acid 
sequence for the HA tag. The C-terminal of TnC sits close to and 
interacts with the other troponin sub-units and the possibility remained 
that the lengthened HA tagged mutant may not integrate into the 
sarcomere. In retrospect, confirmation of integration of sTnC-HA into the 
sarcomere in cell culture should have been sought prior to proceeding to 
in vivo functional experiments.
Experimental Design
Adult New Zealand White rabbits underwent injection of 1ml of 1x1010 
pfu/ml of adenoviral vector by selective right coronary injection as 
previously described (Chapter 6). One group of animals received vector 
encoding nuclear localising beta-galactosidase and a second group 
received the vector CMV-sTnC-A9-HA Ad5. Animals were sacrificed five 
days following vector introduction, and their hearts removed. The hearts 
were immediately placed in Modified Ringer’s Solution containing 30mM 
BDM. The methods used to isolate, permeabilise and determine the 
calcium sensitivity of skinned fibres have been described in detail 
(Chapter 2, Page 97). Importantly, at the time that the trabeculae were 
isolated, it was not known what proportion of cardiac myocytes within 
each trabecula expressed foreign gene product. Following physiological 
investigation, trabeculae were taken for histochemical or immuno-
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histochemical determination of the proportion of myocytes expressing 
foreign gene product. It was anticipated that from the two groups of 
animals, three groups of data would be available: trabeculae with a high 
proportion of cells expressing skeletal troponin C, trabeculae with a high 
proportion of cells expressing nuclear localising beta-galactosidase and 
trabeculae with no (or low) detectable foreign gene expression. The beta- 
galactosidase group was included as previous reports had indicated that 
adenoviral vectors per se could alter contractile characteristics (Novotny, 
Gustafson, Kvapil, & Ransnas 1994). Control groups including sham 
operated animals, animals injected with vehicle alone and animals 
injected with empty virus should have been included.
Immunohistochemistry
The detailed methodology for immuno-histochemical staining of rabbit 
myocardium expressing skeletal troponin C with the haemagglutinin 
antigen motif has been described (Chapter 2, Page 88). To determine an 
appropriate primary antibody dilution, histological sections were obtained 
from areas of rabbit myocardium that had undergone direct needle 
injection of adenoviral vector. The base of the heart had been injected 
with the vector CMV-sTnC-A9-HA Ad5. The apex of the heart had been 
injected with the vector HCA-sTnC Ad5, an adenoviral vector encoding 
skeletal troponin C under the control of the human actin promoter (Khan 
1999). Each injection was of 0.1ml of vector at concentration of 1010
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pfu/ml. The animal was sacrificed 5 days following viral introduction. The 
results are summarised in Table 7.1.
Table 7.1 Immunohistochemistry Results of Direct Needle Injection 
Experiments
Primary
Antibody
1:50
Primary
Antibody
1:100
Primary
Antibody
1:200
No Primary 
Antibody
CMV-sTnC- 
A9-HA Ad5
+++ ++
HCA-sTnC 
Ad 5
Un-injected 
control LV
“+” denotes positive staining for the haemagglutinin antigen motif.
Tissue that had been injected with the vector CMV-sTnC-A9-HA Ad5 five 
days previously stained strongly with a primary antibody dilution of 1:50 
(Plate 7.1.). At this primary antibody dilution, there was no false positive 
staining of tissue exposed to HCA-sTnC Ad5 or uninfected myocardium. 
Thus, the method was thought specific for detection of haemagglutinin 
antigen motif expression in rabbit myocardium infected with adenoviral 
vector. This method would subsequently be employed to identify foreign 
gene product in permeabilised trabeculae after physiological 
investigation.
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Plate 7.1. An example of a histological section of myocardium from a 
rabbit that underwent direct needle injection with the vector CMV-sTnC-A9- 
HA Ad5 five days previously. DAB staining was used and cells staining 
positively for the HA tagged protein appear brown.
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Calcium Sensitivity of Permeabilised Trabeculae.
A total of eighteen trabeculae were isolated from ten adult New Zealand 
white rabbits. Six of the rabbits had been exposed to adenoviral vector 
encoding nuclear localising beta-galactosidase and nine trabeculae were 
tested from these animals. A further nine trabeculae were isolated from 
four rabbits which had been exposed to adenoviral vector CMV-sTnC-A9- 
HA Ad5. The methods used to determine the calcium sensitivity of these 
preparations at pH 6.5 and pH 7.0 have been described (Chapter 2, Page 
92). These data were obtained without the operator knowing what 
proportion of myocytes in each isolated trabecula expressed foreign gene 
product. A macro running in the Mac application ‘Igor Pro’ (Written by Dr 
D Miller, using a Levenberg-Marquadt least squares algorithm) was used 
to generate a best-fit curve to the Hill equation for each preparation 
examined. From the curve thus derived, the calcium sensitivity for each 
preparation could be calculated and expressed in a standard manner as 
the free calcium concentration at which half maximal isometric tension 
was achieved (pCaso). The results are summarised in Table 7.2
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Table 7.2. Calcium Sensitivity of RV Trabeculae at pH 7.0 and 6.5
Number of 
Trabeculae
Mean
pCa5o
Standard
Deviation
SEM
Beta-Gal pH7.0 9 5.505 0.121 0.0403
Beta-Gal pH6.5 9 4.929 0.154 0.0514
sTnC-HA pH 7.0 9 5.395 0.202 0.0673
sTnC-HA pH 6.5 9 4.952 0.213 0.0711
“Beta-Gal”- trabeculae from animals infused with vector encoding nuclear 
localising beta-galactosidase (n=9). “sTnC-HA”-trabeculae from animals infused 
with vector encoding sTnC with a HA tag motif (n=9). “SEM” -  Standard Error of 
the Mean.
It was expected that within groups, there would be a significant reduction 
in calcium sensitivity at lower pH. However, it was not known if comparing 
between groups, trabeculae from animals infused with vector encoding 
the skeletal troponin C construct would be less sensitive to the effects of 
acidosis. An analysis was made on the data from all trabeculae studied 
before the results of histological and immuno-histochemical analysis was 
known. The pCaso data from each group passed the Normality Test for 
normal distribution. Differences between groups were determined by 
employing a t-test. As expected there were significant reductions in 
calcium sensitivity between trabeculae studied at pH7.0 and pH6.5 (Beta- 
Gal pH7 v Beta-Gal pH6.5, p<0.001 and sTnC-HA pH7.0 v sTnC-HA
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pH6.5, p=0.002). However, on comparing the pCaso of trabeculae from 
Beta-Gal pH 6.5 with sTnC-HA pH 6.5 there was no significant difference 
(p=0.8). The mean pCa50 for these groups were 4.929 and 4.952 
respectively. A power calculation was performed and with a difference in 
pCaso of only 0.0229 between the groups, the power for two groups of 
1000 rabbits would have been only 0.675 (assuming a of 0.05). It was 
anticipated that by selecting data from trabeculae with proven foreign 
gene expression, and excluding data from trabeculae with no histological 
evidence of foreign gene expression, the difference in pCaso between 
groups would be greater and that a power calculation could be performed 
to estimate the number of experiments required. In a study of single 
cardiac myocytes from transgenic mice which expressed sTnC in their 
hearts, a significant difference was found between these and cells from 
normal hearts where n=11 in one group and n=7 in the other (Metzger et 
al. 1993).
Histology
Following physiological investigation, the permeabilised trabeculae were 
taken for histological examination. Trabeculae from animals infused with 
the vector encoding sTnC-HA were mounted in wax blocks and 
histological sections examined following immuno-histochemical staining 
using a high affinity rat antibody to the haemagglutinin epitope as 
described above. Trabeculae from animals infused with the vector 
encoding nuclear localising beta-galactosidase were immediately
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immersed in the staining solutions for beta-galactosidase as had been 
used for the whole heart infusion (Chapter 2, Page 87). These trabeculae 
were stored overnight in wash solution at 4°C then mounted in wax blocks 
and sections cut. The results of the histological analysis were very 
disappointing: None of the trabeculae stained positively for their 
anticipated gene product. Using fresh antibody, further sections from 
animals infused with the vector encoding CMV-sTnC-A9-HA were 
carefully stained to detect the presence of foreign gene product. Again, 
no positive staining was observed.
Discussion
The method used to determine the calcium sensitivity of isolated rabbit 
trabeculae had been well characterised (Denvir, MacFarlane, Miller, & 
Cobbe 1996). However, the method requires complete disruption of the 
cellular and sarcoplasmic reticulum lipid membranes by Triton X-100. By 
effectively removing these membranes, the bath into which the 
preparation is immersed becomes an extension of the myocyte cytosol. 
By controlling the constituents of the bath solution, the cytosolic 
characteristics around the contractile matrices are controlled.
It was anticipated that up to 30% of myocytes in trabeculae from infused 
animals would express foreign gene product and that approximately one 
third of trabeculae would exhibit foreign gene expression in more than 
10% of their myocytes. Since not all trabeculae were expected to display
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foreign gene expression, methods of distinguishing infected trabeculae 
either before or after physiological investigation were required.
As expected, physiological experiments found clear reduction in calcium 
sensitivity of trabeculae at pH 6.5 when compared with trabeculae at pH 
7.0. This was true for both the sTnC-HA and nuclear localising beta- 
galactosidase groups. The original hypothesis was that myocardial tissue 
expressing skeletal troponin C would be resistant to the calcium 
desensitising effects of intra-cellular acidosis. Although no significant 
difference was found between sTnC-HA pH 6.5 and B-gal pH 6.5, any 
real difference may have been attenuated by the presence of data from 
un-infected trabeculae within each group.
The most plausible explanation for none of the eighteen trabeculae 
staining positively for their expected gene product is that Triton X-100 
completely disrupted all membranes. During physiological investigation, 
each trabecula underwent twenty-four bath changes at each pH. The two 
resting solutions used were of different ionic concentration and it is 
possible that both cytosolic and nuclear localising gene products would 
have been washed away. This potential problem had not been anticipated 
when the experimental protocol was decided upon. In retrospect in vitro 
experiments should have been undertaken to confirm that the sTnC HA- 
tagged mutant could be incorporated into the sarcomere of myocytes 
prior to proceeding to in vivo experiments. An alternative explanation for 
not detecting gene product was that this was a true negative. This was 
thought unlikely given the result of the original selective coronary injection
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experiments (Chapter 6). In retrospect, the unused trabeculae from each 
animal should have been saved for later immunohistochemistry as this 
would have helped refute the possibility that none of the trabeculae 
expressed foreign gene product. The possibility of using in-situ 
hybridisation to detect viral DNA in histological slides of trabeculae was 
considered. However, adenoviral vector DNA remains epichromosomal 
and it too would be subject to “washout”.
Conclusions
The results of the immuno-histochemical analysis of tissue taken 
following direct needle injection of rabbit myocardium demonstrate that 
the vector CMV-sTnC-A9-HA Ad5 can achieve detectable expression of 
its encoded gene product in rabbit myocardium. However, the presence 
of the gene product within the cell does not infer its incorporation into the 
sarcomere matrix and a physiological benefit remained to be 
demonstrated. In retrospect, in vitro experiments should have been 
undertaken to confirm that the sTnC HA-tagged mutant could be 
incorporated into the sarcomere of myocytes prior to proceeding to in vivo 
experiments.
It is well established that acidosis causes a fall in myocardial contractility 
(Poole-Wilson 1989). Irrespective of the vector infused, trabeculae from
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both groups of animals demonstrated statistically significant reduction in 
calcium sensitivity in conditions of acidosis.
It had been expected that infected trabeculae from animals infused with 
CMV-sTnC-A9-HA Ad5 would be resistant to the calcium desensitising 
effects of acidosis when compared with trabeculae infected with vector 
encoding nuclear localising beta-galactosidase or compared with 
uninfected trabeculae. Control groups of sham operated animals, animals 
injected with empty virus and animals injected with vehicle alone should 
have been included. Had a the group injected with CMV-sTnC-A9-HA 
Ad5 been found to have significantly different physiological characteristic, 
the control groups would have been required to confirm that this was 
conferred by the presence of the gene product and not a consequence of 
the procedure or a non-specific effect of adenoviral vectors. 
Unfortunately, no histological confirmation of foreign gene expression 
could be demonstrated in any of the eighteen trabeculae that had 
undergone permeabilisation and physiological examination. From the 
original gene transfer results (Chapter 6) it would be possible but unlikely 
to have no detectable gene product following intra-coronary injection of 
high concentration adenoviral vector. An alternative explanation is that 
the Triton X-100 used to completely permeabilise all lipid membranes 
within the trabeculae allowed gene product to be washed away during the 
many bath changes required to determine calcium sensitivity.
When the calcium sensitivity of trabeculae at pH6.5 from animals infused 
with CMV-sTnC-A9-HA Ad5 was compared with that of trabeculae from
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animals infused with vector encoding nuclear localising beta- 
galactosidase, only a small statistically insignificant difference was found. 
Without a method to identify the data from only infected trabeculae, a 
power calculation showed that the numbers needed to demonstrate a 
small difference would be impractical.
Selective coronary injection of adenoviral vector using the method 
described cannot guarantee that all RV trabeculae will express foreign 
gene product. An in vivo method of pre-selecting infected trabeculae for 
physiological investigation such as co-expression of Green Fluorescent 
Protein and the gene of interest would be advantageous.
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Chapter 8
General Discussion
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Introduction
The group of Hajjar were the first to demonstrate a change in heart 
function following the in vivo adenoviral mediated gene transfer of 
phospholamban (Hajjar et al. 1998). This was achieved by an aortic 
cross-clamp method in adult rats. Subsequent to this, the group of Koch 
reported successful in vivo delivery of an adenoviral vector encoding the 
potentially therapeutic gene for the beta-2 adrenergic receptor to rabbit 
myocardium using a modified aortic cross-clamp method (Maurice et al. 
1999). Since then, Koch’s group have reported global improvement in left 
ventricular contractility in response to isoproterenol in rabbits where an 
adenoviral vector encoding the gene for the beta-2 adrenergic receptor 
was delivered to rabbit myocardium by a selective coronary route (Shah 
et al. 2000). A direct comparison of the selective coronary injection with 
that of aortic cross-clamp method has not been reported before.
The group of Lawrence have employed isolated perfused rabbit hearts 
and cell culture methods to determine factors important to efficient 
adenoviral mediated gene transfer via the coronary circulation (Donahue 
et al. 1997; Donahue et al. 1998). Factors reported to reduce adenoviral 
mediated gene transfer include mixing of the virus with red blood cells or 
radio opaque contrast but not serum. Factors reported to improve 
efficiency of transfection in isolated perfused hearts include vector 
concentration, coronary flow rate and duration of exposure. However, a 
critical parameter to efficient adenoviral mediated gene transfer was
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coronary circulation microvascular permeability. “Acceleration” of ex vivo 
gene transfer was reported in isolated perfused rabbit hearts where the 
Tyrodes solution had been modified and the calcium concentration 
reduced from 1mM to 50pM. The hypothesis was that low calcium 
perfusate would increase microvascular permeability and improve 
efficiency of gene transfer. Supportive of this hypothesis was that both 
serotonin and histamine, substances known to increase microvascular 
permeability, further improved transfection efficiencies. At optimal 
conditions, practically the whole heart was infected following only a short 
2-minute exposure with a modest viral concentration of only 1.6 x 109 
pfu/ml.
Replication defective adenoviral vectors can provoke an immune 
response which can result in damage to infected tissues (Gilgenkrantz et 
al. 1995; Kasseisler et al. 1994). In the isolated perfused heart 
experiments the heart could not be affected by the systemic immune 
system. In the selective coronary injection experiments by Koch’s group 
an attempt was made to attenuate the potentially damaging effects of the 
immune system by administration of methylprednisolone. Nevertheless, 
the animals that received adenoviral vector exhibited unexplained 
increase in left ventricular end diastolic pressure and increases in resting 
heart rate. These changes were found in the group infused with vector 
encoding beta-galactosidase but not in the group infused only with saline. 
One potential mechanism for these findings would be immune mediated 
myocardial damage. Although a substantial increase in tissue gene 
product was reported, it is not clear if there was homogenous distribution
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of infected myocytes or simply very high levels of gene product in 
perivascular myocytes. This is important, as heterogeneous expression of 
beta-2 adrenergic receptor would have the potential to cause 
heterogeneity of refractory periods within myocardium, and possibly a 
pro-arrhythmic effect.
Comparison of the Aortic Cross-clamp Method with 
Selective Coronary Injection
A direct comparison of the aortic-cross clamp method and the selective 
coronary method of adenoviral mediated gene transfer to myocardium 
had not been reported previously. In Chapter 6 the efficiency of the 
selective coronary injection method was compared to that of the aortic 
cross-clamp method and the selective coronary injection method was 
found to be superior. The viral concentration and dose reaching the 
coronary circulation was expected to be greater with the selective 
coronary method. However, the influence on coronary flow, microvascular 
permeability and left ventricular filling by simultaneous pulmonary 
occlusion in the Hajjar method were not known. The group of Koch have 
reported gene transfer to rabbit myocardium using a method which 
involves aortic cross-clamp but not pulmonary cross-clamp. This group 
used adenosine to temporarily slow or stop the heart. However, 
adenosine can cause coronary vasodilatation and it is not clear if the 
advantage of adenosine was one of only simple rate control.
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The data in Chapter 6 demonstrate that low dose virus can result in 
transfection of cardiac myocytes within the distribution of the injected 
coronary artery without obvious myocardial damage five days following 
viral introduction. This is consistent with the previous report by Barr (Barr 
et al. 1994). However, when a higher concentration of vector was 
introduced by selective coronary injection, the proportion of myocytes 
expressing foreign gene was greater but significant myocardial cell death 
and inflammation was evident. This was detectable five days following 
viral introduction and this was thought early for a humoral mediated 
immune response. One possible explanation for early myocardial damage 
is vector induced cell death. In tissue culture experiments of isolated 
myocytes exposed to an adenoviral vector encoding for sarcoplasmic 
reticulum ATPase, viral titres of more than 4 pfu per cultured myocyte 
were associated with programmed cell death (O’Donnell et al 2001). The 
findings of substantial areas of myocardial damage in rabbits pre-injected 
with serotonin before low dose virus would be compatible with a harmful 
effect of serotonin perse  or an increase in efficiency of viral delivery and 
a harmful effect of excessive numbers of viral particles reaching 
perivascular myocytes. However, the relevant controls with infusion of 
vehicle alone or infusion of empty virus were not performed.
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Specificity of Histochemical and Immunohistochemical 
Methods
On staining the myocardium for detection of the expression of the 
reporter gene product beta-galactosidase the coronary perfusion method 
was found to be specific. No false positive staining was found in areas of 
microinfarction in animals infused with the vector encoding skeletal 
troponin C. However, these areas may not have been accessible to the 
X-gal solution if the inflammatory process resulted in capillary occlusion. 
Furthermore, the exact numbers of positively staining myocytes is subject 
to counting error because of indefinite myocyte borders and myocyte 
orientation. This was a particular concern when employing the non­
nuclear localising beta-galactosidase. Nuclear localising beta- 
galactosidase did not demonstrate the same leakage into neighbouring 
cells but here there remained the possibility that the nuclei would not be 
in section and that cells expressing foreign gene product may be counted 
as not. This potential error would be expected to under-estimate the 
efficiency of gene transfer irrespective of the delivery method used. By 
counting only myocytes where the nucleus was visible, this potential 
problem was minimised.
The use of in vivo gene transfer of an HA tagged protein to rabbit 
myocardium had not been reported previously. The data from the direct 
needle injection experiment demonstrated that the high affinity 
monoclonal rat antibody could specifically detect haemagglutinin antigen
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motif expression in rabbit myocardium exposed to replication defective 
adenoviral vector. This suggests that haemagglutinin antigen motif could 
have wider application and be used in the investigation of other genes of 
interest.
Use of Serum Troponin T to Detect Early Myocardial 
Damage
A sensitive method of detecting serum troponin T is available 
commercially (Roche, Welwyn Garden City). This is used clinically to 
detect minor myocardial damage in patients with acute coronary 
syndromes. W e demonstrated detectable troponin T In the rabbits in 
which intra-coronary serotonin was delivered immediately prior to 
selective coronary injection of low concentration replication defective 
adenoviral vector. Troponin T, indicative of myocardial damage, was 
detected within 24 hours of infusion with adenoviral vector and it is 
unlikely that antibody mediated immune response would occur in this time 
course. Troponin T detection may have application in defining the time 
course of myocardial damage following gene transfer.
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Physiology of Isolated Ventricular Trabeculae
The original hypothesis was that adenoviral mediated gene transfer of 
skeletal troponin C to rabbit myocardium would attenuate the calcium 
desensitising effects of acidosis, one of the components of ischaemia. If 
proven, the methods developed would have potential as a powerful 
investigative tool and would be the first step in developing skeletal 
troponin C as a potential therapy for ischaemic heart disease. It was 
known that adenoviral vectors had the potential to evoke an immune 
response and possibly cause myocardial damage. It was for this reason 
that the experimental design included tissue exposed to adenoviral vector 
encoding a physiologically inert reporter gene product (beta- 
galactosidase). By including this group and comparing physiological data 
with un-infected myocardium, there was the potential to elucidate the 
adverse effects of adenoviral mediated gene transfer on contractile 
physiology.
This was an ambitious goal as success was dependent on efficient gene 
transfer to a significant proportion of myocytes. Although Barr et al had 
reported this in 1994, their results proved difficult to reproduce. In 
addition, it was not known if skeletal troponin C would integrate into the 
sarcomere of infected cells. Integration of tropomyosin and troponin I into 
the sarcomere has been demonstrated in isolated myocytes following 
adenoviral mediated gene transfer (Michele, Albayya, & Metzger 1999).
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Our original aim was to achieve foreign gene expression in a substantial 
proportion of myocytes in the left ventricle of adult rabbit hearts and to 
perform physiological investigations on isolated working hearts. Control of 
preload, afterload and heart rate is possible with the working heart 
preparation. True ischaemia can be induced by coronary artery ligation. 
However, using isolated trabeculae we were still able to test our original 
hypothesis in tissue from a model of gene transfer. The group of 
Hasenfuss have used the method of Donahue et al to infect isolated 
hearts by re-circulation of virus. Trabeculae isolated from these hearts 
remained viable for two days by which point foreign gene expression was 
detectable (Lehnart et al. 2000). This work provides an important tool for 
investigation of adenoviral-mediated alteration of contractile function. 
However, isolated trabeculae cannot remain viable indefinitely. Where 
gene products of interest take many days or weeks to integrate into the 
cell, this method may not be suitable. With adeno-associated viruses it 
may take several weeks before foreign gene expression is detectable 
(Wright et al. 2001). For this reason the method of Hasenfuss would not 
be attractive for investigation of adeno-associated virus mediated gene 
transfer.
Why foreign gene expression was not detected in any of the trabeculae 
that had undergone physiological investigation is uncertain. Selective 
coronary injection of adenoviral vector into the right coronary artery had 
been shown to result in foreign gene expression (Chapter 6). The 
histochemical and immunohistochemical methods employed to detect
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foreign gene had been successful in whole hearts and histological 
sections respectively. The most likely explanation was that the detergent 
Triton X-100 completely dissolved all cell membranes including the 
nuclear membrane and that gene product was washed from the cell 
during frequent bath changes. There would be a clear advantage of being 
able to distinguish tissue which expresses foreign gene product from 
tissue that does not, prior to selection for physiological investigation. Co- 
expression of green fluorescent protein has such an application. This has 
been used to select single cells for unloaded velocity of contraction 
studies (Davia et al. 2001). If successfully applied in selecting infected 
trabeculae, data from isometric contraction would be obtainable.
Advances in Myocardial Gene Therapy
Vascular Endothelial Growth Factor has been the subject of great interest 
as a candidate for gene therapy in patients with ischaemic heart disease 
who are unsuitable for percutaneous coronary intervention or coronary 
artery bypass grafting. The group of Isner have reported promising results 
in patients in whom plasmid DNA encoding Vascular Endothelial Growth 
Factor under the control of the cytomegalovirus promoter was introduced 
to the myocardium by direct needle injection. This was performed on 
patients with inoperable ischaemic heart disease and severe symptoms. 
Preliminary results are that patient’s symptoms are improved, as are 
myocardial perfusion images (Esakof et al. 1999; Kalka et al. 2000; Lathi
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et al. 2001; Losordo et al. 1998; Symes et al. 1999; Vale et al. 1999a; 
Vale et al. 1999b; Vale et al. 2000; Vale et al. 2001). Vascular Endothelial 
Growth Factor is thought to act as a chemotactic agent and encourages 
the growth of new blood vessels towards the injection sites. Vascular 
endothelial Growth Factor has an advantage over many other gene 
therapy candidates in that only small numbers of myocardial cells need to 
express the gene product for the strategy to be effective.
The expression of sarcoplasmic reticulum ATPase is down regulated in 
the myocardial tissue of patients with heart failure and animal models of 
heart failure. In animal models the group of Hajjar have demonstrated 
that adenoviral vector mediated gene transfer can be used to up-regulate 
the expression of myocardial sarcoplasmic reticulum ATPase (Davia et al. 
2001; del Monte et al. 2001; del Monte, Hajjar, & Harding 2001; del 
Monte et al. 1999). For this strategy to be effective in patients, there is a 
need to develop efficient methods of homogeneous gene transfer to the 
majority of myocytes within the heart.
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Selection of Vector System
Adenoviral vectors have a large inset capacity and can easily 
accommodate insertion cassettes of 7Kb. In a “gutless” form inserts of 
28Kb have been achieved (Clemens et al. 1996). They can be 
propagated to high titre and infect a wide variety of cells by attachment to 
Coxsackie adenovirus receptor and enter the cell by way of an integrin 
mediated process (Fechner et al. 1999). First generation adenoviral 
vectors were replication defective because they lacked the E1 region, 
essential for replication. In subsequent generations of vector other 
regions were deleted including E3. However, E3 products may be 
important in suppression of immune response (Efrat et al. 2001). Where 
transient expression in a small number of myocytes is required, 
adenoviral vectors may be useful. However, for the purposes of long-term 
gene transfer to large volumes of myocardium, these vectors are limited 
by transient expression and inflammatory damage. The transient 
expression is thought to be immune mediated. In athymic nude rats 
injected with an adenoviral vector encoding beta-galactosidase, foreign 
gene expression was detectable in these animals 120 days following 
virus introduction but not in similarly injected immunocompetent Sprague- 
Dawley rats (Quinones et al. 1996).
There is increasing interest in adeno-associated vectors. Although these 
vectors are difficult to propagate to high titre and have a smaller capacity 
for insertion cassettes, they can infect myocardial cells and cause foreign
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gene expression without appreciable inflammatory response (Svensson 
et al. 1999; Wright, Wightman et al. 2001). Unlike adenoviral vectors 
where the encoded gene of interest remains episomal, adeno-associated 
vectors result in integration of the encoded gene of interest into the host 
genome. Adeno-associated viruses may have particular application 
where long-term foreign gene expression is desirable in a large 
proportion of myocardial cells.
Adenoviral Vector Production.
In the experiments reported here we used a traditional method of 
propagating and purifying replication defective adenoviral vector. To 
reduce the risk of contamination by replication competent virus, vector 
was propagated from single plaques and checked by restriction enzyme 
assay prior to use. However, one limitation of adenoviral vector is that it 
can never be guaranteed that the vector is completely free of replication 
competent vector. The most sensitive method of detecting replication 
competent contamination is by the supernatant rescue assay method 
(Dion, Fang, & Garver, Jr. 1996). Even here, the detection rate is 1 wild 
type replication competent virus in 109 of recombinant virus. The life 
cycle of adenoviral vector culminates in lysis of the host cell and spillage 
of many thousands of virons to neighbouring cells. With cell lysis 
occurring typically three days following viral exposure, it is possible that 
some of the myocardial damage seen in our delivery experiments at day 
5 could have resulted from contamination by replication competent virus. 
However, if this was the case then the same effect would have been
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expected in the low concentration selective coronary injection group and 
in the high concentration aortic cross-clamp group. The absence of 
intense inflammatory reaction in these groups would be against 
significant contamination by replication competent virus.
There has been the suggestion that at very high titre, adenoviral vector 
can precipitate to form visible crystalline aggregates. The highest 
concentration of vector used in the experiments reported here was of the 
order of 1010 pfu/ml. The vector had been purified with one round of 
caesium chloride gradient ultra centrifugation and although a 2p filter was 
not used, at room temperature the vector was clear to the naked eye.
Following purification on a caesium chloride gradient, vector was desalted 
by dialysis and aliquots placed into Eppendorf tubes to be stored at -  
20°C. The buffer did not contain Glycerol and it is possible that the 
freezing process could have damaged some of the viral particles. The 
assay used to determine viral concentration was a traditional bioassay for 
plaques on agar covered HEK293 cells. In retrospect it would have been 
better to perform a bioassay and a light absorption assay to determine 
the number of defective particles contaminating each thawed aliquot. It is 
not known if the presence of defective non-replicating viral vector may 
have contributed to the inflammatory process seen in some animals.
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Methods of Vector Delivery to Myocardium
There is interest in correcting the inherited conditions that predispose to 
life threatening ventricular arrhythmias. In the original report by Barr et al 
1994, foreign gene expression was seen in a perivascular distribution 
following selective coronary injection of adenoviral vector. The results in 
Chapter 6 confirm this finding. Retrograde infusion of saline into the 
coronary sinus whilst infusing adenovirus into the coronary artery 
circulation has been used to improve efficiency of gene transfer in 
isolated rat hearts (Logeart et al. 2001). Interestingly, retrograde infusion 
of virus into the myocardial venous system has been employed to 
achieve homogeneous gene expression in the infused vascular territory 
(Boekstegers et al. 2000). One group have reported ultra-sound 
mediated destruction of albumin and adenoviral vector coated micro­
bubbles to successfully direct intravenously injected vector to rat heart in 
vivo (Shohet et al. 2000).
Potential therapeutic genes where widespread transfection would be 
potentially advantageous include skeletal troponin C, sarcoplasmic 
reticulum ATPase and Heat Shock Protein. The rationales for the first two 
have been discussed. Heat shock protein may protect myocardium from 
reperfusion or thermal injury and may have an application as a 
prophylactic treatment in patients at risk of coronary artery occlusion 
(Brar et al. 1999; Gray, Amrani, & Yacoub 1999; Jayakumar et al. 2000; 
Jayakumar et al. 2001; Mestril et al. 1996; Okubo et al. 2001).
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However, there may be methods to further refine selective coronary 
artery injection. From the work of Donahue et al it is important to prevent 
mixing of virus with red blood cells. The method of selective coronary 
injection used in Chapter 6 has been described in detail. On introducing 
the selective coronary catheter into the right coronary artery, radio­
opaque contrast was injected to delineate the coronary artery. The artery 
was judged to be blocked by the catheter if the contrast material 
remained in the artery. However, it is possible that the vessel occlusion 
was incomplete in some animals. If the occlusion was incomplete then 
the microvascular permeabilising effect of pre-injecting (nominally calcium 
free) physiological saline would be reduced as would the efficiency of 
adenoviral vector mixed with red blood cells. This is one possible 
explanation for the variability found between animals in the proportion of 
myocardium transfected following apparently identical protocols. The 
selective coronary injection method could be modified to include a 
pressure transducer on a side arm connected to the coronary catheter. 
This could be used to ensure complete occlusion of the selected coronary 
artery and measure pressure. These measures may help achieve 
consistency in efficiency of transfection within groups.
The conditions required for optimal in vivo microvascular permeabilisation 
remain to be fully investigated. Solutions of low calcium content are 
effective but the additive effect of serotonin, histamine, VEGF and 
phosphodiesterase-5 inhibitors deserve further attention (Nagata et al. 
2001). It is likely that measures that achieve efficient delivery of 
adenoviral vectors would be applicable to adeno-associated viruses.
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It is possible to inject adenoviral vectors into the pericardial space. The 
superficial epicardial cells are transfected but homogenous or functionally 
significant gene transfer is yet to be demonstrated using this method 
(Fromes et al. 1999).
The results of the experiments in which a Swan-Ganz catheter was 
employed have been detailed in Chapter 4. The virus used in these 
experiments was subsequently found to be contaminated with replication 
competent virus. Once the vector quality issues were addressed, this 
method was not developed further. Unattractive aspects of this method 
included mixing of virus with red blood cells and contrast in the ascending 
aorta; non-occlusion of the pulmonary artery and high left ventricular 
cavity pressures resulting in a reduction in coronary flow. The group of 
Koch have used intra-ventricular injection of virus with aortic occlusion 
and achieved gene transfer of functional significance without pulmonary 
artery occlusion. This was achieved by pre-injection of adenosine to 
temporarily arrest the heart by blocking AV node conduction. The 
attraction of the Swan-Ganz method was that the arterial circulation of 
both ventricles would be exposed to vector without the risk of damaging 
either coronary artery. Perhaps with adenosine pre-injection the Swan- 
Ganz method could be revisited.
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General Conclusion
This work has given me the opportunity to learn and become competent 
in a wide range of techniques to deliver vectors to myocardial tissue. I 
have gained an understanding of the different vector systems available 
and I have gained experience in amplification of adenoviral vectors. 
Despite amplification of single isolated plaques and testing of the 
resulting viral DNA by restriction enzyme analysis, the possibility of 
contamination by replication competent virus remained. In retrospect the 
supernatant rescue bioassay should have been utilised. I encountered 
problems with the specificity and sensitivity of the original histochemical 
method employed to detect beta-galactosidase expression in transfected 
myocardium. In response I employed a vector encoding a nuclear 
localising beta-galactosidase and modified the staining solutions to avoid 
false positive Prussian Blue staining. The sensitivity of the staining 
method was improved by retrograde infusion of staining solutions down 
the aorta and into the coronary circulation. I developed and optimised an 
immunohistochemical method of detecting the HA-tagged sTnC mutant 
following introduction into rabbit myocardium. In addition, I gained 
experience in using small isometric muscle preparations.
In the time since the original paper by Barr et al in 1994, to completion of 
the experiments presented here, no other group had published data 
confirming the original findings. Whilst developing the method of gene 
transfer to be employed, changes were made to the methods used in an
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apparently unsystematic manner. In particular the Swan-Ganz method 
was abandoned. This decision was taken in response to the data by 
Donahue et al published in 1997.
The results of the coronary injection and aortic cross-clamp experiments 
were presented in oral and abstract form and were the first to compare 
the two methods in the rabbit. However, sham operated controls and 
controls injected only with vehicle were not performed. A control group 
injected with a adenoviral vector encoding a sTnC mutant was used and 
although it is reassuring that no false positive beta-galactosidase staining 
was found, empty virus would have been a better control here.
A serious flaw was to have proceeded to in vivo gene transfer of the 
sTnC HA-tagged mutant and physiological investigation of the exposed 
myocardial tissue without first confirming integration of the gene product 
into the myocyte sarcomere in vitro.
If I were to do it all again what would I do differently? I would not accept 
adenoviral vector for amplification without first performing quality 
assurance checks. In particular, I would screen for wild type 
contamination by the supernatant rescue bioassay method. In future, 
“clinical grade” vector is likely to be required which has been screened for 
a range of contaminants including wild type adenovirus, Hepatitis A virus, 
Herpes Simplex-1 virus, Murine Leukaemia virus, Porcine Parvovirus, 
Bovine Viral Diarrhoea virus, Cytomegalovirus and Minute Mouse Virus. 
In addition contamination by mycoplasma and bacteria endotoxins should
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be excluded. There are now commercial organisations which provide 
such quality assurance services ((Microbix Biosystems Inc, Toronto, 
Canada). At each stage of development I would decide upon the 
experimental design, including appropriate positive and negative controls 
and perform the controls concurrently within the planned experiments. 
Finally, I would answer as many of the relevant questions using in vitro 
methods before proceeding to in vivo work.
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